 
Official Title:  A Randomized, Single -Blind, Multicenter Phase 2 Study to Evaluate the 
Activity of 2 Dose Levels of Imetelstat  in Subjects With Intermediate -2 or 
High -Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) 
Inhibitor  
 
Study ID: [REMOVED]  
 
Document  Date :  
Protocol Amendment 5 : 28 March  2019 
 
   
 
 
 
 
1 
Status: Approved , Date: 28 March 2019   Geron Corporation * 
 
Clinical Protocol  
 
A Randomized, Single -Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose 
Levels of Imetelstat in Subjects with Intermediate -2 or High -Risk Myelofibrosis (MF) 
Relapsed/Refractory to Janus Kinase (JAK) Inhibitor  
 
Protocol  63935937MYF2001 ; Phase 2 
AMENDMENT 5 
 
 GRN163L  (imetelstat)  
 
 
* As of protocol amendment 5, the term “sponsor”, as used throughout this protocol, refers to Geron 
Corporation.  Prior to protocol amendment 5, this study was sponsored by Janssen Research & 
Development or its related legal entities.  
 
 
 
 
 
 
 
 
 
US sites of this study will be conducted  under US Food & Drug Administration IND regulations  
(21 CFR Part 312).  
 
EudraCT NUMBER:           2015 -000946 -41 
 
 
Status:  Approved  
Date:  28 March 2019  
Prepared by:  Geron Corporation  
 
GCP Compliance:  This study will be  conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .  
Confidentiality Statement  
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be d isclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed  by 
them. These res trictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
2 
Status: Approved , Date: 28 March 2019   TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ...............................  2 
LIST OF ATTACHMENTS  ................................ ................................ ................................ ............................  4 
LIST OF IN -TEXT TABL ES AND FIGURES  ................................ ................................ ................................  5 
PROTOCOL AMENDMENTS  ................................ ................................ ................................ .......................  6 
SYNOPSIS  ................................ ................................ ................................ ................................ ..................  19 
TIME AND EVENTS SCHE DULE (MAIN STUDY) ................................ ................................ .....................  23 
TIME AND EVENTS SCHE DULE (EXTENSION PHAS E) ................................ ................................ .........  27 
TIME AND EVENTS SCHE DULE (PK SAMPLING)  ................................ ................................ ..................  28 
ABBREVIATIONS  ................................ ................................ ................................ ................................ ...... 29 
1. INTRODUCTION  ................................ ................................ ................................ ................................  31 
1.1. Background  ................................ ................................ ................................ ................................ .... 31 
1.1.1.  Imetelstat  ................................ ................................ ................................ ................................ .... 31 
1.1.2.  Myelofibrosis  ................................ ................................ ................................ ...............................  31 
1.1.3.  Treatment Options for Myelofibrosis  ................................ ................................ ...........................  31 
1.1.4.  Rationale for Use of Imetelstat in Myeloprol iferative Neoplasm (MPNs)  ................................ ... 33 
1.1.5.  Study CP14B019 With Imetelstat in Myelofibrosis  ................................ ................................ ..... 34 
1.1.5.1.  Clinical Efficacy Results  ................................ ................................ ................................ ..........  34 
1.1.5.1.1.  Spleen and Anemia Response ................................ ................................ .............................  35 
1.1.5.1.2.  Constitutional Symptoms  ................................ ................................ ................................ ..... 35 
1.1.5.1.3.  Subject Status a nd Time on Treatment  ................................ ................................ ...............  35 
1.1.5.1.4.  Efficacy Data in Subjects Previously Treated With a JAK Inhibitor  ................................ ..... 35 
1.1.5.2.  Clinical Pharmacology of Imetelstat  ................................ ................................ ........................  36 
1.1.5.3.  Clinical Safety of Imetelstat in Myelofibrosis  ................................ ................................ ...........  36 
1.1.5.3.1.  Hematologic Toxicities  ................................ ................................ ................................ .........  36 
1.1.5.3.2.  Non-Hematologic Toxicities  ................................ ................................ ................................ . 37 
1.1.5.3.3.  Hepatotoxicity  ................................ ................................ ................................ .......................  37 
1.1.6.  Target Engagement With Imetelstat  ................................ ................................ ...........................  37 
1.1.7.  Differentiation of Response by Exposure  ................................ ................................ ...................  38 
1.2. Overall Rationale for the Study  ................................ ................................ ................................ ...... 38 
2. OBJECTIVES AND HYPOT HESIS  ................................ ................................ ................................ ... 39 
2.1. Objectives  ................................ ................................ ................................ ................................ ...... 39 
2.2. Hypothesis  ................................ ................................ ................................ ................................ ..... 40 
3. STUDY DESIGN AND RAT IONALE  ................................ ................................ ................................ . 40 
3.1. Overview of Study Design  ................................ ................................ ................................ ..............  40 
3.2. Study Design Rationale  ................................ ................................ ................................ ..................  44 
3.2.1.  Rationale for Protocol Changes Following the First Interim R eview  ................................ ..........  46 
3.2.2.  Rationale for the Extension Phase  ................................ ................................ .............................  48 
4. SUBJECT POPULATION  ................................ ................................ ................................ ..................  48 
4.1. Inclusion Criteria  ................................ ................................ ................................ ............................  49 
4.2. Exclusion Criteria  ................................ ................................ ................................ ...........................  50 
4.3. Prohibitions and Restrictions  ................................ ................................ ................................ .........  52 
5. TREATMENT ALLOCATION  AND BLINDING  ................................ ................................ .................  52 
6. DOSAGE AND ADMINISTR ATION  ................................ ................................ ................................ .. 53 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
3 
Status: Approved , Date: 28 March 2019     54 
  55 
  55 
6.4. Infusion -Related Reactions  ................................ ................................ ................................ ............  55 
7. TREATMENT COMPLIANCE  ................................ ................................ ................................ ............  56 
8. PRESTUDY AND CONCOMI TANT THERAPY  ................................ ................................ ................  56 
9. STUDY EVALUATIONS  ................................ ................................ ................................ ....................  57 
9.1. Study Procedures  ................................ ................................ ................................ ...........................  57 
9.1.1.  Overview  ................................ ................................ ................................ ................................ ..... 57 
9.1.2.  Screening Phase  ................................ ................................ ................................ ........................  58 
9.1.3.  Single -Blind Treatment Phase  ................................ ................................ ................................ .... 59 
9.1.4.  Posttreatment Phase (Follow -Up) ................................ ................................ ..............................  60 
9.1.5.  Extension Phase  ................................ ................................ ................................ .........................  61 
9.2. Efficacy  ................................ ................................ ................................ ................................ ...........  62 
9.2.1.  Evaluations  ................................ ................................ ................................ ................................ . 62 
9.2.2.  Endpoints  ................................ ................................ ................................ ................................ .... 65 
9.3. Pharmacokinetic and Immunogenicity Evaluations  ................................ ................................ ....... 66 
9.3.1.  Sample Collection and Handling  ................................ ................................ ................................  66 
9.3.2.  Analytical Procedures  ................................ ................................ ................................ .................  67 
9.3.3.  Pharmacokinetic Parameters  ................................ ................................ ................................ ..... 67 
9.3.4.  Immunogenicity Assessments  ................................ ................................ ................................ .... 68 
9.4. Pharmacodynamic Evaluations  ................................ ................................ ................................ ...... 68 
9.5. Pharmacokinetic/Pharmacodynamic Evaluations  ................................ ................................ ..........  68 
9.6. Biomarkers  ................................ ................................ ................................ ................................ ..... 68 
9.7. Patient Reported Outcomes  ................................ ................................ ................................ ...........  69 
9.8. Safety Evaluations  ................................ ................................ ................................ .........................  70 
9.9. Sample Collection and Handling  ................................ ................................ ................................ .... 73 
10. SUBJECT COMPLETION/W ITHDRAWAL  ................................ ................................ .......................  73 
10.1.  Completion  ................................ ................................ ................................ ................................ ..... 73 
10.2.  Discontinuation of Study Treatment  ................................ ................................ ...............................  74 
10.3.  Withdrawal From the Study  ................................ ................................ ................................ ............  74 
11. STATISTICAL METHODS  ................................ ................................ ................................ .................  75 
11.1.  Analysis Set  ................................ ................................ ................................ ................................ ... 75 
11.2.  Sample Size Determination  ................................ ................................ ................................ ...........  75 
11.3.  Subject Information  ................................ ................................ ................................ ........................  76 
11.4.  Efficacy Analyses  ................................ ................................ ................................ ...........................  76 
11.5.  Pharmacokinetic Analyses  ................................ ................................ ................................ .............  77 
11.6.  Immunogenicity Analyses  ................................ ................................ ................................ ..............  78 
11.7.  Pharmacokinetic/Pharmacodynamic Analyses  ................................ ................................ ..............  78 
11.8.  Biomarker Analyses  ................................ ................................ ................................ .......................  78 
11.9.  Safety Analyses  ................................ ................................ ................................ .............................  78 
11.10.  Interim Review  ................................ ................................ ................................ ...............................  80 
11.11.  Data Analysis Committees  ................................ ................................ ................................ .............  80 
12. ADVERSE EVENT REPORT ING ................................ ................................ ................................ ...... 81 
12.1.  Definitions  ................................ ................................ ................................ ................................ ...... 81 
12.1.1.  Adverse Event Definitions and Classifications  ................................ ................................ ...........  81 
12.1.2.  Attribution Definitions  ................................ ................................ ................................ ..................  82 
12.1.3.  Severity Criteria  ................................ ................................ ................................ ..........................  83 
12.2.  Special Reporting Situations  ................................ ................................ ................................ ..........  83 
12.3.  Procedures  ................................ ................................ ................................ ................................ ..... 84 
12.3.1.  All Adverse Events  ................................ ................................ ................................ ......................  84 
12.3.2.  Serious Adverse Events  ................................ ................................ ................................ .............  85 
12.3.3.  Adverse Events of Interest  ................................ ................................ ................................ .........  87 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
4 
Status: Approved , Date: 28 March 2019   12.3.3.1.  Elevated Liver Function Tests (LFTs)  ................................ ................................ .....................  87 
12.3.3.2.  Hepatic Adverse Events  ................................ ................................ ................................ ..........  87 
12.3.4.  Pregnancy  ................................ ................................ ................................ ................................ ... 87 
12.4.  Contacting Sponsor Regarding Safety  ................................ ................................ ...........................  87 
13. PRODUCT QUALITY COMP LAINT HANDLING  ................................ ................................ ..............  88 
13.1.  Procedures  ................................ ................................ ................................ ................................ ..... 88 
13.2.  Contacting Sponsor Regarding Product Quality  ................................ ................................ ............  88 
14. STUDY DRUG INFORMATI ON ................................ ................................ ................................ .........  88 
14.1.  Physical Description of Study Drug(s)  ................................ ................................ ...........................  88 
14.2.  Packaging  ................................ ................................ ................................ ................................ ...... 88 
14.3.  Labeling  ................................ ................................ ................................ ................................ ..........  88 
14.4.  Preparation, Handling, and Storage  ................................ ................................ ...............................  89 
14.5.  Drug Accountability  ................................ ................................ ................................ ........................  89 
15. STUDY -SPECIFIC MATER IALS  ................................ ................................ ................................ ....... 89 
16. ETHICAL ASPECTS  ................................ ................................ ................................ .........................  90 
16.1.  Study -Specific Design Considerations  ................................ ................................ ...........................  90 
16.2.  Regulatory Ethics Compliance  ................................ ................................ ................................ ....... 91 
16.2.1.  Investigator Responsibilities  ................................ ................................ ................................ ....... 91 
16.2.2.  Independent Ethic s Committee or Institutional Review Board  ................................ ...................  91 
16.2.3.  Informed Consent  ................................ ................................ ................................ .......................  92 
16.2.4.  Privacy of Personal Data  ................................ ................................ ................................ ............  93 
16.2.5.  Long -Term Retention of Samples for Additional Future Research  ................................ ............  94 
16.2.6.  Country Selection  ................................ ................................ ................................ .......................  94 
17. ADMINISTRATIVE REQUI REMENTS  ................................ ................................ ..............................  94 
17.1.  Protocol Amendments  ................................ ................................ ................................ ....................  94 
17.2.  Regulatory Documentation  ................................ ................................ ................................ ............  95 
17.2.1.  Regulatory Approval/Not ification  ................................ ................................ ................................  95 
17.2.2.  Required Prestudy Documentation  ................................ ................................ .............................  95 
17.3.  Subject  Identification, Enrollment, and Screening Logs  ................................ ................................  96 
17.4.  Source Documentation  ................................ ................................ ................................ ...................  96 
17.5.  Case Report Form Completion  ................................ ................................ ................................ ...... 97 
17.6.  Data Quality Assurance/Quality Control  ................................ ................................ ........................  98 
17.7.  Record Retention  ................................ ................................ ................................ ...........................  98 
17.8.  Monitoring  ................................ ................................ ................................ ................................ ...... 98 
17.9.  Study Completion/Termination  ................................ ................................ ................................ ....... 99 
17.9.1.  Study Completion  ................................ ................................ ................................ .......................  99 
17.9.2.  Study Termination  ................................ ................................ ................................ .......................  99 
17.10.  On-Site Audits  ................................ ................................ ................................ ..............................  100 
17.11.  Use of Information and Publication  ................................ ................................ ..............................  100 
REFERENCES  ................................ ................................ ................................ ................................ ..........  102 
INVESTIGATOR AGREEME NT ................................ ................................ ................................ ...............  119 
 
LIST OF ATTACHMENTS  
Attachment 1:  Modified Myelofibrosis Symptom Assessment Form v2.0 (modified MFSAF 
v2.0)  ................................ ................................ ................................ ..........................  104 
Attachment 2:  European Organization for Research and Treatment of Cancer QLQ -C30  
(EORTC QLQ -C30)  ................................ ................................ ................................ .. 105 
Attachment 3:  Brief Pain Inventory (Short Form) (BPI)  ................................ ................................ ... 107 
Attachment 4:  Patient’s Global Impression of Change (PGIC)  ................................ ........................  109 
Attachment 5:  EuroQol -EQ-5D (EQ -5D-5L) ................................ ................................ .....................  110 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
5 
Status: Approved , Date: 28 March 2019   Attachment 6:  World Health Organization (WHO) Diagnostic Criteria for Polycythemia Vera, 
Essential Thrombocythemia and Primary Myelofibrosis  ................................ ..........  113 
Attachment 7:  International Working Group for Myeloproliferative Neoplasms Research and 
Treatment (IWG -MRT) Recommended Criteria for Post -Polycythemia Vera 
and Post -essential Thrombocythemia Myelofibrosis  ................................ ................  114 
Attachment 8:  Dynamic International Prognostic Scoring System (DIPSS)  ................................ .... 115 
Attachment 9:  Eastern Cooperative Oncology Group (ECOG) Performance Status  ......................  116 
Attachment 10:  Screening Myelofibrosis (MF) Symptom Form  ................................ .........................  117 
Attachment 11:  Myelofibrosis (MF) Symptom Recall Form  ................................ ...............................  118 
 
LIST OF IN -TEXT TABL ES AND FIGURES  
TABLES  
Table 1:  Dose Reductions  ................................ ................................ ................................ .......................  53 
Table 2:  Dose Modifications for Grade 3 Hematologic Toxicities  ................................ ...........................  54 
Table 3:  Dose Modifications for  Grade 4 Hematologic Toxicities  ................................ ...........................  54 
Table 4:  Dose Modifications for Precipitous Drop in Hematologic Parameters  ................................ ...... 55 
Table 5:  Dose Modifications for Grade 3 and 4 Non -hematologic Toxicities  ................................ ..........  55 
Table 6:  Dose Modifications for Grade 3 and 4 LFT Elevations and Hepatic Adverse Events  ..............  55 
Table 7 : Management of Infusion -related Reactions  ................................ ................................ ..............  56 
Table 8:  Volume of Blood to be Collected From Each Subject  ................................ ...............................  58 
Table 9:  Response Categories  ................................ ................................ ................................ ...............  64 
Table 10:  Remission Parameters  ................................ ................................ ................................ ..............  65 
 
FIGURES  
Figure 1:  Schematic Overview of the Study Following Amendment 2  ................................ .....................  43 
Figure  2: Schematic Overview of the Extension Phase Following Amendment 4  ................................ ... 44 
 
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
6 
Status: Approved , Date: 28 March 2019   PROTOCOL AMENDM ENTS  
Protocol Version  Issue Date  
Original Protocol  8 Apr 2015  
Amendment 1  23 November 2015  
Amendment 2  29 September 2016  
Amendment 3  13 March 2018  
Amendment 4  
Amendment 5  20 December 2018  
28 March  2019  
 
Amendments are listed beginning with the most recent amendment.  
Amendment 5 (28 March 2019) 
The overall reason for the amendment:  To update sponsorship change to Geron Corporation.  
 
Applicable Section(s)  Description of Change(s)  
Rationale: To reflect change of sponsorship as of protocol amendment 5. 
Cover page, 
3.2.1.  Rationale for 
Protocol Changes 
Following the First 
Interim Review , 
6. Dosage and 
Administration, 
Investigator 
Agreement  Change of sponsor name from Janssen Research & Development to Geron Corporation, 
including change of product designation.  
Rationale:  To align with new sponsor policies  and manuals  and to provide the most up -to-date version of the 
investigator brochure .  
7.Treatment 
Compliance, 14.4 
Preparation. 
Handling, and 
Storage, 15. Study -
specific Materials  To replace the 2 Janssen Pharmacy Manuals (Site Investigational Product Procedures 
Manual [SIPPM] and the Investigator Product Procedure Manual [IPPM]) by 1 manual, 
named ‘Site Investigational Product Manual (SIPM)”.  
12. Adverse Event 
Reporting  Added “or its affiliates” to the statement mentioning that the sponsor has established 
Standard Operating Procedures in conformity with regulatory requirements.  
16.2.4. Privacy of 
Personal Data  Clarified that personal data collected during the study will  be processed in compliance 
with the patient information and informed consent form and agreements with the 
sponsor.  
References  To provide the most up -to-date version of the investigator brochure (ie, Edition 14, 
dated 30 October 2018).  
 
Amendment 4 (20 December 2018)  
The overall reason for the amendment:  This amendment allows the Extension Phase  established in 
Amendment 3  to continue for a second year.  
 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
7 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Rationale: Continuation of the Extension Phase is required to allow subjects still benefiting  from study drug to 
continue treatment. It is anticipated that increasing the duration of the  Extension Phase from 1 year to 2 years  will 
allow all subjects to receive adequa te treatment and  will allow for  additional maturity of the survival data  and a 
more precise estimate of overall survival .    
Synopsis (Overview 
of Study Design);  
3.1 Overview of 
Study Design;   
3.2.2 Rationale for 
the Extension Phase ; 
9.1.5 Extension 
Phase ; 
17.9.1 Study 
Completion  The duration of the Extension Phase was increased from 1 year to 2 years.  The 
Extension Phase will end approximately 2 years after the clinical cutoff for the final 
analysis of the main study, or when the sponsor terminates the st udy, whichever occurs 
first.   
3.2.2  Rationale for 
the Extension Phase  Text added:  
 
Rationale:  Clarification of text was required.  
Title page  The underlined text was added: “US sites of  this study will be conducted under US Food 
& Drug Administration IND regulations (21 CFR Part 312). ” 
Time and Events 
(Extension Phase)  Footnote b was clarified  for consistency with reporting requirements : “Submit a Serious 
Adverse Event Form to the sponsor within 24 hours of onset  awareness of the event  for 
all serious adverse events.”  
Amendment 3 (13 March 2018)  
The overall reason for the amendment:  Sufficient data for the final study analysis have been collected . An 
Extension Phase was added to the protocol  to allow continued treatment for subjects  benefi ting from treatment 
with study drug . The Extension Phase includes safety follow -up of subjects via serious adverse event collection 
and continued follow -up for survival status . 
 
Applicable Section(s)  Description of Change(s)  
Rationale: The study is closed to further subject enrollment.  Subjects who have not withdrawn from the main 
study may continue  study participation  in an Extension Phase. It is anticipated that 1 year will allow sufficient 
time for all subjects to receive adequate treatment and allow additional maturity of the survival data.  
Synopsis (Overview 
of Study Design);  
3.1. Overview of 
Study Design  Subjects who are benefi ting from imet elstat  treatment when the end of the main study is 
reached may continue treatment in the newly added Extension Phase . Treatment may 
continue  until there is loss of benefit or unacceptable toxicity, as determined by the 
investigator according to local stand ard of care . Subjects in the Posttreatment Follow -up 
Phase will enter the Extension Phase to continue  follow -up of survival status.  The 
Extension Phase will end approximately 1 year  after the clinical cutoff for the final 
analysis of the main study, or when the sponsor terminates the study, whichever occurs 
first. 
Synopsis (Dosage and 
Administration) ; 
6. Dosage and 
Administration  Text was added stating that g uidelines for imetelstat  dosage and administration for 
subjects who continue treatment during the Extension Phase will follow those described 
for the Treatment Phase .   

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
8 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Synopsis (Safety 
Evaluations);  
3.1. Overview of 
Study Design ; 
11.11. Data Analysis 
Committee  Confirmation was added that the Hepatic Expert Committee and Sponsor Committee 
will continue to review data collected during the Extension Phase, as required.  
3.1. Overview of  
Study Design   A schematic overview of the Extension Phase  was added  as Figure 2 . 
3.2.2. Rationale for 
Extension Phase ; 
9.1.5. Extension 
Phase  New  section s were added.  
7. Treatment 
Compliance  A statement was added to clarify that guidelines for study drug administration and data 
collection in place during  earlier phases of the study are in ef fect for the Extension 
Phase.  
8. Prestudy and 
Concomitant Therapy  A statement was added to clarify that all recommendations regarding the use of 
concomitant therapy are applicable to the Extension Phase.  
17.9.1. Study 
Completion  Text was added to indicate that t he full study will end with the completion of the 
Extension Phase.  
Synopsis (Overview 
of Study Design);  
Time and Events 
Schedule (Main 
Study);  
3.1. Overview of 
Study Design;  
9.1.1. Overview ; 
11.4. Efficacy 
Analyses;  
17.4. Source 
Documentati on; 
17.9.1. Study 
Compl etion  Clarification was added to distinguish between the main study and the full study . The 
full study includes the Extension Phase.  
Rationale:  Sufficient data will have been collected at the time of  Amendment 3 to allow the final s tudy analysis 
to occur; therefore, the scope of  data collect ed during the Extension Phase  has been reduced .   
Time and Events 
Schedule (Extension 
Phase)  A new Time and Events Schedule was added for the Extension Phase.  
Synopsis (Safety 
Evaluations);  
9.1.1. Overview;  
12.3.4. Pregnancy  The scope of d ata collection during the Extension Phase was described .  
12.3.1. All Adverse 
Events  As of Amendment 3, only serious adverse event will be reported  using the Serious 
Adverse Event Form.   
17.4. Source 
Documentation  Text was added to describe requirements for source documentation during the Extension 
Phase.  
Rationale:  The sponsor’s commitment to provide  continued treatment  beyond the 1 -year Extension Phase  has 
been restated . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
9 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
17.9.1. Study 
Completion   The sponsor will ensure that subjects benefiting from treatment with imetelstat will be 
able to continue treatment after the end of the study  their assigned treatment .   
Rationale:  Enhanced data collection is required to help characterize serious hemorrhagic adverse events and 
serious hepatic adverse events.  
12.3.2. Serious 
Adverse Events  A subsection was added to guide collection of additional data for subjects who 
experience serious hemorrhagic adverse events or serious hepatic adverse events.   
Rationale:  A description of the analysis planned for data collected during the Extension Phase is required.  
Synopsis (Statistical 
Methods);  
11.4. Efficacy 
Analyses  The last 2  planned efficacy analy ses include: (4) the final analysis at the end of the main 
study, which is defined as 18 months after the last subject is enrolled or when the 
sponsor terminates the study , whichever come s first ; and (5) OS -related analysis will be 
performed or updated when the Extension Phase has ended.  
Rationale: Updated information regarding hematologic toxicity, non -hematologic toxicity, and hepatotoxicity is 
available.  
1.1.5.3.1. 
Hematologic 
Toxicity;  
1.1.5.3.2. Non -
hematologic Toxicity ; 
1.1.5.3.3. 
Hepatotoxicity  Text was added directing investigators to the current In vestigator’s Brochure for the 
latest description of hematologic, non -hematologic, and hepatic safety information. The 
information retained in Section 1 support the design of the main study.  
Rationale:  Progressive disease of myelofibrosis was incorrectly identified as an anticipated event rather than a 
study endpoint.   
12.3.1. All Adverse 
Events  Text was corrected to indicate that progressive disease of myelofibrosis  is not an 
anticipated event, but r ather a study endpoint.  
Rationale:  A later version of the Investigator’s Brochure is available.  
References  Reference 21 was updated to the current version of the Investigator’s Brochure.  
Rationale:  Minor errors were noted  
Throughout the 
protocol  Minor  grammatical, formatting, or spelling changes were made.  
 
Amendment 2  (29 September 2016)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.    
The overall reason for the amendment:  Changes to study conduct  are required following the first  interim 
review , which included  data for  40 subjects ( 20 subjects per treatment  arm) followed -up for at least 12 weeks.  
 
Applicable Section(s)  Description of Change(s)  
Rationale:  
 
 
 
 
 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
10 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Synopsis (Overview 
of Study Design);  
3.1. Overview of 
Study Design  
11.2. Sample Size 
Determination  Text was added to acknowledg e that the original study design allowed for enrollment of 
approximately 200 subjects; however, following the first interim review of data, and in 
line with Protocol Amendment 2, enrollment of new subjects into Arm A was suspended 
and enrollment into Arm B was perman ently closed. Therefore, total enrollment in the 
study may be approximately 160 subjects if enrollment in Arm A is resumed after the 
second interim review.  
Synopsis (Overview 
of Study Design);  
3.1. Overview of 
Study Design  
5. Treatment 
Allocation and 
Blinding  
9.1.2. Screening 
Phase  
9.1.3.  Single -Blind 
Treatment Phase  Text was modified where appropriate to indicate that randomization is no longer part of 
the study design.  References to “randomization” have been changed to 
“randomization/registration” to  accurately reflect that  subjects in  the Screening Phase at 
the time randomization was stopped  may enter the study through registration rather than 
randomization .  
Synopsis (Overview 
of Study Design);  
3.1. Overview of 
Study Design  
5. Treatment 
Allocation and 
Blinding  
9.1.3. Single -Blind 
Treatment Phase  
16.1. Study -Specific 
Design 
Considerations  Beginning with Protocol Amendment 2, neither subjects nor investigators will be 
blinded to subject treatment assignment . 
Synopsis (Dosage and 
Administration) ; 
3.1. Overview of 
Study Design;  
5. Treatment 
Allocation and 
Blinding  Beginning with Protocol Amendment 2, enrollment of new subjects into Arm A 
(9.4 mg/kg) is suspended and enrollment into Arm B (4.7 mg/kg) is permanently closed. 
Subjects in Arm B may continue their current treatment or h ave their dose increased to 
9.4 mg/kg at the investigator’s discretion according to the guidance provided in Section 
6. Subjects in Arm A may continue treatment at the investigator’s discretion. Subjects in 
either arm who discon tinue treatment will continue in the Posttreatment Follow -up 
Phase.   
 
Synopsis (Dosage and 
Administration);  
Time and Events 
Schedule (footnote 
‘a’) 
3.1. Overview of 
Study Design  
5. Treatment 
Allocation and 
Blinding  Any subject already in the Screening Phase at the time study enrollment was suspended, 
and who was subsequently determined to be eligible for the study, was allowed to 
proceed with treatment assignment to the 9.4 mg/kg arm per investigator discretion , 
subject agreement , and IRB/IEC notification . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
11 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Synopsis (Interim 
Review);  
3.1. Overview of 
Study Design;  
11.10. Interim 
Review  Text was added to clarify that the first interim review has occurred but was designed 
prospectively.  
Figure 1, Schematic 
Overview of the 
Study  The study schematic diagram was updated  to show suspension of enrollment and the 
option for eligible subjects to have their dose increased  from 4.7 mg/kg to 9.4 mg/kg .  
Synopsis (Interim 
Review);  
Synopsis (Statistical 
Methods)  
3.1. Overview of 
Study Design  
11.4. Efficacy 
Analyses  
11.10 . Interim 
Review  Text was added describing the timing of a new, second planned interim review, data to 
be assessed in the second interim review, and guidelines for interpretation of results.  
3.2.1. Rationale for 
Protocol Changes 
Following First 
Interim Review  A new section was added to describe the results of the first interim data review  and the 
resulting changes to study conduct .  
Rationale:  Subjects in the 4.7 mg/kg arm should only be escalated to  the 9.4 mg/kg dose if their current status 
supports administration of the higher dose . 
6.0. Dosage and 
Administration (Dose 
Escalation Following 
Amendment 2)  Beginning with Protocol Amendment 2, subjects in Arm B may continue to receive their 
current dose of imetelstat or, at the discretion of the investigator, have their dose 
increased to 9.4 mg/kg. Subjects being considered for dose escalation from 4.7 mg/kg to 
9.4 mg/kg must meet the eligibility  criteria for hematologic laboratory values (inclusion 
criterio n 8.1) and biochemical laboratory values (inclusion criterion 9.1). In addition, 
these subjects cannot meet any threshold for dose modification , nor can they have had 
an earlier imetelstat dose reduction.   
Rationale: Additional study  procedures  are required  for subjects who have their dose increased from  4.7 mg/kg 
to 9.4 mg/kg so that the effect of dose escalation on safety, efficacy (including spleen volume) , PK exposure, and 
target inhibition can be assessed.   
Time and Events 
Schedule;  
Time and Events 
Schedule (PK 
Sampling)  Columns have been added to the Time and Events Schedules to show study procedures 
required for subjects who have their dose increased from  4.7 mg/kg to 9.4 mg/kg.  
Footnote ‘w’ was added to the Time and Events Schedule.   
Synopsis (Statistical 
Methods);   
11.4. Efficacy 
Analyses (Secondary 
Endpoint Analyses) ; 
11.9. Safety Analyses  
 Additional safety and efficacy analyses will be performed for subjects initially treated 
with imetelstat 4.7  mg/kg who had their dose increased to  9.4 mg/kg.  
Time and Events 
Schedule (footnote 
‘h’) Subjects who se dose is increased  from 4.7 mg/kg to 9.4 mg/kg must have an abdominal 
MRI within approximately 14 days  before starting treatment at the  9.4 mg/kg  dose. 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
12 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Time and Events 
Schedule (footnote 
‘i’) Subjects whose dose is increased from 4.7 mg/kg to 9.4 mg/kg must have spleen 
palpation performed within approximately 14 days before starting treatment at the 9.4 
mg/kg dose.  
Time and Events 
Schedule 
(footnote  ’r’); Time 
and Events Schedule 
(PK Sampling, 
footnote ‘e’)  Subjects whose dose is increased from 4.7 mg/kg to 9.4 mg/kg will have sparse PK 
blood samples collected during the first cycle of treatment at the 9.4 mg/kg dose.  
Time and Events 
Schedule 
(footnote  ‘v’); 
9.4. Pharmaco - 
dynamic Evaluations  Subjects whose dose is increased from 4.7 mg/kg to 9.4 mg/kg will have additional 
samples collected for assessment of TA, TL, and hTERT during the first 2 cycles of 
treatment at the 9.4 mg/kg dose.  
9.1.1. Study 
Evaluations 
Overview  
16.1. Study -Specific 
Design 
Considerations  The total blood volume to be collected was increased from 508.5 mL to 604 mL. Table 8 
was updated to reconcile with study procedures and current requirements for sample 
volumes by the central laboratory . PK blood sample s will be collected at the 2 hour 
post-infusion time point  for all subjects until the sponsor notifies investigators that this 
collection can stop.  Additional blood samples for PD and PK analyses are required only 
for subjects who have their dose increased  from 4.7 mg/kg to 9.4 mg/kg , or who have 
bone marrow aspirate collected for PK analysis (Table 8 footnotes  ‘f’ and ‘g’).  
Rationale: Changes or clarification  to study procedures were required to improve quality of the data record.  
Synopsis (Statistical 
Methods)  
11.4. Efficacy 
Analyses  Clarification was made that t he spleen response data reviewed by the IRC will be used 
for the primary analysis, the interim data reviews , and the final analysis.  
Time and Events 
Schedule (Abdominal 
MRI; footnote ‘h’);  
9.1.4. Posttreatment 
Phase (Follow -Up) 
 Two abdominal MRIs were added. The first, which will be performed within 30 days 
after the last dose of imetelstat, was added as an End -of Treatment Visit procedure. This 
MRI is not required if one already exists con firming disease progression or otherwise 
demonstrating cause for treatment discontinuation. The second added MRI will be 
performed during the Posttreatment Follow -up Phase, 3 months after the subject’s last 
dose of study drug , if feasible . 
Time and Events  
Schedule (Spleen 
palpation; 
footnote  ‘i’); 
9.2.1. Evaluations 
(Spleen Length 
Measurement)  Spleen palpation during the Posttreatment Follow -up Phase  was added at 3 months after 
the subject’s last dose of study drug , if feasible . Assessment time points were  specified 
in Section 9.2.1.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
13 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Time and Events 
Schedule (Bone 
marrow aspirate and 
biopsy; footnote ‘j’);  
Time and Events 
Schedule (PK 
samples; footnote ‘f’)  
9.1.1. Overview  
9.3.1. Sample 
Collection and 
Handling;  
9.3.2. Analytical 
Procedures  A sample of bone  marrow aspirate and a time -matched plasma sample will be collected, 
if feasible, 24 -48 hours after imetelstat dosing at Weeks 24 and 48 for evaluation of 
imetelstat concentration.  
Time and Events 
Schedule (PK 
samples; footnote 
‘r’); 
Time and Events 
Sched ule (PK 
Sampling, 
footnote  ‘f’) For each administration of imetelstat starting at Cycle 3, all subjects will have a 2 -hour 
postdose (immediately before the end of infusion) PK blood sample collected. This will 
continue until the sponsor notifies investigat ors that the collection can stop.  
4.2. Exclusion 
Criteria;  
6.0. Dosage and 
Administration  Clarification was added that if a subject's status changes (including laboratory results or 
receipt of additional medical records) after screening but before the first dose of study 
drug is given such that he or she no longer meets all hematologic eligibil ity criteria, the 
decision to administer study drug on Cycle 1 Day 1 is at the discretion of the 
investigator provided that the subject does not meet any threshold for dose delay 
modification .  
9.1.4. Posttreatment 
Phase (Follow -Up) Clarification was adde d that a plasma sample for immunogenicity testing should be 
collected at the first follow -up visit.  
9.2.1. Evaluations 
(Imaging)  Clarification was added that there will be local MRI review in addition to central MRI 
review by the IRC. Text referring to MR I interpretation by the central imaging vendor 
was deleted. Text was added to emphasize that treatment decisions following spleen 
volume assessment will be based on the  IRC assessment.  
Rationale: Janssen Research & Development standard protocol text has been updated.  
Title Page  Janssen Infectious Diseases BVBA was deleted as one of the legal entities comprising 
Janssen Research & Development.  
12.3.1. All Adverse 
Events  Additional text was added describing Anticipated Events and the reporting process for  
serious Anticipated Events.  
Rationale:  Minor errors were noted  
Throughout the 
protocol  Minor grammatical, formatting, or spelling changes were made.  
 
 
Amendment 1  (23 November 2015 ) 
This amendment is considered to be substantial  based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.   
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
14 
Status: Approved , Date: 28 March 2019   The overall reason for the amendment:  This amendment makes revisions to study eligibility criteria based on 
feedb ack from investigators and discussion with the  Independent Hepatic Expert Committee, and clarifies some 
aspects  of study conduct.  
 
Applicable Section(s)  Description of Change(s)  
Rationale:  Additional clarification was required for the d efinition of disease progression during or after JAK  
inhibitor therapy . In addition, b ecause MRI  or palpation measurement may  not always be considered routine 
standard of care , eligibility may be demonstrated using  CT or ultrasound  measurements . 
4.1. Inclusion Criteri a 
(criterion 6.1)  Subjects are required to have worsening of splenomegaly -related abdominal pain in 
conjunction with either  no reduction in spleen volume or size  after 12 weeks of JAK 
inhibitor therapy ; or documented worsening splenomegaly from nadir at an y time after 
the start of JAK inhibitor therapy. For documentation of splenomegaly, CT was added as 
an accepted imaging modality by which to demonstrate increase in spleen volume. CT 
and ultrasound were added as accepted imaging modalities to demonstrate i ncrease in 
spleen size.  
Rationale: Redundant information deleted. All screening procedures are to be completed within 21 days before 
randomization.  
4.1. Inclusion Criteria  
(criterion 8 .1) Reference to the 21-day period before randomization for absolute neutrophil count  and 
platelet  count  was deleted .  
Rationale:  Criteria for liver function test  values  did not account for  the high prevalence of elevated ALP and 
bilirubin abnormalities  in the target population , which reflect disease course rather than presence of liver damage .  
4.1. Inclusion Criteria  
(criterion 9 .1) ALP  criteria changed from ≤2.5 x ULN to  ≤5 x ULN. Criteria for bilirubin changed 
from direct bilirubin ≤1.5 x ULN to total bilirubin ≤3 x ULN  and direct bilirubin ≤ 2 x 
ULN.  
Rationale: Clarification of exclusion criterion required . 
4.2. Exclusion  
Criteria (criterion 3.1)  Clarification added that subjects are excluded if they experienced major surgery prior to  
randomization.  
Rationale: Subjects must be free from the effects of all prior MF therapy to prevent confounding  of the imetelstat 
treatment effect .  
  
4.2. Exclusion 
Criteria  
(criterion 4 .1) Any MF-directed therapy  was added  categorically  as a possible prior therapy  requiring 
washout before study entry . Reference to p rior treatment with growth factor s was 
removed , as independence from growth factor support is a ddressed in inclusion 
criterion  8.1.  
. 
9.1.2. Screening 
Phase   
 
 
. 
Time  and Events 
Schedule (footnote s 
e, h) Collection of screening symptoms using the Screening Myelofibrosis Symptom Form 
(footnote “e”) and the screening abdominal MRI (footnote “h”) must be performed after 
.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
15 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Rationale:  Subjects with hepatitis infections that are unlikely to cause long -term liver damage may be included 
without additional risk .   
4.2. Exclusion 
Criteria  
(criterion 9 .1) History of prior hepatitis infection was deleted as part of the exclusion criterion. 
Subjects with active systemic hepatitis infection requiring treatment are excluded 
(carriers of hepatitis virus are permitted to enter the study).  
Rationale:  To allow for investigator discretion regarding continued subject eligibility given the labile clinical 
course of this patient population . 
4.2. Exclusion 
Criteria;  
6. Dosage  and 
Administration  Text was added to the note below the list of exclusion criteri a. If a subject’s status 
changes  after screening but before the first dose of study drug is given , such that he or 
she no longer meets all eligibility criteria,  the decision to administer study drug on 
Cycle 1 Day 1 is at the discretion of the investigator  provided that the subject does not 
meet any threshold for dose delay.    
Rationale: The flexibility to use p eripheral blood instead of bone marrow aspirate  for cytogenetic testing  will 
allow cytogenetic testing to occur when bone marrow aspiration is clinically unfeasible. Bone marrow aspirate is 
preferred to peripheral blood for cytogenetic assessment . The same sample type should be collected at screening 
and subsequent time points, if possible, because changes in cytoge netic findings may result for a given subject 
when different sample types are used .  
Synopsis (Efficacy 
Evaluations);  
Time and Events 
Schedule ( footnote t ); 
9.1.2. Screening  
Phase ; 
9.2.1. Evaluations 
(Bone marrow);  
9.6. Biomarkers  Text was added emphasizing that bone marrow aspirate is preferred over peripheral 
blood for cytogenetic analyses. However, a  peripheral blood sample may replace bone 
marrow aspirate for cytogenetic analysis when  collection of aspirate is not clinic ally 
feasible .  
9.6. Biomarkers ; 
Time and Events 
Schedule (footnote t)  Text added that e very effort should be made to continue collecting the same type of 
sample (bone marrow aspirate or peripheral blood) at screening and subsequent time 
points when possible.  
Rationale: Revisions  or clarifications  to study procedures facilitate assessment of study data.  
Time and Events 
Schedule (Expanded 
LFT, footnote p ); 
9.8. Safety 
Evaluations (Clinical 
Laboratory)  An expanded liver function panel was added as a Screening Phase evaluation for all 
subjects. In the Time and Events Schedule, a n expanded LFT panel was added to the 
End-of-Treatment Visit and Posttreatment Follow -up Phase for subjects with an ongoing 
adver se event of interest  (consistent with Section 9.8 , Safety Evaluations ).  
Time and Events 
Schedule (Chemistry)  Clinical chemistry was added as a Posttreatment Follow -up Phase evaluation for 
subjects being followed -up for elevated LFT values (consistent wit h Section 9.8, Safety 
Evaluations). Footnote “o” was applied to the End -of- Treatment Visit time point .  
Time and Events 
(footnote d)  
9.8. Safety 
Evaluations (Viral 
hepatitis)  Hepatitis D serology is only required if the subject tests positive for the hepatitis B 
surface antigen (HBsAg).  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
16 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Time and Events 
Schedule (footnote s 
e, i, o); 
Section 9.1.2.  
Screening Phase  Clarification was added that the MFSAF v2.0 e -diary  (footnote “e”), spleen palpation 
(footnote “i”), and hematology assessment for eligibility (footnote “o”) must be started 
or performed  after . 
Time and Events 
Schedule (footnote h)  Clarifi ed that a bdominal MRI will be read locally for volume measurement.  
Time and Events 
Schedule (footnote 
h); 
9.1.2. Screening  
Phase  Clarified that t he abdominal MRI may include a portion of the pelvis in cases where the 
spleen protrudes into the pelvic cavity.  
Time  and Events 
Schedule (PK 
Sampling, footnote a)  Footnote “a” was added to clarify that all sampling times are relative to the start of 
imetelstat infusion.  
9.8. Safety 
Evaluations (Clinical 
Laboratory)  Text was added to the serum chemistry panel stating that bilirubin fractionation is 
required at screening. The presentation of the expanded LFT panel was changed to 
match that used for the hematology and serum chemistry panels. Text was added to state 
that the expanded LFT panel is required at screening.  
Rationale: Text was updated to address the situation at some centers where imetelstat dose cannot be accurately 
measured out and administered to the nearest 0.1 mg by study personnel.  
6. Dosage and 
Administration  The instruction to calculate the dose of imetelstat to the nearest 0.1 mg has been deleted.  
Rationale: Blood volumes to be collected from subjects during the study have changed.  
9.1.1. Procedures 
Overview ; 
16.1. Study -Specific 
Design 
Considerations  In Table 8 , the blood volume collected for hepatitis serology was increased from 3 mL 
to 7.5 mL. Footnote “d” was added to explain that 2.5 mL of this sample will be used for 
PCR testing , when required.  The b lood volume for each biom arker (mutational 
analysis) sample was increased from 5 mL to 6 mL ( subtotal  volume increased from 
20 mL to 24 mL).  The total volume of blood to be collected increased from 
approximately 500 mL to approximately 508.5 mL. Text was added below Table 8 
noting  that some subjects may have additional 4-mL blood samples collected if 
peripheral blood is used for cytogenetic analysis in place of  bone marrow aspirate .   
Rationale:  Study drug presentation may change during the study.  Updated study drug information became 
available and was included in the Investigational Product Preparation Instructions (IPPI).  
14.1. Physical 
Description of Study 
Drug  The p recise size (10 mL) was deleted from description of the single -dose imetelstat vial. 
Each vial will deliver a minimum of  200 mg of reconstituted Imetelstat Sodium for 
Inject ion. The concentration of reconstituted Imetelstat Sodium for Injection was 
changed from 20  mg/mL to 33.33 mg/mL.  
14.2. Packaging  Text was revised to state that imetelstat vials are provided in a protective carton and that 
all packaging will meet applicable regulatory requirements. Redundant information 
regarding the concentration of reconstituted imetelstat was deleted.  
14.4. Preparation, 
Handling, Storage  Text stating that the product must be protected from light was deleted.  The specific 
period of time  following imetelstat reconstitution when the study drug can be used was 
deleted , and investigator s are directed to the IPPI for this information .  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
17 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Rationale: Clarification added to aid interpretation or for consistency with other parts of the protocol.  
Synopsis (Efficacy 
Evaluations);  
Time and Events 
Schedule (physical 
examination)  Clarification  was made that physical examination includes spleen palpation, as specified 
in other parts of the protocol.  
Time and Events 
Schedule (footnote 
o); 
9.8. Safety 
Evaluations (Clinical 
Laboratory Tests)  Text was aligned between Section 9.8, Safety Evaluations, and footnote “o” of the Time 
and Events Schedule, regarding requirements for follow -up of bilirubin, AST, ALT, and 
ALP after Grade ≥3, and Grade 1 and 2, treatment -emergent elevations are reported.  
4.2. Exclusion 
Criteria  A sentence was added to the note following the final exclusion criterion specifying that 
the last laboratory result obtained before randomization will be used to establish 
eligibility.  
6.1. Dose 
Modification s for 
Hematologic 
Toxicities (Table 2, 
Table 3)  Table footn otes were revised to state that dose modifications in response to Grade 3 and 
Grade 4 hematologic malignancies are at the investigator’s discretion.  
6.3. Dose 
Modifications for 
Hepatic Toxicities 
(Table 6)  A footnote was added to the table providing guida nce for handling hepatic abnormalities 
not addressed in the table.   
8. Prestudy and 
Concomitant Therapy  MF-directed therapy added as a prohibited medication during the study, consistent with 
exclusion criterion 4.1.  
9.1.2. Screening  
 Consistent with other sections of the protocol, text was added stating that the sponsor 
will inform the sites which subjects have a cytogenetic abnormality based on the 
baseline analysis and who will need to have subsequent samples collected for 
cytogenetic analysis.  
Clarification  was added that bone marrow aspirate and biopsy used for disease 
assessment must be performed up to 60 days before randomization.  
9.2.1. Evaluations 
(Bone marrow)  Clarification was added that bone marrow biopsy and aspirate  samples must be collected 
according to the Time and Events Schedule. Central review of bone marrow aspirate for 
efficacy analysis was deleted. Central review of bone marrow biopsy will be used to 
assess response to imetelstat for the efficacy analysis.  
9.2.1. Evaluations 
(MFSAF Diary)  Unnecessary text “(prior to randomization)” describing the Day -7 time point was 
deleted.  
9.2.1. Evaluations 
(Table 9)  Footnote “a” was added to Table 9. For all response categories, benefit must last 12 
weeks. This applies to clinical improvement, anemia response, spleen response, and 
symptoms response.  
Rationale:  Janssen Research & Development standard protocol text has been updated.  
4. Subject Population  Clarification was added that waivers to required entry criteria are not permitted.  
12.2. Special 
Reporting Situations  Exposure to a sponsor study drug from breastfeeding was added as an event that may 
require expedited reporting and safety evaluation.  
16.2.2. IEC or IEB  Clarification was made that IEC/IRB annual approval of the protocol will be obtained, 
where required . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
18 
Status: Approved , Date: 28 March 2019   Applicable Section(s)  Description of Change(s)  
Rationale:  Minor errors were noted  
Throughout the 
protocol  Minor grammatical, formatting, or spelling changes were made.  
 
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
19 
Status: Approved , Date: 28 March 2019   SYNOPSIS  
A Randomized, Single -Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of 
Imetelstat in Subjects with Intermediate -2 or High -Risk Myelofibrosis (MF) Relapsed/Refractory to Janus 
Kinase (JAK) Inhibitor   
Myelofibrosis (MF) is classified as one of the  myeloproliferative neoplasm s (MPN), a group of related 
clonal disease s that includes polycythemia vera (PV) and essential thrombocythemia (ET). Allogeneic stem 
cell transplantation is the only treatment that can induce long -term remissions in patien ts with MF. 
Hydroxyurea, interferon, and, more recently , Janus kinase (JAK) inhibitors have been evaluated in clinical 
studies . Imetelstat, a first -in-class telomerase inhibitor, may provide clinical benefit to MF patients 
previously treated with a JAK inh ibitor primarily due to its novel mechanism of action compared with 
available therapies.  
OBJECTIVES AND HYPOTHESISES  
Primary Objective s 
The primary objectives of this study are to evaluate spleen response rate  and symptom response rate of 
2 dose regimens o f imetelstat (9.4 mg/kg and 4.7 mg/kg imetelstat given intravenous [IV] every 3 weeks) 
in subjects with intermediate -2 or high -risk MF who are relapsed  after or refractory to JAK inhibitor 
treatment.  
Secondary Objectives  
The secondary objectives are  to ass ess the safety of imetelstat;  to assess complete remission (CR) or partial 
remission (PR), clinical improvement (CI), spleen  response , symptoms response and anemia response  per 
modified 2013 International Working Group – Myeloproliferative Neoplasms Research and Treatment  
(IWG -MRT ) criteria , duration of responses , and overall survival (OS) ; to evaluate the pharmacokinetics 
(PK) of imetelstat ; to evaluate  the PK/response and pharmacodynamic (PD) relationship s with  factors that 
include  hemoglobin  concentration , spleen size, and platelet count;  to evaluate the immunogenicity  of 
imetelstat ; and to assess the effect of treatment on  patient -reported outcomes  (PROs) . 
Exploratory Objectives  
The exploratory objectives are  to assess the PK relationship with telomerase activity (TA), telomere length 
(TL) or human telomerase reverse transcriptase (hTERT ), to characterize the baseline cytogenetic and 
mutational status for their association with clinical response, and to evaluate the change of cytogenetic 
abnormalities or mutant allele burden for assessing cytogenetic and molecular response s. 
Hypothesis  
The primary hypothesis of the study is that treatment with the selected dose of imetelstat will result in a 
 with intermediate -2 or high-risk 
MF who are relapsed  after or refractory to JAK inhibitor treatment.  
OVERVIEW OF STUDY DESIGN  
This was originally designed as a randomized (1:1), single -blind, multicenter, Pha se 2 study of 2 dosing 
regimens of single -agent imetelstat in approximately 200 subjects with intermediate -2 or high risk MF  
(primary MF  [PMF ], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who  are relapsed  after or 
refractory to JAK inhibitor treatment. When the randomization was in effect, e ligible subjects  were  
stratified based on a) spleen size ≥ 15 cm below the left costal margin by palpation (yes v s. no) and b) 
platelet count at study entry (platelets ≥75 x 109/L and < 150 x 109/L vs. ≥ 150 x 109/L). Study treatment 
will be administered on a 21 -day cycle. The main  study will have 3  phases: a screening phase of up to 
21 days before randomization /registration  during which subject eligibility will b e reviewed and approved 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
20 
Status: Approved , Date: 28 March 2019   by the sponsor  prior to randomiz ation /registration ; a treatment phase will extend from 
randomization /registration  until study drug discontinuat ion; and a posttreatment follow -up phase that 
begins when the subject discontinues imetelstat. The posttreatment follow -up phase will continue un til 
death, lost to follow -up, withdrawal of consent or study end, whichever occurs first. Th e end of the main 
study is defined as 18  months after the last subject is enrolled or when the sponsor  terminates the study, 
whichever comes first.    
The original s tudy design allowed for enrollment of approximately 200 subjects; however, following the 
first interim review of data, and in line with Protocol Amendment 2, enrollment of new subjects into Arm  A 
was suspended and enrollment into Arm B was permanently closed . Therefore, total enrollment in the study 
may be approximately 1 60 subjects if enrollment in Arm A is resumed after the second interim review. In 
addition, neither subjects nor investigators will be blinded to subject treatment assignment.   
The co -primary endpoints of this study are spleen response rate and symptom response rate. Spleen 
response rate is defined as the proportion of subjects who achieve ≥35% reduction in spleen volume at 
Week 24 from baseline as measured by imaging scans. Symptom resp onse rate is defined as the proportion 
of subjects who have ≥50% reduction in total symptom score  at Week 24 from baseline as measured by the 
modified Myelofibrosis Symptom Assessment Form  (MFSAF) v2.0 diary.  
With Protocol Amendment 3, the study is closed to further subject enrollment. Subjects in the Treatment 
Phase who are benefiting from study treatment  may enter an Extension Phase and continue to receive 
imetelstat until there is loss of benefit or unacceptable toxicity, as determined by the investigato r according 
to local standard of care. Subjects in the Posttreatment Follow -up Phase will enter the Extension Phase to 
continue follow -up for survival status. In line with Protocol Amendment 4, t he Extension Phase will end 
approximately 2 years after the clinical cutoff for the final analysis of the main study, or when the sponsor 
terminates the study, whichever occurs  first. 
SUBJECT POPULATION  
Key eligibility criteria include the following: ≥18 years of age ; diagnosis of PMF per the revised Wor ld 
Health Organization (WHO) criteria, or PET-MF or PPV -MF per the IWG -MRT criteria ; Dynamic 
International Prognostic Scoring System  (DIPSS) intermediate -2 or high risk M F; measurable 
splenomegaly prior to study  entry ; active symptoms of MF ; documented pro gressive disease during or after 
JAK inhibitor therapy ; and an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 
0, 1 or 2.  
DOSAGE AND ADMINISTRATION  
Imetelstat will be administered as a 2 -hour IV infusion . Subjects in Arm A will receive imetelstat 9.4  mg/kg 
every 3 weeks and subjects in Arm B will receive 4.7 mg/kg every 3 weeks. Subjects may receive treatment 
until disease progression or unacceptable toxicity.   
Subjects in Arm B may continue with their current imetelstat dose or have it increased to 9.4 mg/kg at the 
investigator’s discretion according to the guidance provided in Section 6 (Dosage and Administration) of 
the protocol . Subjects in Arm A may continue treatment at the investigator’s discretion. Subjects in either 
arm w ho discontinue treatment will continue in the Posttreatment Follow -up Phase.  
Any subject already in the Screening Phase at the time study enrollment was suspended, and who was 
subsequently determined to be eligible for the study, was allowed to proceed wit h treatment assignment to 
the 9.4 mg/kg arm per investigator discretion , subject agreement , and IRB/IEC notification .  
Guidelines for imetelstat dosage and administration for subjects who c ontinue  treatment during the 
Extension Phase will follow those desc ribed for the Treatment Phase.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
21 
Status: Approved , Date: 28 March 2019   EFFICACY EVALUATIONS  
Efficacy evaluations will include magnetic resonance imaging ( MRI ) scans, laboratory testing, limited 
physical examinations  (including spleen palpation) , bone marrow biopsy and aspirate  for disease 
assessment , peripheral blood smears, and symptom assessment . Bone marrow aspirate for cytogenetic 
testing must be submitted for all subject s when  clinically feasible. Peripheral blood may be submitted in 
place of an aspirate only if  a bone mar row aspirate cannot be obtained.     
PHARMACOKINETIC E VALUATIONS  
Sparse PK samples will be obtained from all subjects and the derived PK parameters will provide 
information about the determina nts of inter -subject variability in this population. In addition,  for a subset 
of subjects at selected sites, serial PK sampling will be performed in both treatment arms to increase the 
robustness of the population PK model. Samples may also be used to evaluate the formation of metabolites 
of imetelstat.  
IMMUNOGENICITY EVALUATIONS  
Blood samples will be collected from all subjects to determine immunogenicity to imetelstat (anti -drug 
antibody generation).  
PHARMACOKINETIC /PHARMACODYNAMIC EVALUATIONS  
Different PK/PD models will be built to understand and characterize the exposure -response relationship for 
key efficacy and safety parameters, to detect the influence of covariates, and identify inter -individual 
variability in response.  
BIOMARKER EVALUATIONS  
Blood and bone marrow samples will be collected to evaluate the pharm acodynamic effects of imetelstat 
and to determine cytogenetic and molecular response rates. Other markers may be assessed to evaluate 
potential inter -individual variability in clinical outcomes or identification of population subgroups that 
respond differe ntly to treatment with imetelstat.  
PATIENT REPORTED OUTCOMES  
Patient -reported outcome  questionnaires and an e -diary will be collected  to provide an assessment of the 
subject’s functional status, well -being, and MF symptoms over time and to provide estimate s of utility to 
include in future cost effectiveness models.  
SAFETY EVALUATIONS  
Safety will be assessed by adverse events, physical examinations, clinical  laboratory parameters , vital sign 
measurements, ECOG performance status, and concomitan t medication usage.  
A Sponsor  Committee will review all the safety data on a quarterly basis, or more frequently , if needed. 
The study will have enhanced reporting for adverse events of interest, which include Grade 3 or greater 
elevations of AST, ALT, ALP and bilirubi n, and all hepatic adverse events. Additionally, all hepatic adverse 
events and LFT abnormalities will be reviewed at least on a quarterly basis, or as needed, by an Independent 
Hepatic Expert Committee.  
During the Extension Phase, serious adverse event s will be collected for subjects receiving imetelstat , and 
all subjects will be followed -up for overall survival and reported pregnancy. The Hepatic Expert Committee 
and Sponsor Committee will continue to review study data collected during  the Extension Phas e.   
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
22 
Status: Approved , Date: 28 March 2019   INTERIM REVIEW  
The first interim data review  was designed as follows:  The interim data review will  be performed by the  
sponsor after approximately 20 subjects have been randomized in each arm and followed for at least 12 
weeks. At this time, the spons or will assess  all available data (eg, PK, safety, efficacy, PD biomarkers: TA, 
TL or hTERT), and conduct integrated exposure -response analyses with PK/PD, safety and efficacy 
modeling. Based on these analyses, the sponsor will determine if enrollment in o ne or both treatment arms 
should continue, or if an alternative dose should be selected for further development. Enrollment will 
continue during this time and response data assessed by the investigator will be used for the interim review.  
 
 
 
  
STATISTICAL METHODS  
The study was originally designed to  enroll approximately 200 subjects ( approximately 100/arm). For each 
treatment arm, the sample size is calculated based on the following assumptions:  
1) null hypothesis:  
2) alternative hypothesis:  
3) the null hypothesis is tested by the intersection -union test. Each of the co -primary endpoints is 
tested at one sided α=0.025, and the maximum Type I error rate for testing co -primary endpoints is the 
same as one sided α=0.025 . 
 
 
 
 
 
 
 
Planned efficacy analyses are as follows : (1) a first interim review after approximately 20 subjects in each 
arm have been followed for at least 12 weeks; (2)  a second interim review with a clinical cutoff that is 6 
months after the clinical cutoff used for the first interim review ; (3) the primary efficacy analysis after all 
subjects have been followed for at least 24 weeks; ( 4) the final analysis at the end of the main study, which 
is defined as 18 months after the last subject is enrolled or when the sponsor  terminates the study ; and (5) 
OS-related analysis will be performed or updated when the Extension Phase has ended . 
The analysis for the co -primary endpoints (spleen response rate and symptom response rate) will be based 
on the Treated Population. For each treatment arm, spleen response rate and symptom response rate will be 
presented along with their 9 5% 2 -sided exact confidence  interval . The spleen response data reviewed by 
the Independent Review Committee  (IRC ) will be used for the primary analysis , the interim data reviews , 
and the final analysis . The symptom response data measured by the modified MF SAF v2.0 Total Symptom 
Score (TSS) will be calculated as the 7 -day average of daily TSS, which is the summation of 6 individual 
symptom scores.  Additional analyses will be performed for subjects initially treated with imetelstat 4.7 
mg/kg who had their dose increased to 9.4 mg/kg as described in Section 6 (Dosage and Administration)  
of the protocol . 
  
EudraCT NUMBER:           2015 -000946 -41 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
23 
Status: Approved , Date: 28 March 2019  TIME AND EVENTS SCHEDULE  (MAIN STUDY)  
Beginning with Amendment 3, follow the Time and Events Schedule for the Extension Phase . 
PHASE  Screening Phase  Treatment Phasea 
(21-day treatment cycle) Posttreatment 
Follow -up 
Phaseb 
  Cycle 1  Cycle 1  Cycle 2  Cycle 3 until 
End-of-Treatment  Dose Escalationw 
(4.7 to 9.4 mg/kg)  End-of-Treatment 
Visit   
 Day -21 to -1 Day 1  Day 8, 15  Day 1, 8, 15  Day 1   Within 30  days 
after last dose  Every 16 weeks  
Study Procedures          
Screening/Administrative          
Informed consent  X        
Inclusion/exclusion criteria  X        
Medical history and 
demographics  X        
ECOG performance status  X X  X (D1 only)  X  X  
Transfusion history and statusc X X X X X    
Hepatitis serologiesd X        
Pregnancy test  X        
Screening Myelofibrosis  
Symptom Forme X        
Study Drug Administration          
Randomization   Xa       
Dispense/administer study drug   X  X (D1 only)  X    
Safety Assessments          
Physical examination including 
spleen palpationf X X  X (D1 only)  X  X  
Vital signsg X X  X (D1 only)      
12-lead ECG  X        
Efficacy Assessments          
Abdominal MRIh X Every 12 weeks up to Week 48 then every 24 weeks and at time of 
CR/PR  Xh X 3 months 
posttreatment  
Spleen palpationi X Every 12 weeks up to Week 48 then every 24 weeks and at time of 
CR/PR  Xi 
X 3 months 
posttreatment  
BM aspirate and biopsyj X Every 24 weeks and at time of CR/PR   X (if feasible)   
Peripheral blood smeark X Every 12 weeks up to Week 48 then every 24 weeks and at time of 
CR/PR   X  
Response assessment per 
modified 2013 IWG -MRT   Every 12 weeks up to Week 48 then every 24 weeks     
Modified MFSAF v2.0 e -diarye To be completed each evening from Day -7 through Week 48     
MF Symptom Recall Form      X (After Week 48)l    
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
24 
Status: Approved , Date: 28 March 2019  PHASE  Screening Phase  Treatment Phasea 
(21-day treatment cycle) Posttreatment 
Follow -up 
Phaseb 
  Cycle 1  Cycle 1  Cycle 2  Cycle 3 until 
End-of-Treatment  Dose Escalationw 
(4.7 to 9.4 mg/kg)  End-of-Treatment 
Visit   
 Day -21 to -1 Day 1  Day 8, 15  Day 1, 8, 15  Day 1   Within 30  days 
after last dose  Every 16 weeks  
Study Procedures          
EORTC QLQ -C30 questionnaire   Xm X (D8 
only)  X (D1 only)  X and also at 
Week  24n  X X 
EQ-5D-5L questionnaire   Xm  X( D1 only)  X and also at 
Week  24n  X X 
BPI questionnaire   Xm X (D8 
only)  X( D1 only)  X and also at 
Week  24n  X X 
PGIC questionnaire    X (D8 
only)   Only at Week 24n  X  
Survival status         X 
Clinical Laboratory Assessments          
Hematologyo X X X X X X X  
Expanded liver function panelp X If adverse event of interest occurs   Xp Xp 
Chemistryo X X X X X X Xo Xo 
INR (or PT) and aPTTq X X  X (D1 only)  X  X   
Pharmacokinetics          
PK samplesr  X  X (D1 only)  Xr  Xr   
Immunogenicity samples   X (pre -
dose)    X (pre -dose D1)   
X X (first visit if 
feasible)  
Pharmacodynamics          
TA, TL and hTERT   Xs X (D8 
only) X (D1 only) At time of CR/PR  Xv 
X (at progression)   
Biomarkers          
Blood samples for mutation 
analysis  X At time of CR/PR and every 12 weeks thereafter   
X (at progression)   
BM aspirate/peripheral blood for 
cytogeneticst X For subjects with baseline cytogenetic abnormalities at time of 
CR/PR and at each subsequent BM biopsy   
X (at progression)   
Blood samples for 
immunophenotyping  X   X (D1 only)  At time of CR/PR   
X (at progression)   
Ongoing Subject Review          
Concomitant therapy  X Continuous  X  
Adverse events  X Continuous  X  
Subsequent therapy     X Xu 
Abbreviations: ALP=alkaline phosphatase; ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate aminotransferase; BM = bone marrow;  
BPI = Brief Pain Inventory  (Short Form) ; CR = complete remission; D1 = Day 1; ECG=electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EORTC QLQ -C30 = 
European Organization for Research and treatment of Cancer (EORTC) QLQ -C30; EQ-5D-5L = EuroQol -EQ-5D; INR = international normalized ratio; IWG -MRT = International 
Working Group – Myeloproliferative Neoplasms Research and Treatment; JAK = Janus kinase; LFT=liver function test; MFSAF = Myelofibrosis Symptom Assessment Form; MRI 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
25 
Status: Approved , Date: 28 March 2019  = magnetic resonance imaging;  PGIC = Global Impression of Change; PK=pharmacokinetic; PR = partial remission; PT = prothrombin time; RBC = red blood cell ; ULN = upper 
limit of normal; WBCs  = white blood cells  
Footnotes:  
a A treatment cycle is defined as 21 days ± 3 days.  Subjects shou ld start study treatment within 72 hours after randomization.  Any subject already in the Screening Phase at the 
time study enrollment was suspended, and who was subsequently determined to be eligible for the study, was allowed to proceed with treatment assignment to the 9.4 mg/kg 
arm per investigator discretion , subject agreement , and IRB/IEC notification . 
b Post-treatment follow -up can be performed via a clinic visit or a phone call  every 16 weeks ± 7 days . 
c Assessment of RBC transfusion requirements 1 2 weeks prior to baseline and at each clinic visit.  
d Screening for hepatitis will include comprehensive hepatitis serology A  through E. Hepatitis D serology is only required if the subject tests positive for the hepatitis B surface 
antigen (HBsAg).  
e Screening symptoms using the Screening Myelofibrosis Symptom Form must be completed  and as close as possible 
to Day -7, prior to the start of the modified MFSAF v2.0 e -diary.  Subjects should start th e MFSAF v2.0 e -diary  
f Only a limited symptom -directed physical examination including spleen palpation  and measurement . Weight assessment is required on Day 1 of all cycles after baseline.  
g Vital s igns should be measured and recorded prior to imetelstat infusion and will include measurements of temperature, pulse/ heart rate, and systolic and diastolic blood 
pressure, preferably while the subject is in a seated position.  
h Abdominal MRIs will be perf ormed on all subjects at baseline, then every 12 weeks up to Week 48, then every 24 weeks until disease progression or unacceptable toxicity , and  
at the time of CR/PR . MRIs are required within 30 days after last dose of study drug for the End-of-Treatment  Visit, unless an MRI confirming disease progression or leading 
to treatment discontinuation was already performed . A follow -up MRI will be performed 3 months after the subject’s last dose of study drug , if feasible. All scans will be read 
locally for volum e measurement and by a central review facility. Abdominal MRI includes a portion  of the pelvis when  the spleen protrudes into the pelvic cavity. After 
baseline, scans can be performed with a window of ± 7 days.  Abdominal MRI for spleen assessment at screening must be completed  
 and as close as possible to randomization.  Subjects who have their dose increased from 4.7 mg/kg to 9.4 mg/kg must have an abdomina l MRI performed 
 with 9.4  mg/kg.  
i The edge of the spleen shall be determined by palpation, and measured in centimeters from the costal margin to the point of g reatest splenic protrusion.  Assessments wi ll be 
performed every 12 weeks up to Week 48, then every 24 weeks until disease progression or unacceptable toxicity , and at the time of CR/PR.  Spleen palpation at screening must 
be completed . Follow -up spleen palpation will be performed 3  months after the subject’s last dose of study drug, if 
feasible.  Subjects who have their dose increased from 4.7 mg/kg to 9.4 mg/kg must have spleen palpation conducted within approximately 14 days before starting t reatment 
with 9.4  mg/kg.  
j Bone marrow aspirate (if clinically feasible) and biopsy must be performed during screening or up to 60 days before randomization . All subjects must have baseline bone 
marrow evaluation, and then repeat bone marrow evaluation every 24 weeks and at time of suspected CR/PR until disease progression . After CR/PR is observed a repeat bone 
marrow evaluation should be obtained 12 weeks later for response confirmation. Fibrosis assessment will be performed on the biopsy by a central p athologist. After baseline, 
bone marrow biopsy can be performed with a window of ± 7 days.  A sample of bone marrow aspirate and a time -matched plasma sample  will be collected, if feasible, 24 -48 
hours after imetelstat dosing at Weeks 24 and 48  for evaluati on of imetelstat concentration . 
k Peripheral blood smear will be performed every 12 weeks up to Week 48, then every 24 weeks until disease progression or unacc eptable toxicity and at time of CR/PR. 
Peripheral blood smear review will be performed by a centr al pathologist.  
l MF Symptom Recall Form will be completed starting after Week 48, on Day 1 of every cycle at time of other PROs, and at time o f CR/PR if occurring after Week 48.  
m EORTC QLQ -C30 questionnaire, EQ5D -5L, and BPI questionnaires on Cycle 1 Day  1 should be completed prior to the first dose of study treatment.  
n Week 24 PRO questionnaires should be performed the same day as Week 24 MRI.  
o Hematology and chemistry laboratory assessments to determine subject eligibility must be performed within 21 days prior to randomization . The last result obtained prior to 
randomization will be used to determine eligibility.  Hematology assessment for eligibility must be completed . For 
Cycle 1, Day 1  only, clinical laboratory hematology and chemistry assessments do not need to be repeated if the Screening tests were performed wit hin 5 days of the first dose 
of study treatment. After Cycle 1, Day 1, required laboratory tests must be performed within 48  hours prior to the scheduled visit. For subjects with AST, ALT, ALP or 
bilirubin Grade ≥3, laboratory assessments need be to repeated weekly until bilirubin with fractionation is <3  x ULN , and AST, ALT  and ALP  are <5 x ULN. Subjects with 
Grade 1 and Grade 2 treatment emergent elevations in AST, ALT, ALP  or bilirubin at time of treatment discontinuation should continue to have laboratory assessments 
monthly until resolution to at least baseline . For further guidance on liver function tests, see section on labo ratory evaluations in Section 9.8. Subjects who have their dose 
increased f rom 4.7 mg/kg to 9.4 mg/kg must meet the eligibility criteria for hemato logic laboratory values (inclusion criterion 8.1) and biochemical laboratory values (inclusion 
criterion 9.1)  before starting treatment with 9.4  mg/kg.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
26 
Status: Approved , Date: 28 March 2019  p An expanded liver panel should be performed at screening. Thereafter, if an adverse event of interest is reported, then an expanded liver panel should be performed which 
should include GGT, chlori de, bicarbonate, magnesium, and fractionated bilirubin . The expanded liver panel will need to be repeatedly weekly until adverse event of interest 
has resolved.  
q Repeat INR (or PT) and aPTT during study if subject has a hemorrhagic event.  
r Sparse PK sampling will be performed in all subjects. In a subset of subjects, intensive PK sampling will be performed for a maximum o f 7 time  points in approximately 
10 subjects per treatment arm . Refer to the Time & Events Schedule ( PK Sampling) for detail s. All subjects , regardless of imetelstat dose received,  must have a 2-hour 
postdose (ie, immediately before the end of infusion) PK sample collected each time  imetelstat is administered , beginning with Cycle 3  and continuing until the sponsor 
determines that the PK objective has been met and notifies investigators that blood collection for this PK analysis can stop . Sparse PK samples must be collected for subjects 
who have their dose increased from 4.7 mg/kg to 9.4 mg/kg during the first cycle at the higher dose. Refer to the Time and Events Schedule (PK Sampling) for details.  
s A pre-dose and 24 hours post -dose blood sample, if feasible, will be obtained for determination of TA, TL and hTERT . 
t Where clinically feasible, bone marrow aspirates will be collected for cytogenetic testing. Peripheral blood may be submitted  in place of an aspirate only if  a bone marrow  
aspirate cannot be obtained . The same sample type collected at screening must be collected throughout the subject’s participation in the study  if possible. The sponsor  will 
notify the sites to specify which subjects have a cytogenetic abnormality based on  baseline analysis and will need to have subsequent BM aspirate samples collected.  
u Subsequent anti-MF treatment to be collected throughout posttreatment follow -up phase . 
v For subjects who have their dose increased from 4.7 mg/kg to 9.4 mg/kg, 4 additional blood samples for PD analysis ( TA, TL and hTERT ) are required  during the first 2 cycles 
receiving  the 9.4 mg/kg dose at the following time points: first cycle at 9.4 mg/kg  Day 1 predose and 24 hr postdose (if feasible) ; first cycle at 9.4 mg/k g Day 8 ; and second 
cycle at 9.4  mg/kg  Day 1 pre -dose.  
w Beginning with Protocol Amendment 2, subjects in Arm B (4.7 mg/kg) may continue to receive their current imetelstat dose  or have the dose increased to 9.4 mg/kg at the 
investigator’s discretion and according to the guidance provided in Section 6. Dose escalation for these subjects  may occur at  any cycle of the Treatment Phase. Subjects who 
have their dose increased  will have additional MRI and spleen assessments before receiving the first dose of imetelstat 9.4 mg/kg . Additional blood samples will be collected 
for biomarker assessm ents before and after the first dose of imetelstat 9.4 mg/kg, and blood samples for PK assessment will be collected after receiving the first dose of 
imetelstat 9.4 mg/kg.   
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
27 
Status: Approved , Date: 28 March 2019  TIME AND EVENTS SCHE DULE (EXTENSION  PHASE ) 
Use this Time and Events Schedule after local IEC/IRB approval of Amendment 3 . 
Study Procedures  All Subjects  Extended Treatment  
(21-day treatment cycle)   
Extended Follow -up 
(Every 16 weeks  ± 7 days ) 
Informed consent  Xa   
Dispense/administer study drug   X (Day 1)   
Serious adverse event monitoringb  Xb   
Survival status    Xc 
a All subjects must provide informed consent to enter the Extension Phase. This must occur before the first dose of imetelstat for subjects continuing treatment in the 
Extension Phase.  
b Submit a Serious Adverse Event Form to the sponsor within 24 hours of awareness of the event for all serious  adverse events. If the subject has a hemorrhagic serious 
adverse event, INR (or PT) , aPTT , and platelet count will be assessed and reporte d in the serious adverse event report. If the subject experiences a hepatic serious adverse event, 
serum chemistry and an expanded liver panel will be assessed  and reported ; if the event includes Grade 3 or 4 ALP elevation, ALP fractionation or 5’neucleoti dase will also be 
assessed  and reported . Serious adverse events will be reported from the time the  Extension Phase  ICF is signed and dated until 30 days after the last dose of imetelstat .  
c Assessment of survival status is required for all subjects who enter the Extension Phase , including those who discontinued  treatment  during the main study .  
 
 
 
 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
28 
Status: Approved , Date: 28 March 2019  TIME AND EVENTS SCHE DULE (PK SAMPLING)  
Study Day  PK Blood  
Sampling Timea Serial (Intense) PK 
Blood Samplingb Sparse PK Blood 
Samplingb Sparse PK Blood 
Sampling  
Dose Escalation  
(4.7 to 9.4 mg/kg)e 
Cycle 1, Day 1  0 (before start of 
infusion)  X   
Cycle 1, Day 1 1 h X   
Cycle 1, Day 1  2 hc X   
Cycle 1, Day 1  3h-5h X   
Cycle 1, Day 1  6h-10h X   
Cycle 1, Day 1  12h-16h X   
Cycle 1, Day 1  18h-24h X   
     
Cycle 1, Day 1  0 (before start of 
infusion)     
Cycle 1, Day 1  2 hc  X  
Cycle 1, Day 1  3h-6h  X  
Cycle 1, Day 1  8h-12h  X  
Cycle 1, Day 1  16-24hd  X  
     
Cycle 2, Day 1  0 (before start of 
infusion)     
Cycle 2, Day 1  2 hc  X  
Cycle 2, Day 1  3h-6h  X  
Cycle 2, Day 1  8h-12hd  X  
     
First Cycle 9.4 mg/kg, 
Day 1  0 (before start of 
infusion)     
First Cycle 9.4 mg/kg, 
Day 1  2 hc   X 
First Cycle 9.4 mg/kg, 
Day 1  3h-6h   X 
First Cycle 9.4 mg/kg, 
Day 1  8h-12h   X 
First Cycle 9.4 mg/kg, 
Day 1  16-24hd   X 
     
Every cycle starting 
from Cycle 3f 2 hc X X X 
a  All sampling times are relative to the start of the imetelstat infusion.  
b  Of the subjects who participate in the study and receive imetelstat, approximately 10 subjects per arm  will undergo serial PK 
blood sample collections, with the remaining subjects undergoing sparse PK sampling . 
c  Immediately before end of the infusion . 
d  If feasible . 
e  Subjects who have their dose increased from 4.7 mg/kg to 9.4 mg/kg will have sparse PK samples collected during the first 
cycle receiving 9.4 mg/kg.  
f  All subjects, regardless of imetelstat dose received, must have a 2 -hour postdose (ie,  immediately before the end of infusion) 
PK sample collected each time imetelstat is administered , beginning with Cycle 3 and continuing until the sponsor determines 
that the PK objective has been met and notifies investigators that blood collection for th is PK analysis can stop.  In addition, time -
matched plasma PK samples will be collected for subjects with bone marrow aspirate (if feasible) at Weeks 24 and 48.   
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
29 
Status: Approved , Date: 28 March 2019  ABBREVIATIONS  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
AUC  area under the curve  
BAT  best available therapy  
βhCG  beta human chorionic gonadotropin  
BM bone marrow  
BPI Brief Pain Inventory  (Short Form)  
CFU -Meg megakaryocyte colony -forming unit  
CFU -MK malignant megakaryocyte colony -forming unit  
CI clinical improvement  
CL clearance  
Cmax maximum plasma concentration  
CR complete remission  
CRF  case report form  
CSC  circulating stem cells  
DCF  data clarification form  
DIPSS  Dynamic International Prognostic Scoring System  
DMC  Data Monitoring Committee  
DSM -IV Diagnostic and Statistical Manual of Mental Disorders (4th edition)  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
eDC electronic data capture  
Emax maximum efficacy  
EMH  extramedullary hematopo iesis 
EORTC QLQ -C30 European Organization for Research and treatment of Cancer (EORTC) QLQ -C30 
EQ-5D-5L EuroQol -EQ-5D 
ET essential thrombocythemia  
EU European Union  
FDA  Food and Drug Administration  
FFPE  formalin -fixed, paraffin -embedded  
G-CSF granulocyte colony stimulating factor  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transpeptidase  
Hb hemoglobin  
HBsAg  hepatitis B surface antigen  
HEENT  head, eye, ear, nose, and throat  
HIV human immunodeficiency virus  
HR heart rate  
hTERT  human telomerase reverse transcriptase  
IAC Interim Analysis Committee  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
INR international normalized ratio  
IRB Institutional Review Board  
IRC Independent Review Committee  
IV intravenous  
IVRS  interactive voice response system  
IWG -MRT  International Working Group – Myeloproliferative Neoplasms Research and Treatment  
IWRS  interactive web response system  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
30 
Status: Approved , Date: 28 March 2019  JAK Janus kinase  
LCM  left costal margin  
LC-MS/MS  liquid chromatography/mass spectrometry/mass spectrometry  
LDH  lactic acid dehydrogenase  
LFT liver function test  
MDS  myelodysplastic syndrome  
MedDRA  Medical Dictionary f or Regulatory Activities  
MF myelofibrosis  
MFSAF  Myelofibrosis Symptom Assessment Form  
MM multiple myeloma  
MPN  myeloproliferative neoplasm  
MRI  magnetic resonance imaging  
MRU  medical resource utilization  
NCI-CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
NGS  next-generation sequencing  
NONMEM  nonlinear mixed effects modeling  
OS overall survival  
PBMC  peripheral blood mononuclear cells  
PD pharmacodynamic(s)  
PET-MF post-essential thrombocythemia -myelofibrosis  
PGIC  Global Impression of Change  
PK pharmacokinetic (s) 
PMF  primary myelofibrosis  
PPV-MF post-polycythemia vera -myelofibrosis  
PQC  product quality complaint  
PR partial remission  
PRO  patient -reported outcome(s)  
PT prothrombin time  
PV polycythemia vera  
QRS  part of electrocardiographic wave representing ventricular depolarization  
RBC  red blood cell  
RNA  ribonucleic acid  
SD standard deviation  
SIPM  Site Investigational Product Manual  
STAT  signal transducers and activators of transcription  
SUSAR  suspected unexpected serious adverse reaction  
SVR  spleen volume reduction  
TA telomerase activity  
TI transfusion independence  
TIC tumor inducing cell  
TGI tumor growth inhibition  
TIW  3 times per week  
TL telomere length  
TRAP  telomere repeat amplification protocol  
TSS Total Symptom S core 
ULN  upper limit of normal  
USP United States Pharmacopeia  
V volume of distribution  
WBC  white blood cell  
WHO  World Health Organization  
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
31 
Status: Approved , Date: 28 March 2019  1. INTRODUCTION  
For the most comprehensive nonclinical and clinical information regarding imetelstat , refer to the 
latest version of the Investigator's Brochure (IB) and IB Addenda for imetelstat .21 The term 
"sponsor " used throughout this document refers to the entities listed in the Contact Information 
page(s), which will be provided as a separate document.  
1.1. Background  
1.1.1.  Imetelstat  
Imetels tat is a covalently -lipidated 13 -mer thiophosphoramidate oligonucleotide that acts as a 
potent specific inhibitor of telomerase. Telomerase inhibition leads to loss of a cancer cell’s ability 
to maintain telomere length, resulting in cell -cycle arr est, apo ptosis, or senescence. Imetelstat  
binds with high affinity to the template region of the ribonucleic acid (RNA ) component of human 
telomerase reverse transcriptase (hTERT) and is a competitive inhibitor of telomerase enzymatic 
activity .3,19 Treatment of various cancer cells with imetelstat in vitro increases their sens itivity to 
radiation, decreases their clonogenic potential, and results in altered expression of stem -cell related 
genes.14,16 
1.1.2.  Myelofibrosis  
Myelofibrosis (MF) is classified as one of the  myeloproliferative neoplasm s (MPN ), a group of 
related clonal disease s that includes polycythemia vera (PV ) and essential thrombocythemia (ET) . 
MF can arise on its own (primary myelofibrosis, [PMF]), or as a progression of polycythemia vera 
(post -PV-MF) or essential thrombocythemia (post -ET-MF). The manifestations of PMF, post -PV-
MF and post -ET-MF are virtuall y identical and treatment is generally the same for all 3 (World 
Health Organization [WHO] classification 2008). The disease is characterized by clonal 
myeloproliferation, ineffective erythropoiesis, bone marrow stromal changes, hepatosplenic 
extramedullar y hematopoiesis and aberrant cytokine expression.30 Patients present with 
splenomegaly, constitutional symptoms, moderate to severe anemia, thrombocytopenia and 
leukocytosis.  
There is a strong association between survival after the diagnosis of MF and the Dynamic 
International Prognostic Scoring System (DI PSS) risk category . Patients in the  low risk category 
have more than 15 years median survival . Patients with  intermediate risk -1, intermediate risk -2 or 
high risk have median survivals of 14.2, 4, and 1.5 years , respectively .27 Approximately  70% of 
individuals with MF are in the intermediate -2 or high -risk categories ,15 representing the greatest 
unmet medical need. Symptomatic enlargement of the spleen and liver, the necessity for red cell 
transfusions, cachexia , and the other MF -associated symptoms result i n compromised quality of 
life for these patients.26 
1.1.3.  Treatment Options for Myelofibrosis  
Allogeneic stem cell transplantation is the only treatment that can induce long -term remission of 
MF. However , many patients will not be transplanted beca use of the advanced age at which MF is 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
32 
Status: Approved , Date: 28 March 2019  diagnosed (mean=65 years) . Hydroxyurea, interferon, and, more recently , Janus kinase (JAK) 
inhibitors have been evaluated in clinical studies.  Treatment with these agents may result i n a 
spleen volume  reduction (SVR ), alleviation of discomfort due to splenomegaly,  and improvement 
in anemia, but not in an anti -clonal effect.  
In recent years, the understanding of MPNs in general and the molecular mechanisms of these 
diseases, including MF, has improved . In 2005, the JAK2V617F mutation was discovered . This 
mutation is  observed in approximately 50%  to 60% of patients with PMF and ET, and  in 90% to 
95% of patients with PV. This discovery , and the observation of other mutations that activate the 
JAK/signal transducers and activators of transcription (STAT) pathway established dysregulation 
of the JAK signaling pathway as the major c ontributor to the pathogenesis of MPNs. It also led to 
the development of small -molecule JAK inhibitors.  
The JAK1/2 inhibitor ruxolitinib currently is the only approved therapy for MF. Two randomized, 
controlled studies (COMFORT -I and COMFORT -II) compared ruxolitinib to placebo and to the 
best available therapy (BAT), respectively. The studies demonstrated benefit, with a significantly 
higher proportion of subjects in the rux olitinib arms exhibiting a ≥35%  reduction in spleen volume 
as measured by magnetic resonance imaging at 24 weeks in COMFORT -I (41.9% ruxolitinib v s. 
0.7% placebo) and a t 48 weeks in COMFORT -II (28.5%  ruxolitinib v s. 0% BAT).33,17 In 
COMFORT -I there was >50% improvement in the Total Symptom Score (TSS) measured by the 
Myelofibrosis Symptom Assessment Form (MFSAF) at 24 weeks in 45.9% of ruxolitinib subjects 
compared with 5.3% of placebo subjects. In COMFORT -II, 2 quality of life measures were used 
to assess symptom improvement, and both demonstrated a significant response in the ruxolitinib 
treated group. Improveme nt in survival among patients treated with ruxolitinib was demonstrated 
in COMFORT -I (8.4% mortality vs. 15.6%  with BAT ) and in a 3 -year follow -up of the 
COMFORT -II study . The median survival at the time of publication had not yet been reached ; 
however , treatment with ruxolitinib led to a 52% risk of death reduction as compared with BAT.9 
The benefit of ruxolitinib therapy in terms of spleen response and constitutional symptoms is 
associated with a lower rate  of treatment -associated anemia (40.4% v s. 12.3% for BAT) and 
thrombocytopenia (44.5% v s. 9.65% for BAT).18 The 1 -, 2-, and 3 -year discontinuation rates are 
49%, 71% and 86%, respectively. Major reasons for discontinuation are loss of therapeutic effect, 
lack of response and drug -induced cytopenias . Based on the 2013 International Working Group – 
Myeloproliferative Neopla sms Research and Treatment (IWG -MRT) response criteria for efficacy 
in patients with MF,28 no subjects achieved complete remission (CR) or partial remission (PR) on 
treatment with ruxolitinib,2 suggesting that ruxolitin ib does not affect the underlying neoplastic 
process.  
Responses to ruxolitinib are typically observed within the first 3  to 6 months after therapy 
initiation .33,17 It has been suggested that for patients who have not had a reduction in spleen size 
or improvement in symptoms after that period, alternative therapies should be considered.23 The 
median survival for patients who relapse after treatment with or are refractory to ruxolitinib is 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
33 
Status: Approved , Date: 28 March 2019  6 months.22 Therefore, there remains a need for effective treatments for the patients who have been 
treated previously with a JAK inhibitor.  
Imetelstat, a first -in-class telomerase inhibitor, may provide clinical benefit to MF patients . In 
patients previously treated with a JAK inhibitor,  imetelstat may improve clinical signs and 
symptoms and may  induce CR and PR including normalization of fibrotic bone marrow .29 This is 
likely due  to its novel mechanism of action compared with available therapies, such as JAK 
inhibitors.  
1.1.4.  Rationale for Us e of Imetelstat in Myeloproliferative Neoplasm ( MPNs ) 
Myelofibrosis is characterized by clonal myeloproliferation that arises from malignant progenitor 
cell clones that have shorter telomeres and  multiple clonal genetic abnormalities. Telomerase is 
highly activated and continually upregulated in malignant progenitor clones , enabling continued 
and uncontrolled proliferation. While telomerase activity (TA) is generally undetectable in normal 
somatic cells, it is expressed in approximately 85% of human cancers , as well as in cancer 
progenitor cells, which are believed to play a critical role in dysregulated cell growth and tumor 
metastasis.16 Telomerase activity (as measured in granulocytes) is high in patients with 
myeloproliferative neoplasms.12 Telomere length (TL) in patients with myeloproliferative 
neoplasms is short, regardless of JAK2 mutational status . Therefore, telomerase inhibition may be 
effective in both JAK2V617F and JAK2 wild -type MF.31,13,7 
Emerging data suggest that malignant hematopoietic progenitor cells are more susceptible than 
normal progenitor cells to telomerase inhibition, which results in  telomere shortening and 
apoptotic cell death. Several preclinical studies have shown that imetelstat is an effective inhibitor 
of clonogenicity and proliferation of malignant progenitor cells derived from primary patient 
samples with myeloproliferative ne oplasms such as MF. A study of CD34+ progenitor cells 
isolated from either normal cord blood or from MF patients treated with imetelstat ex vivo showed 
that the drug had minimal effect on proliferation and apoptosis of normal CD34+ cells but a 
profound eff ect on CD34+ cells from MF patients, which leads to reduction of colony formation 
and depletion of malignant progenitor cells.34 
In vitro studies ha ve demonstrated that imetelstat selectively inhibits spontaneous megakaryocytic 
colony -forming unit (CFU -Meg) growth from the blood of patients with MPNs such as ET, but 
not from healthy individuals . Inhibition of neoplastic progenitor cell growth was obse rved ex -
vivo.5 Furthermore, imetelstat demonstrated the ability to reduce selectively the malignant 
megakaryocyte colony -forming unit (CFU -MK) from patients with MF and ET, but had a minimal 
effect on clonogenicity of normal MK progenitors.20 
In the Phase 2 Study CP14B015 in ET , which is the fir st proof of concept study in hematological 
malignancies, patients who were resistant to, intolerant of or had refused conventional therapies  
were enrolled. I metelstat induced and maintained hematologic responses in 100% of the subjects, 
with 16 of 18 (89%)  achieving a complete response . Ten of 18 (56%) patients remain on 
maintenance therapy (median duration of treatment is 18 months; range 7.5 –34.5 months) and 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
34 
Status: Approved , Date: 28 March 2019  continue to be responsive to imetelstat . Importantly, 7 of 8 subjects with the JAK2V617F mutation 
achieved partial molecular response with 72% to 96% reduction in allele burden.4 In addition, 
imetelstat accumulates in bone marrow , has the ability  to target circulating stem cells (CSCs) and 
tumor inducing cells (TICs) , inhibit s CFU -MK in vitro , and target s diseases with short TL. All 
such properties are relevant to patients with MF and myelodysplastic syndrome (MDS)/MPN, 
which arise from malignant progenitor cell clones , have short TLs, and highly active telomerase. 
These data suggest that imetelstat can selectively inhibit neoplastic clonal proliferation in patients 
with ET, and provided the rationale for evaluating imetelstat in patients with othe r MPNs, such as 
MF. 
1.1.5.  Study CP14B019 With Imetelstat in Myelofibrosis  
An open -label, Phase 2 (Study CP14B019) study was conducted to evaluate the safety and efficacy 
of single -agent imetelstat in patients with DIPSS -plus intermediate -2 or high -risk PMF, PPV -MF, 
or PET -MF, blast phase MF , and MDS patients . The primary endpoint for the MF cohorts of the 
study was overall response rate, defined as clinical improvement ( CI), PR, or CR, consistent with 
IWG -MRT criteria.28 Secondary endpoints included safety, reduction of spleen size by palpation, 
improvement in anemia, or achievement of red blood cell transfusion independence.  
As of Dec ember  2014, preliminary data from 33 subjects with MF are available. Subjects in Arm 
A (n=19) received i metelstat 9.4 mg/kg on Day 1 every 21 days. Subjects in Arm B (n=14) received 
9.4 mg/kg imetelstat on Days 1, 8 and 15 of Cycle 1, followed by 9.4 mg/kg on D ay 1 every 21 
days for subsequent cycles.  
The median age of the eligible subjects was 67 years. Eighteen (54.5%) subjects had primary MF, 
5 (15.2%) subjects had post -ET MF, and 10 (30.3%) subjects had post -PV MF. Sixteen (48.5%) 
subjects had intermediate -2 risk MF and 17 (51.5%) subjects had high risk MF. Thirteen (39.4%) 
subjects were transfusion dependent  at entry ; 23 (69.7%) subjects had a palpable spleen (median 
spleen size =15 cm below the costal margin)  and 21 (63.6%) had symptoms at baseline. The 
majority of the subjects (26 [78 .8%]) had prior treatment including 16 (48.5%) who had received 
a prior JAK inhibitor.  
1.1.5.1.  Clinical Efficacy  Results  
Twelve of the 33 subjects (36.4%) achieved a response (C R+PR+CI) as defined by 2013 
IWG -MRT criteria. In Arm A, 7  (36.8%) of 19 subjects achieved a response and in Arm B, 
5 (35.7%) of 14 subjects achieved a response. Seven (7)  subjects (4 in Arm A and 3 in Arm B) had 
a CR or PR, and 4 of these subjects (3 in Arm A and 1 in Arm B) had a CR. Five (5)  subjects 
(15.2%) had CI , 4 (12.1%) by spleen reduction (3 subjects in Arm A and 1 subject in Arm B) and 
1 (3%) by anemia improvement (in Arm B).29 
All 4 of the subjects who had CR had reversal of bone marrow fibrosis and 3 of the 4 achieved a 
molecular response. Four subjects who initially achieved PR converted to CR with continued 
treatment. The median time to onset of response was 1.6 months (range 0.7 to 5.6  months) and the 
responses were durable with a median of 14 m onths (range 4.4 -18.9 months) .29 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
35 
Status: Approved , Date: 28 March 2019  1.1.5.1.1.  Spleen and Anemia Response  
Spleen and  anemia response s were  assessed according to the 2013 IWG -MRT criteria . Eight 
(34.8%) of 23 subjects with baseline splenomegaly had a spleen response (5 of 14 subjects in Arm 
A and 3 of 9  subjects in Arm B)  defined as ≥50% spleen size reduction by palpatio n lasting at least 
12 weeks . Four  (4) of 13 (30.8%)  subjects who were trans fusion dependent at baseline (3  of 8 
subjects in Arm A and 1 of 5 subjects in Arm B) became transfusion independent during the 
study .29 Among 7 subjects who had CR or PR, 4 subjects with splenomegaly at baseline also 
achieved splenic response, and 3 subjects who were transfusion dependent at baseline became 
transfusion indepe ndent . Additional analysis of spleen response, defined as ≥50% spleen size 
reduction by palpation at 24  weeks from treatment initiation , were performed and 9 (39.1%) of 23 
evaluable subjects (6  subjects in Arm A and 3 subjects in Arm B) had a response.  
1.1.5.1.2.  Constitutional Symptoms  
Study CP14B019 did not use a patient -reported outcomes (PROs) instrument to assess symptoms . 
However , the presence of constitutional symptoms such as fever, weight loss, night sweats, and 
bone pain were documented at baseline and asses sed by physician s during the study. Among the 
subjects who achieved CR and PR in both Arms A and B, 4  of 7 had constitutional symptoms at 
baseline and all demonstrated resolution of symptoms  by the onset of the response .  
1.1.5.1.3.  Subject Status and Time on Treatment  
The median duration of treatment was 8.6 months (range 1.4 to 21.7 months) for all 33  subjects in 
Arms A and B. The median duration of treatment was  15.5 months (range 6.5 to 21.7  months) for 
the subjects with CR, PR, or CI, 15.5 months (range 1 4.0 to 21.7 months) for subjects with CR or 
PR, and 6.9 months (range 1.4 to 19.3 months) for subjects with stable disease. Subjects who did 
not have CR, PR, CI, or evidence and maintenance of clinical benefit (defined as ≥50% 
improvement in leukocytosis, a ≥50% improvement in thrombocytosis, a ≥50% decrease in 
palpable splenomegaly, or a ≥50% improvement in RBC transfusion requirement ) were 
discontinued from treatment even if they did not meet c riteria for progression. Of the 33 subjects, 
25 (75.8%) discon tinued treatment, 16 (48.5%) of whom discontinued due to insufficient response 
or the start of alternative therapy. Two (2)  subjects progressed and 1 subject relapsed while on 
treatment. Two (2)  subjects (6.1%) discontinued due to an adverse event. As of t he cut -off date 
(Dec ember  2014) for this analysis, 8 subjects are still on treatment, 6 of them with ongoing CR, 
PR, or CI.  
1.1.5.1.4.   Efficacy Data in Subjects Previously Treated With a JAK Inhibitor  
The data from this study suggest that treatment with imetelstat may provide benefit to patients 
previously treated with a JAK inhibitor. Among the 16 subjects who were previously treated with 
a JAK inhibitor, 5 (31.3%) achieved a response (CR+PR +CI; as def ined by the 2013 IWG -MRT 
criteria). Two  (2) subjects had CR and 1 had PR. In addition, 2 subjects had CI , 1 subject by 
improvement in spleen volume  and 1 subject by improvement in anemia. Three  (3) of 11 subjects 
(27.3%) evaluable for spleen response had a spleen  response that was durable for at least 12 weeks 
and 3 of 7 (42.9%)  transfusion -dependent subjects became transfusion independent during the 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
36 
Status: Approved , Date: 28 March 2019  study. Additional analysis of spleen response, defined as ≥50% spleen size reduction by palpation 
at 24 week s from treatment initiation, was performed : 3 of 11 (27.3%) evaluable subjects had a 
response.  
1.1.5.2.  Clinical Pharmacology of Imetelstat  
Single -dose kinetics showed dose dependent increases in exposure with half -life ranging from 4  to 
5 hours. At the 6  mg/kg to 11.7 mg/kg range, imetelstat clearance  appears to be independent of 
dose. The excretion and metabolism of imetelstat has not been evaluated in the clinical setting. 
However, it is anticipated that imetelstat is predominantly metabolized in systemic circula tion and 
its component fragments are excreted mainly via the urinary tract, as observed for other 
oligonucleotides. Drug interaction potential has not been tested clinically.   
1.1.5.3.  Clinical Safety of Imetelstat in Myelofibrosis  
1.1.5.3.1.  Hematologic Toxicities  
Cytopenias , in particular thrombocytopenia, are dose -limiting in both single -agent imetelstat 
studies and when imetelstat is combined with other chemotherap y. The frequency and severity of 
all cytopenias, particularly thrombocytopenia and neutropenia, was associated  with the dose 
intensity (dose and frequency of dosing) of imetelstat, concomitant administration with other 
cytotoxic agents, the number and nature of prior chemotherapy regimens to which patients had 
been exposed , and low marrow reserve.  
In Study CP14B019, the incidence of treatment -emergent Grade 3 and 4 thrombocytopenia in Arm 
A was 42.1% and 10 .5% respectively. Seven ( 7; 36.8%) subjects from this arm required dose 
reduction, and 2 discontinued following these events. No major bleeding events or deaths due to 
thrombocytopenia were reported in this arm. There appear ed to be more pronounced toxicity  for 
Arm B : treatment -emergent Grade 3 thrombocytopenia was 7.1% and Grade 4 was 35.7%. Five 
(5; 35.7%) subjects in this arm required dose reduction, but none discontinued due to 
thrombocytopeni a. One subject  (1) died after suffering intracerebral hemorrhage in the setting of 
Grade 4 thrombocytopenia and febrile neutropenia.  
The incidence of treatment -emergent Grade 3 and 4 neutropenia in Arm A was 21.1% and 10.5% , 
respectively. Three (3) subjects from this arm required dose reduction following Grade 3 or 
4 neutropenia, but none discontinued due to this event. Again, there appear ed to be more 
pronounced toxicity  for Arm B : treatment -emergent Grade 3 and Gr ade 4 neutropenia were 
reported for 14.3% and 28.6%  of subjects , respectively. Four (4) subjects in this arm required dose 
reduction, but none discontinued due to this event.  No Grade 4 treatment -related anemia was 
reported . A higher number of Grade 3 events w as reported in Arm B than in Arm A (64.3%  vs. 
42.1%).  In conclusion, hematologic toxicities were less pronounced in Arm A and , from a safety 
perspective, this dose and regimen warrants further investigation.   
Refer to the latest version of the Investigator’s Brochure21 for updated information regarding 
hematologic toxicity.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
37 
Status: Approved , Date: 28 March 2019  1.1.5.3.2.  Non-Hematologic Toxicities  
In Study CP14B01 9, the incidence  of severe (Grade 3 or greater) non -hematologic adverse events 
was low . Events that happened in more than 1 subject are  as follows : fatigue in 3 patients , and 2 
patients each who had a prolonged  activated partial thromboplastin time  (aPTT ), atrial fibrillation, 
heart failure, hyperuricemia, and hyperkalemia.  
Refer to the latest version of the Investigator’s Brochure21 for updated infor mation regarding non-
hematologic toxicity.  
1.1.5.3.3.  Hepatotoxicity  
The adverse event s of concern in the clinical studies thus far have been liver function test ( LFT) 
abnormal ities or clinical hepatic adverse events . In Study CP14B019, in Arms A and B, worsening  
in aspartate aminotransferase (AST) (60.6%) is the most commonly  reported treatment -emergent 
LFT parameter , followed by alkaline phosphatase (ALP) (57.4%), total bilirubin (48.5%), and 
alanine aminotransferase (ALT) (42.4%). Worsening is defined as Nation al Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI -CTCAE)  grade elevated after baseline 
OR if baseline result  was > upper limit of normal (ULN) and on-study result  elevated to ≥ 1.5 x 
baseline. Most LFT abnormalities were Grade  1 and Grade 2, with only 3  subjects experienc ing 
Grade 3 events (2 with ALP and 1 with total bilirubin). No subject had Grade 3 or higher AST or 
ALT elevation. No hepatic adverse events attributed to imetelstat in MF subjects were reported 
and no treatment discontinuations or delays were due to LFT abnormalities. The CP14B -019 study 
is ongoing and LFT monitoring continues.  
Reversibility of liver function test abnormalities was demonstrated. Following cessation of 
imetelstat in the ET/PV and multiple myeloma study patients, there were no new liver -related 
adverse events and the LFT abnormalities resolved  in the majority of the patients whose data w ere 
available. However, the clinical significance and long -term consequences of the abnormal hepatic 
biochemistry findings with ongoing treatment remain unknown at this time. Severe hepatobiliary 
events, including acute hepatic failure and cirrhosis have been observed  and relationship to 
imetelstat cannot be excluded . 
Refer to the latest version of the Investigator’s Brochure21 for updated information regarding 
hepatotoxicity.  
1.1.6.  Target Engagement  With Imetelstat  
Preclinical and clinical target engagement data  suggest that ≥30% inhibition of telomerase is 
required to exert a measurable pharmacological effect. In the Phase 1 Study  CP05 -101, inhibition 
of telomerase activity (TA) in peripheral blood mononuclear cells (PBMC) was measured 24  hours 
after a single dos e of imetelstat (ranging from 4.8 mg/kg to 11.7 mg/kg) in 23 subjects. Telomerase 
activity was analyzed using the telomere repeat amplification protocol (TRAP) assay. Measurable 
inhibition of telomerase was observed across different doses. A maximum effica cy (E max) model 
was constructed to relate percent of TA change to the observed C max.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
38 
Status: Approved , Date: 28 March 2019   
 
  
1.1.7.  Differentiation of Response  by Exposure  
A dose of 4.7 mg/kg every 3 weeks was the minimum dose that engages the target, as demonstrated 
by telomerase inhibition. To evaluate the pharmacokinetic ( PK) overlap between the lower dose 
of 4.7 mg/kg and 9.4 mg/kg given every 3 weeks,  a population PK model was developed for 
imetelstat using a 2 -compartment target -mediated drug disposition model with saturable binding. 
The PK simulation result s showed minimal  overlap of exposure range (90%  confidence interval 
of both area under the curve  (AUC ) and maximum plasma concentration [C max]) associated with 
the 9.4 mg/kg dose and 4.7 mg/kg, thus theoretically allowing for a differentiated response.  
The data summarized above provide support for 9.4 mg/kg every 3 weeks as an effective and 
tolerable dosing regimen . A dose of 4.7 mg/kg is anticipated to be the lowest dose associated with 
a measurable level of target engagement. Exposures associated with the  4.7 and 9.4 mg/kg doses 
show minimal overlap . Therefore , these are  rational choice s to cover the potential  therapeutic 
range.  
In conclusion, data to date from Study CP14B019 show the overall response rate (CR+PR+CI, 
2013 IWG -MRT criteria) was 36.4%. Durab le remissions (CR+PR) evaluated per modified 2013 
IWG -MRT criteria were also seen. In addition, 34.8% of subjects had a spleen response (by 
palpation, lasting ≥ 12 weeks) and 30.8% of subjects who were transfusion dependent at baseline 
became transfusion i ndependent during the study. Thirty -nine point one percent  (39.1%) of 
subjects had a spleen response (50% reduction by palpation at 24 weeks) , including subjects  who 
were previously treated with a JAK inhibitor.  
The safety profile of imetelstat is consiste nt with its mechanism of action. The safety profile of 
Arm A (9.4 mg/kg every 21 days) is acceptable in the setting of patients with relapsed/refractory 
MF. Treatment -related cytopenias are expected in this population given their compromised bone 
marrow re serve and reliance on extramedullary hematopoiesis. These events can be managed by 
rigorous safety monitoring , timely dose modifications , transfusions and immediate treatment of 
patients with fever and neutropenia or other signs of infections . Liver functi on test abnormalities 
were mainly Grade 1 and 2 and were reversible . However,  they remain adverse event s of special 
interest that will be closely monitored.  Given the efficacy and safety findings from Study 
CP14B019, imetelstat 9.4  mg/kg every 21 days appears to have an acceptable balance of benefit 
and risk  in this patient population . 
1.2. Overall Rationale for the Study  
Myelofibrosis, particularly intermediate -2 or high risk disease, is a fatal condition. Ruxolitinib, a 
JAK inhibitor, is the only drug appr oved for the treatment of patients with intermediate or high 
risk MF. Several other JAK inhibitors such as pacritinib and momelotinib are currently in Phase  3 
development. For patients who have been previously treated with a JAK inhibitor, there is no 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
39 
Status: Approved , Date: 28 March 2019  approved therapy and the prognosis is very poor. Despite the demonstrated clinical activity of JAK 
inhibitor in MF, many subjects discontinued treatment . For example, the 3 -year discontinuation 
rates after treatment with ruxolitinib have been reported to be approximately 50%, with major 
reasons for discontinuation being loss of therapeutic effect and lack of respons e.30 The median 
survival of patients wit h relapsed and refractory MF who discontinued ruxolitinib has been 
reported to be 6 months.22 Therefore, there remains great unmet need for the pat ients who have 
been treated previously with a JAK inhibitor.  
Imetelstat, a first -in-class telomerase inhibitor, with its novel mechanism of action, may provide 
clinical benefit to MF patients. In addition to reduction in palpable splenomegaly in subjects 
previously treated with a JAK inhibitor, treatment with  imetelstat has induce d CR and PR in 
subjects with MF , including improvement of bone marrow  fibrosis .29 Imetelstat has also 
demonstrated an acceptable and manageable safety profile . 
2. OBJECTIVES AND HYPOT HESIS  
2.1. Objectives  
Primary Objective s 
The primary objectives of this study are to evaluate spleen response rate and symptom response 
rate of 2 dose regimens of imetelstat (9.4 mg/kg and 4.7 mg/kg imetelstat given intravenous [IV] 
every 3 weeks) in subjects with intermediate -2 or high -risk MF who are relapsed  after or refractory 
to JAK inhibitor treatment.  
Secondary Objectives  
The secondary objectives are : 
• To assess the safety of imetelstat  
• To assess CR  or PR, CI, spleen response , symptoms response, and anemia response  per 
modified 2013 IWG -MRT criteria, duration of responses, and overall survival ( OS). 
• To evaluate the pharmacokinetics of ime telstat  
• To evaluate the PK/response and pharmacodynamic (PD) relationships with factors that 
include hemoglobin concentration, spleen size, and platelet count  
• To evaluate the immunogenicity of imetelstat  
• To assess the effect of treatment on PROs ( patient -reported outcomes ) 
Exploratory Objectives  
The exploratory objectives are:  
• To assess the pharmacokinetic relationship with TA, TL or hTERT  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
40 
Status: Approved , Date: 28 March 2019  • To characterize the baseline cytogenetic and mutational status  for their association with 
clinical response , and to evaluate the change of cytogenetic abnormalities or mutant allele 
burden for assessing cytogenetic and molecular responses.  
2.2. Hypothesis  
The primary hypothesis of the study is that treatment with the selected dose of imetelstat will result 
in a  in subjects with intermediate -
2 or high-risk MF who are relapsed  after or refractory to JAK inhibitor treatment.  
3. STUDY DESIGN AND RAT IONALE  
3.1. Overview of Study Design  
This was originally designed a s a randomized, single -blind , multicenter, Phase 2 study  of 2 dosing 
regimens (treatment arms) of single -agent imetelstat in subjects with intermediate -2 or high risk 
MF (PMF, PET -MF, or PPV -MF) who se disease is  relapsed  after or refractory to JAK inhibitor 
treatment. Approximately  200 subjects were to  be enrolled  in this study with approximately 100 
subjects per treatment arm.  
The original study design allowed for enrollment of approximately 200 subjects ; however, 
following the f irst interim review of data, and in line with Protocol Amendment 2 , enrollment of 
new subjects into Arm A was suspended and enrollment into Arm B was permanently closed . 
Therefore, total enrollment in the study may be approximately 1 60 subjects if enrollment in Arm 
A is resumed after the second interim review. In addition, neither subjects nor investigators will 
be blinded to subject treatment assignment.  
The main study will have 3 phases: a screening phase of up to 21 days before 
randomization /registration  during which subject eligibility will be reviewed and approved by the 
sponsor  prior to randomization /registration ; a treatment phase will extend from 
randomization /registration  until study drug discontinuation ; and a posttreatment fo llow-up phase 
that begin s when  the subject discontinues imetelstat. The posttreatment follow -up phase will 
continue until death, lost to follow -up, withdrawal of consent or study end, whichever occurs first. 
The end of the main study is defined as 18 month s after the last subject is enrolled or when  the 
sponsor  terminates the study, whichever comes first.  
Study treatment will be administered on a 21 -day cycle . When the randomization was in effect, 
eligible subjects  were  stratified based on  a) spleen size ≥15 cm below the left costal margin by 
palpation ( yes v s. no) and b ) platelet count at study entry (platelets ≥ 75 x 109/L [ie, ≥ 75,000 /mm3] 
and <150 x 109/L [ie,  <150,000 /mm3] vs. ≥150 x 109/L [ie, ≥150,000 /mm3]). Subjects were  then 
randomized  within each stratum in a 1:1 ratio to one of the treatment arms. Subjects on Arm A 
receive d 9.4 mg/kg every 3 weeks and subjects on Arm B receive d 4.7 mg/kg every 3 weeks. Study 
drug will be administered intravenously (IV) until disease progress ion, unacceptable toxicity , or 
study end.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
41 
Status: Approved , Date: 28 March 2019  Subjects in Arm B may continue with their current imetelstat dose or have it  increased to 9.4  mg/kg 
at the investigator’s discretion according to the guidance provided in Section 6. Subjects in Arm 
A may  continue treatment at the investigator’s discretion. Subjects in either arm who discontinue 
treatment will continue in the Posttreatment Follow -up Phase.  Any subject already in the Screening 
Phase at the time study enrollment was suspended, and who was subsequently determined to be 
eligible for the study, was allowed to proceed with treatment assignment to the 9.4 mg/kg arm per 
investigator discretion , subject agreement , and IRB/IEC notification . 
The co-primary endpoint s of this study are spleen response rate and symptom response rate.  Spleen 
response rate is defined as the proportion of subjects who achieve ≥35% reduction in spleen 
volume at Week 24 from ba seline as measured by imaging scans. Symptom response rate is defined 
as the proportion of subjects who have ≥50% reduction in TSS at Week 24 from baseline as 
measured by the modified Myelofibrosis Symptom Assessment Form  (MFSAF ) v2.0 (Attachment 
1) diary . The selected dose of imetelstat will be considered effective if both of the endpoints pass 
the defined lower rate threshold. Seco ndary efficacy endpoints include CR  or PR, CI, spleen 
response, symptoms response, and anemia response per modified 2013 IWG -MRT criteria, 
duration of responses , and OS.  
Assessment of disease response and disease progression will be conducted based on modi fied 2013 
IWG -MRT response criteria28 at the time points specified in the Time and Events Schedule. Safety 
evaluations will include adverse event monitoring, physical examinations, clinical laboratory 
parameters (hematology and chemistry), vital sign measurements, Eastern Cooperative Oncology 
Group (ECOG) performance status , and concomitant medication usa ge. All study evaluations will 
be conducted according to the Time and Events Schedule.  
The first interim data review was designed as follows: The interim data review will be performed  
by the sponsor after approximately 20 subjects have been randomized in e ach arm and followed 
for at least 12 weeks. At this time, the sponsor will assess all available data (eg, PK, safety, 
efficacy, PD biomarkers: TA, TL or hTERT), and conduct integrated exposure -response analyses 
with PK/PD, safety and efficacy modeling. Bas ed on these analyses, the sponsor will determine if 
enrollment in one or both treatment arms should continue, or if an alternative dose should be 
selected for further development. Enrollment will continue during this time and response data 
assessed by the investigator will be used for the interim review.  
At the time of Protocol Amendment 2, enrollment of new subjects in this study is suspended. A 
second interim review will be performed with a clinical cutoff that is 6 months after the clinical 
cutoff used f or the first interim review.  IRC assessment  of SVR will be used for efficacy 
evaluation.  
 
  
The Sponsor  Committee will review all the safety data on a quarterly basis, or more frequently , as 
needed. The study will have  enhanced reporting for adverse events of interest, which include s 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
42 
Status: Approved , Date: 28 March 2019  Grade 3 or greater elevations of AST, ALT, ALP and bilirubin , and all hepatic adverse events. 
Additional details can be found in Section s 9.8 (Safety Evaluations) and 12.3.3  (Adverse Events 
of Interest) . Additionally, all hepatic adverse events and LFT abnormalities will be reviewed at 
least on a quarterly basis , or as needed , by an Independent Hepatic Expert Committee . 
With Protocol Amendment 3, the study is closed to further subject enrollment. Subjects  in the 
Treatment Phase who  are benefiting from study treatment  may enter an Extension Phase and 
continue to receive imetelstat until there is loss of benefit or unacceptable toxicity, as determined 
by the investigator according to local standard of care. Subjects in the Posttreatment Follow -up 
Phase will enter the Extension Phase to continue follow -up for survival status. In line with Protocol 
Amendment 4, t he Extension Phase will end approximately 2 years  after the clinical cutoff for the 
final analysis o f the main study, or when the sponsor terminates the study, whichever occurs first. 
The Hepatic Expert Committee and Sponsor Committee will continue to review study data 
collected during the Extension Phase.   
 
   
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
43 
Status: Approved , Date: 28 March 2019  A diagram of the study design following Ame ndment 2 is provided below  in Figure 1. 
Figure  2 presents the design of the Extension Phase following Amendment 4. 
Figure 1: Schematic Overview of the Study  Following Amendment 2  
 
Note: Any subject already in the Screening Phase at the time study enrollment was suspended, and who was 
subsequently determined to be eligible for the study, was allowed to proceed with tre atment assignment to the 
9.4 mg/kg arm per investigator discretion, subject agreement, and IRB/IEC notification.  
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
44 
Status: Approved , Date: 28 March 2019  Figure  2: Schematic Overview of the Extension Phase  Following Amendment 4 
 
3.2. Study Design Rationale  
Study  Population  
Treatment options for patients with advanced MF who are not allogeneic stem cell transplant 
candidates are limited to hydroxyurea, interferon , and JAK inhibitors. The effectiveness of these 
treatments mainly is limited to symptom burden relief and reductio n in splenomegaly. Current 
therapies have not been shown to induce remissions or change the natural history of MF and result 
in high discontinuation rates and a lack of durab le responses . Survival for patients who se disease  
has relapsed or is refractory to  ruxolitinib is approximately 6 months.22 Therefore, there remains a 
highly unmet need for effective treatments for the patients who have been treated previously with 
a JAK inhibitor.  
Primary Endpoint s 
The co-primary endpoints of this study are spleen response rate and symptom response rate. Sple en 
response rate is defined as the proportion of subjects achieving a ≥35% reduction in spleen volume 
at Week 24 from baseline as measured by imaging scans. Symptom response rate is defined as the 
proportion of subjects who have ≥50% reduction in TSS at We ek 24 from baseline as measured 
by the modified MFSAF v2.0 diary.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
45 
Status: Approved , Date: 28 March 2019  Splenomegaly is a cardinal feature of MF and is linked to abdominal pain and impairment of 
quality of life. Therefore, spleen volume reduction (SVR ) by ≥35% has been shown to be a valid 
endpoint that predicts clinical benefit.  Recent data by Vannucchi32 suggests positive correlation of 
on-treatment SVR at Week 24 with a reduced risk of  death.  
As was seen in COMFORT -I and COMFORT -II, treatment of MF with ruxolitinib led to a 
significant reduction in spleen volume as well as improvement in clinical symptom burden (u sing 
the MFSAF TSS in COMFORT -I). Notably, some patients without SVR demonstrated symptom 
improvement in these studies . Mature data from both studies  also have demonstrated significant 
improvements in OS.33,9  
Secondary Endpoints  
The depth of the response will be captured by assessment of CR and PR. The data from Study 
CP14B019 suggest the potential for disease modification (eg , reversal of bone marrow fibrosis , 
resolution of leukoerythroblastosis , blast count reduction ) and long -term benefit to patients that 
has not been observed with  current therapies . Duration of response s will be assessed. Subjects  will 
be followed for OS. 
Dose and Regimen Selection  
Based on data from the  MF CP14B019  study , 9.4 mg/kg given on a 3 -week cycle has an acceptable 
safety profile and favorable efficacy. Therefore, this is one of the doses to be used in the study . 
In Phase 1 and 2 studies  in various  solid tumor types, lower as well as higher doses of imetelstat 
were explored  allowing for the derivation of dose  and exposure -response relationships .  
 
 
 
 
Pharmacokinetic and Immunogenicity Evaluations  
The PK data from this study will be used for PK/PD modeling to aid in the selection of a 
development dose.  Therefore, PK samples will be obtained from all subjects and the derived PK 
parameters will provide information about the determina nts of inter -subject variability in this 
population.  Samples may also be used to evaluate the formation of metabolites of im etelstat.  
Immunogenicity to imetelstat has not been studied in preclinical or clinical studies . Therefore, 
samples to determine the presence of antibodies to imetelstat (immunogenicity) will be collected 
from all subjects . 
Biomarkers  
Based on the mechanism  of action of imetelstat and results from preclinical and previous clinical 
studies, imetelstat is expected to cause TA inhibition, TL shortening , and hTERT level reduction. 
Blood samples will be collected to evaluate TA, TL, or hTERT RNA level changes as PD 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
46 
Status: Approved , Date: 28 March 2019  biomarkers. Karyotyping on bone marrow samples will be performed to evaluate cytogenetic 
response by assessing the reduction or depletion of clones with cytogenetic abnormalities. Blood 
samples will be analyzed to characterize mutation status and decrea se or eradication of specific 
mutation burden, for determining molecular response. Other biomarker goals include evaluation 
of potential inter -individual variability in clinical outcomes or identification of population 
subgroups that respond differently to  imetelstat . 
Patient -reported Outcomes  
The purpose of the PRO questionnaires, EORTC QLQ -C30 (Attachment 2), Brief Pain Inventory 
(Short Form)  (BPI ) (Attachment 3) and The Patient Global Impre ssion of Change (PGIC)  
(Attachment 4), is to provide an assessment of the subject’s functional status, well -being, and MF 
symptoms over time and will be used to further validate the modified MFSAF v2.0. The EuroQol -
EQ-5D (EQ-5D-5L) (Attachment 5) assessment will provide estimates of utility to include in 
future cost effectiveness models.  
3.2.1.  Rationale for Protocol Changes Following the First Interim Review   
The first interim data review to assess safety  and early efficacy , and to perform comprehensive 
exposure -response analyses was performed after approximately 20 subjects in each arm were 
followed -up for at least 12 weeks. The safety analysis for this interim review included data for 79 
subjects (40 in the 4.7 mg/kg arm; 39 in the 9.4 mg/kg arm) who received at least 1 dose of study 
drug. The efficacy analysis included 40 evaluable subjects (20 in 4.7 mg/kg arm; 20 in the 9.4 
mg/kg arm) who received at least 1 dose of study drug, had a ba seline MRI, and at least 1 post -
baseline MRI assessed by investigator.  
First Interim Review of Safety  
The patient populations enrolled into each arm were balanced in terms of type of myelofibrosis 
(primary -MF, PPV -MF, or PET -MF) and DIPSS prognostic risk.  
With a median treatment duration of 4 cycles (range 1 -15 cycles) , both the 4.7 mg/kg and 
9.4 mg/kg arms were found to have an acceptable safety profile consistent with that observed in 
prior studies with imetelstat.  
 
 
 
 
 
 
  
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
47 
Status: Approved , Date: 28 March 2019  First Interim Review of Efficacy  
The landmark analysis of spleen response demonstrated that at Week 12,  
 
 
 
  
 
 
 
  
 
 
 
    
 
 
 
 
 
First Interim Review of PK  
No prior PK data were available from subjects with myelofibrosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Summary  
Data from the first interim review  indicate that  
 
 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
48 
Status: Approved , Date: 28 March 2019   
 
 
Consequently, the following protocol changes will be implemented with Protocol Amendment 2:  
• Enrollment of new subjects was suspended for Arm A  (9.4 mg/kg)  and permanently closed 
for Arm B  (4.7 mg/kg) .  
• Subjects currently in the  9.4 mg/kg arm may continue  treatment at the investigator’s  
discretion . 
• Subjects in the 4.7 mg/kg arm may continue to receive treatment and may have their dose 
escalated to 9.4 mg/kg if pre -defined safety parameters are met and at the investigator ’s 
discretion  (see Section 6). Subjects who have clinical benefit per investigator assessment but 
do not meet eligibility for dose escalation may choose to cont inue to be treated with the 
4.7 mg/kg dose and continue assessments per protocol.  
• PK sampling will continue for all subjects to allow further characterization of the imetelstat 
exposure -response relationship in patients with MF  until the PK/PD objectives are met . 
The determination of whether a subject is to continue on treatment is to be made by the inv estigator 
in consultation with the subject and will be based on the assessment of benefit -risk for each 
individual subject . 
3.2.2.  Rationale for the Extension Phase  
Once the end of the main study has been reached (Section 17.9.1 ), accommodation must be made 
to allow subjects benefiting from imetelstat to continue  treatment , if considered to be in the 
subject’s interest , until there is loss of benefit or unacceptable toxicity, as determined by the 
investigator according to local standard of care.  The addition of an Extension Phase  allows this 
unmet -need population to continue treatment  with imetelstat for approximately 2 years  after the 
clinical cutoff for  the final analysis of the main study, or until the sponsor terminates the study, 
whichever occurs first . It is anticipated that 2 years  will allow sufficient time for all subjects to 
receive adequate treatment and  allow additional maturity of the survival  data and a more precise 
estimate of overall surviva l.  
 Because sufficient data  will have been collected  during 
the main study  to allow the  planned  final analysis , data collection during the Extension Phase is 
limited to imetelstat treatment information, survival status, pregnancy, and serious adverse event 
reporting.  Data review by the Hepatic Expert Committee and Sponsor Committee during the 
Extension Phase provides  continued  independent oversight of subject safety . 
4. SUBJECT POPULATION  
Subject eligibility will be reviewed and approved by the sponsor  prior to randomization.  Screening 
for eligible subjects will be performed within 21 days before randomization . 
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. Waivers are not allowed.  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
49 
Status: Approved , Date: 28 March 2019  4.1. Inclusion Criteria  
Each potential subject must satisfy all of the following criteria to be enrolled in the study.  
1. ≥18 years of age  
2. Diagnosis of PMF  according to  the revised WHO criteria ( Attachment 6); or PET-MF 
or PPV -MF according to  the IWG -MRT criteria ( Attachment 7). A report from  the local 
laboratory for diagnosis of MF must be reviewed and approved by the sponsor . 
3. DIPSS intermediate -2 or high risk MF  (Attachment 8) 
4. Measurable s plenomegaly prior to study entry as demonstrated by:  
• palpable spleen measuring ≥5 cm below the left costal margin. The edge of the 
spleen should be measured in centimeters fr om the mid-clavicular line on the left 
side of the abdomen to the point of greatest splenic protrusion.  
OR 
• spleen volume of ≥ 450  cm3 measured by magnetic resonance imaging ( MRI ) 
5. Active symptoms of MF as demonstrated by a symptom score of at least 5 points (on a 
0 to 10 scale) on at least one of the symptoms or a score of 3 or greater on at least 2 of 
the following symptoms: night sweats, itchiness, abdominal discomfort,  pain under ribs 
on left side, early satiety, bone or  muscle pain, and inactivity.  
6. Criterion modified per Amendment 1.  
6.1 Documented progressive disease during or after JAK inhibitor therapy defined as  
worsening of splenomegaly -related abdominal pain at any time after the start of JAK 
inhibitor therapy , and 
EITHER  
• no reduction in spleen volume or size after 12 weeks of JAK inhibitor therapy  
OR 
• worsening splenomegaly at any time after the start of JAK inhibitor therapy 
documented by : 
− increase in spleen volume from nadir by 25% measured by MRI  or computed 
tomography (CT),  or  
− increase in spleen size by palpation , CT, or ultrasound   
o for splenomegaly of 5 -10 cm at the start of JAK inhibitor treatment, at 
least 100% increase in palpable spleen size from nadir is required;  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
50 
Status: Approved , Date: 28 March 2019  o for splenomegaly of >10  cm at the start of JAK inhibitor treatment, at least 
50% increase in palpable spleen size  from nadir  is required;  
o new splenomegaly must measure at least 5  cm. 
7. ECOG performance status 0, 1 or 2 (Attachment 9) 
8. Criterion modified per Amendment 1.  
8.1 Hematology lab oratory  test values within the following limits :  
• Absolute neutrophil count (ANC)  ≥1.5 x 109/L (ie, ≥ 1,500/mm3) independent of 
growth factor support  
• Platelets ≥ 75 x 109/L (ie, ≥ 75,000/ mm3) independent of platelet transfusion support  
9. Criterion modified per Amendment 1.  
9.1 Biochemical laboratory test values must be within the following limits  
• AST  and ALT ≤2.5 x UL N 
• ALP ≤5 x ULN  
• Serum creatinine ≤2 x ULN  
• Total bilirubin ≤3 x ULN  and direct bilirubin  ≤2 x ULN  
10. Women of childbearing potential and men who are sexually active must be practicing a 
highly effective method of birth control during and after the study consistent with local 
regulations regarding the use of birth control methods for subjects participating in 
clinical trials. Men must agree to not father a child or donate sperm during and after the 
study. For females, these restrictions apply for  1 month after the la st dose of study drug. 
For males, these restrictions apply for 3 months after the last dose of study drug.  
11. A woman of childbearing potential must have a negative serum ( -human chorionic 
gonadotropin [ -hCG]) or urine pregnancy test at  Screening.  
12. Each subject  (or their legally  acceptable representative ) must sign an informed consent 
form  (ICF) indicating that he or she  understand s the purpose of and procedures required 
for the study and are willing to participate in the study.  
4.2. Exclusion Criteria  
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study.  
1. Peripheral blood blast count of ≥10% or bone marrow blast count of ≥10%  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
51 
Status: Approved , Date: 28 March 2019  2. Prior treatment with imetelstat  
3. Criterion modified per Amendment 1.  
3.1 Major surgery within 4 weeks prior to randomization  
4. Criterion modified per Amendment 1.  
4.1 Any chemotherapy  or MF -directed therapy , investigational drug regardless of class or 
mechanism of action , hydroxyurea , immunomodulatory or im munosuppressive 
therapy, corticosteroids >30  mg/day prednisone or equivalent, or JAK inhibitor therapy 
≤14 days prior to randomization.  
5. Prior history of hematopoietic stem cell transplant  
6. Diagnosis or treatment for malignancy other than MF, except  
• Malignancy treated with curative intent and with no known active disease present 
for ≥3  years before randomization  
• Adequately treated non -melanoma skin cancer or lentigo maligna without evidence 
of disease  
• Adequately treated cervical carcinoma in situ wit hout evidence of disease  
7. Clinically significant cardiovascular disease such as uncontrolled or symptomatic 
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of 
Screening, or any Class 3 (moderate) or Class 4 (severe) cardi ac disease as defined by 
the New York Heart Association Functional Classification.  
8. Known history of human immunodeficiency virus (HIV) or any uncontrolled active 
systemic infection requiring IV antibiotics  
9. Criterion modified per Amendment 1.  
9.1. Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are 
permitted to enter the study), or any type or known acute or chronic liver disease 
including cirrhosis  
10. Females who are pregnant or currently breastfeeding  
11. Any life -threatening illness, medical condition, or organ system dysfunction which, in 
the investigator’s opinion, could compromise the subject’s safety, interfere with the 
imetelstat metabolism, or put the study outcomes at undue risk.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
52 
Status: Approved , Date: 28 March 2019  NOTE:  Investigator s should ensure that all study enrollment criteria have been met at screening. 
The last laboratory result obtained prior to randomization will be used to determine eligibility. If 
a subject's status changes (including laboratory results or receipt of addit ional medical records) 
after screening but before the first dose of study drug is given such that he or she no longer meets 
all hematologic eligibility criteria, the decision to administer study drug  on Cycle 1 Day 1 is at the 
discretion of the investigato r provided that the subject does not meet any threshold for dose 
modification (per Section 6, Dosage and Administration ). Section  17.4, Source  Documentation, 
describes the required documentation to support meeting the enrollment criteria.  
4.3. Prohibitions and Restrictions  
Potential subjects must be willing and able  to adhere to the following prohibitions and restrictions 
during the course of the study to be eligible for participation:  
1. A woman of childbearing potential must remain on a highly effective method of birth 
control (see inclusion criteria)  during the st udy and for 1 month after the last dose of 
study drug.  
2. A man who is sexually active with a woman of childbearing potential must use an 
adequate method of birth control and all men must also not donate sperm during the 
study and for  3 months after rece iving the last dose of study drug.  
3. Section 8 details prestudy and concomitant therapies used in this study.  
5. TREATMENT ALLOCATION  AND BLINDING  
This was originally designed as  a single -blind study, in which subjects will be blinded to th e 
treatment arms . This was to reduce potential bias during data collection, eg, modified MFSAF v2.0 
diary  and PROs , which may be subject to self -assessment bias.  Central randomization was 
implemented in this study. Subjects were assigned  randomly  to 1 of 2 treatment arms  in a 1:1 ratio 
based on a computer -generated randomization schedule prepared before the study by or under the 
supervision of the sponsor . The randomization was stratified by  a) spleen size ≥15 cm below the 
left costal margin by palpation (y es vs. no) and b) platelet count (≥75 x 109/L and <150 x 109/L 
vs. ≥150 x 109/L) and balanced by using randomly permuted blocks . The interactive web response 
system (IWRS) assign ed a unique treatment code  that dictate d the treatment assignment and 
matching study drug kit for the subject. The requestor must use his or her user identification and 
personal identification number when contacting the IWRS , and will then give the relevant subject 
details to identify the subject.  
Beginning with Protocol Amendment 2, enrollment of new subjects into Arm A (9.4 mg/kg) is 
suspended and enrollment into Arm B (4.7 mg/kg) is permanently closed. Any subject already in 
the Screening Phase at the time study enrollment was suspended, and who was subsequently 
determined to be eligible for the study, was allowed to proceed with treatment assignment to the 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
53 
Status: Approved , Date: 28 March 2019  9.4 mg/kg arm per investigator discretion , subject agreement , and IRB/IEC notification . In 
addition, neither subjects nor investigators will be  blinded to treatment assignment.  
6. DOSAGE AND ADMINISTR ATION  
Imetelstat Sodium ( GRN163L) for Injection (imetelstat) is the investigational product in this study 
and will be provided by the sponsor . Imetelstat will be administered as a 2 -hour IV infusion 
(± 10 minutes) at a constant rate using a programmable volumetric infusion pump. The baseline 
weight will be used to calculate the dose of imetelstat. The dose should be r ecalculated if there is 
a ≥ 10% weight change from baseline. Subjects in Arm A will receive imetelstat 9.4 mg/kg every 
3 weeks and subjects in Arm B will receive 4.7 mg/kg every 3 weeks. Subjects may receive 
treatment until disease progression or unacceptable toxicity. Study drug may be held for up to 
21 days from the expected start date of the scheduled  cycle ; a hold >21 days must be reviewed and 
approved by the sponsor . Imetelstat should be discontinued permanently if i t cannot be restarted 
within 21  days due to toxicity, unless appr oved by the sponsor . For treatment of hematologic 
toxicities, granulocyte colony stimulating factors (G -CSF) are permitted for neutropenia as well 
as blood transfusions for anemia or thrombocytopenia.  
If a subject's status changes (including laboratory res ults or receipt of additional medical records) 
after screening but before the first dose of study drug is given such that he or she no longer meets 
all hematologic eligibility criteria, the decision to administer study drug o n Cycle 1 Day 1 is at the 
discr etion of the investigator provided that the subject does not meet any threshold for dose  
modification . 
 
 
  
     
   
   
   
  
 
   
  
   
 
Dose Escalation  Following Amendment 2  
Beginning with Protocol Amendment 2, subjects in Arm B (4.7 mg/kg) may continue to receive 
their current dose of imetelstat or, at the discretion of the investigator, have their dose increased to 
9.4 mg/kg. To be eligible for this dose escalation, a subject must meet study eligibility  criteria for 
hematology  laboratory values  (inclusion criterion 8.1; ie, ANC ≥1.5 x 109/L; plat elets ≥75 x 109/L) 
and biochemical laboratory values ( inclusion criterion 9.1; ie, AST and ALT ≤2.5 x ULN, ALP ≤5 
x ULN, serum creatinine ≤2 x ULN, total bilirubin ≤3 x ULN, direct bilirubin ≤2 x ULN ). In 
addition, subjects  may not meet any threshold for d ose modification for hematologic toxicity 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
54 
Status: Approved , Date: 28 March 2019  (Section 6.1), non -hematologic toxicity (Section 6.2), or hepatic toxicity (Section  6.3). A s ubject 
who had a dose reduction at any time during the study is not permitted to dose escalate.   
Treatment During the Extension Phase  
Once the end of the main study has been reached, subjects who are receiving benefit from study 
treatment may continue to receive imetelstat during  the Extension Phase . Dose modification 
guidelines provided in the follow ing sections  will continue in the Extension Phase.  Subjects may 
receive treatment in the Extension Phase until there is loss of benefit or unacceptable toxicity, as 
determined by the investigator  according to local standard  of care . 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
55 
Status: Approved , Date: 28 March 2019  6.4. Infusion -Related Reactions  
Subjects should be observed carefully during imetelstat infusions. Trained study staff at the clinic 
should be prepared to intervene in case of an infusion -related  reaction. If an infusion -related 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
56 
Status: Approved , Date: 28 March 2019  reaction develops, then the infusion should be interrupted temporarily and the actions in Table 7 
should be taken . 
Table 7: Management of Infusion -related Reaction s 
Severity  Recommended action  
Grade 1  • Evaluate and manage symptomatically as needed.  
• May complete infusion if reaction remains mild, with stable 
vital signs and does not worsen to Grade 2.  
Grade 2  • Stop infusion  
• Manage symptomatically as needed  
• After recovery, resume infusion at half the previous rate for 
30 minutes  
− If no further symptoms occur, complete the infusion at 
the full dose rate 
− If symptoms recur, discontinue infusion  for that cycle   
Grade 3  • Stop infusion  
• Administer supportive care as indicated  
• Observe subject carefully until the resolution of the adverse 
event  or until the intensity of the event decreases to Grade 1, 
at which point the infusion may be restarted at the 
investigator’s discretion. Upon restart, the infusion rate should 
be half of that used before the interruption. Subsequently, the 
infusion rate m ay be increased at the investigator’s discretion.  
− If the intensity of the adverse event  returns to Grade 3 
after restart of the infusion, then the procedure described 
in this section may be repeated at the investigator’s 
discretion. Should the intensity of  the adverse event  
increase to Grade 3 for a third time, discontinue 
imetelstat  
Grade 4  • Stop infusion  
• Administer supportive care as indicated  
• Discontinue imetelstat  
 
7. TREATMENT COMPLIANCE  
Study drug (imetelstat) will be administered by qualified site staff, and the details of each 
administration will be recorded in the electronic case report form (eCRF). Additional details are 
provided in the Site Investigational Product Manual (SIPM) or eq uivalent document.   
These guidelines for study drug administration and data collection will continue in the Extension 
Phase.  
8. PRESTUDY AND  CONCOMITANT THERAPY  
All recommendations regarding the use of concomitant therapy  are applicable to the Extension 
Phase . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
57 
Status: Approved , Date: 28 March 2019  All subjects receiving imetelstat must be premedicated with diphenhydramine (25 to 50 mg) and 
hydrocortisone ( 100 to 200 mg), or equivalent . It is recommended that subjects are monitored for 
at least 1 hour after the infusion has been completed.  
Subjects may receive supportive care as clinically indicate d. This includes blood product support 
(blood transfusions and the use of granulocyte colony stimulating growth factors), anti -diarrheals , 
anti-emetics, analgesics, antibiotic treatment, and treatm ent of other medical conditions.  
The following medications are prohibited during the study : chemotherapy (anticancer)  or MF -
directed therapy , immunotherapy, experimental therapy, and radiotherapy. Systemic use of  
corticosteroids in excess of prednisone 20 mg/day or its equivalent for more than 10 days is 
prohibited unless reviewed and approved by the sponsor ’s medical monitor. Long -term, chronic 
use of corticosteroids at any dose also should be reviewed and approved by the sponsor ’s medical 
monitor. Cortico steroids used as premedication are permitted. The sponsor  must be notified in 
advance (or as soon as possible, thereafter) of any instances in which prohibited therapies are 
administered.  
Prestudy therapies administered up to 30  days before first dose of s tudy drug must be recorded at 
screening . Transfusion s up to 12 weeks prior to baseline also must be recorded at screening.  
Concomitant therapies  (prescription or over -the-counter medications, including vaccines, 
vitamins, herbal supplements) , including growth factors, transfusions,  anti-infective s 
(antibacterials, antivirals, and antimycotics) , steroids, anti -arrhythmics and other cardiac 
supportive therapy, anti -histamines, anti-emetics, anti -diarrheals, and anti -coagulants  must be 
recorded throughout the study beginning with signing  of the ICF to 30 days after the last dose of 
study drug  or until the start of subsequent anticancer treatment, if earlier. Modification of an 
effective preexisting therapy should not be made for the explicit purpose of entering a subject into 
the study.  Concomitant therapies should be recorded beyond 30 days only in conjunction with new 
or worsening adverse events or serious adverse events that meet the criteria outlined in Section  
12.3.2 , Serious Adverse Events . 
The sponsor  must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are adm inistered.  
9. STUDY EVALUATIONS  
9.1. Study Procedures  
9.1.1.  Overview  
The Time and Events Schedule s summarize the frequency and timing of efficacy, 
pharmacokinetic, immunogenicity, pharmacodynamic,  biomarker , and safety  measurements 
applicable to the main  study  and to the Extension Phase . As of Amendment 3, subjects will follow 
the Time and Events Schedule for the Extension Phase. Additional detail is provided in Section 
9.1.5 . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
58 
Status: Approved , Date: 28 March 2019  The total blood volume for the study is approximately  604 mL (Table 8).  
Table 8: Volume of Blood to be Collected From Each Subject  
Type of Sample  Volume per 
Sample (mL)  No. of Samples 
per Subjecta Total Volume of 
Blood (mL)b 
Safety (including screening and posttreatment assessments )    
 - Hematology  including efficacy  5 19 95 
 - PT/INR and aPTT  5 15 75 
 - Serum chemistry  and expanded liver panelc 10 20 200 
 - Hepatitis Serologyd  13 1 13 
- Serum -hCG pregnancy tests  2 1 2 
Pharmacokinetic samples (intensive or sparse)g 2 22 44 
Immunogenicity  2 14 28 
Pharmacodynamic samplesf 14.5 6 87 
Biomarkers (Mutation analysis)e 6 4 24 
Peripheral blood for cytogenetics (if required)  4 5 20 
Biomarkers (Immunophenotyping)  4 4 16 
Approximate Total    604  
a. Volumes below derived for median 12 cycle duration and includes end of study visit.  
b. Calculated as number of samples multiplied by amount of blood per sample  
c. Serum chemistry includes basic liver function tests. An expanded panel of liver function tests is required at screening and 
may also be required for safety reasons.  
d.  Includes 2.5 mL of blood  for hepatitis PCR testing when required to confirm study eligibility.   
e. Samples will be collected every 12 weeks until disease progression . 
f. Four additional 14.5 -mL blood samples (58 mL total) for pharmacodynamic analysis are required for subjects who have 
their dose increased from 4.7 mg/kg to 9.4 mg/kg.  
g. Up to 4 additional 2 -mL blood  samples (up to 8 mL total) for sparse PK analysis are required for subjects who have their 
dose increased from 4.7 mg/kg to 9.4 mg/kg; and up to two, 2 -mL time -matched  blood PK samples are required for 
subjects who have bone marrow aspirate collected for PK analysis at Weeks 24 and 48.  
Note: An indwelling intravenous cannula may be used for blood sample collection.  
 
The total blood volume to be collected from each subj ect will be approximately 604 mL, including 
additional samples t o be collected for subjects who have their dose increased from 4.7  mg/kg to 
9.4 mg/kg for pharmacodynamic analysis (58 mL) and PK analysis (up to 12 mL). Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues  with the samples.  
Additional 4-mL blood samples may be required for subjects who have peripheral blood collected 
for cytogenetic testing in place of bone marrow aspirate.   
Additional serum or urine pregnancy  tests may be performed, as determined necessary by the 
investigator or required by local regulation, to establish the absence of pregnancy at any time 
during the subject's participation in the study.  Repeat or unscheduled samples may be taken for 
safety r easons or technical issues with the samples.   
9.1.2.  Screening Phase  
All subjects must sign an ICF prior to the conduct of any study -related procedures. Screening 
procedures will be performed up to 21 days before randomization /registration . Screening 
symptoms usi ng the Screening Myelofibrosis Symptom Form must be completed after  
 and as close as possible to Day -7. An abdominal MRI 
for spleen assessment  (including a portion of the pelvis when the spleen protrudes into pelvic 
cavity)  must be completed  and as close 
as possible to randomization.  Screening spleen palpation and hematology mu st also be completed 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
59 
Status: Approved , Date: 28 March 2019  . The bone marrow aspirate (if  
clinically feasible) and biopsy must be performed for disease assessment up to 60 days before  
randomization. Additionally, where clinically feasible, a bone marrow aspirate will be collected 
prior to randomization for cy togenetic assessment. Peripheral blood may be submitted in place of 
an aspirate only if a bone marrow aspirate cannot be obtained . The sponsor will inform the sites  
which subjects have a cytogenetic abnormality based on  the baseline analysis and will need to have 
subsequent samples collected for cytogenetic  analysis . 
Laboratory tests noted in the inclusion criteria must be performed and the results within the limits 
specified in the inclusion criteria. Testing may be repeated for this purpose  and can be repeated if 
needed to fall within the screening period . The last result obtained prior to randomization will be 
used to determine eligibility.  Assessments performed as part of the subject’s routine clinical 
evaluation and not specifically for t his study need not be repeated after signed ICF has been 
obtained provided the assessments fulfill the study requirements and are performed within the 
specified timeframe prior randomization.  
Diagnosis of MF must be confirmed by the  sponsor . A laboratory  report from the local laboratory 
and supporting documentation consistent with a diagnosis of MF must be made available to the 
sponsor  prior to randomization . The sponsor  will review eligibility criteria and approve enrollment 
of each subject into the study.  
The modified MFSAF v2.0 e-diary will be completed each evening starting on Day -7 (  
) and will continue to be completed each  
evening through Week 48. The first EORTC QLQ -C30, EQ-5D-5L and BPI  assessment s will be 
administered prior to the first dose of study treatment. Subjects should be provided a private, quiet 
area to complete the questionnaires. The study site staff should instruct the subject to carefully 
read the instructions and question s of the PRO instrument(s) prior to marking responses, that there 
are no right or wrong answers, and that their responses to the questionnaire will not be used to 
determined their study eligibility.  
9.1.3.  Single -Blind  Treatment Phase  
Day 1/Day of Randomization /Registration  
This was originally a  single -blind study, in which subjects were  blinded to the treatment arms . 
Beginning with Protocol Amendment 2, neither subjects nor investigators will be blinded to 
subject treatment assignment.  The Treatment Phase will begin at randomization /registration  and 
will continue until study drug discontinuation. Subjects should start study treatment within 72 
hours after randomization /registration  in the IWRS.  
Treatment Phase  
A cycle is defined as 21 days. Details of the proced ures performed during the Treatment Phase are 
outlined in the Time and Events Schedule . A window of ±3  days is allowed  for visits to the clinic. 
Subjects will be closely monitored for adverse events , laboratory abnormalities, and clinical 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
60 
Status: Approved , Date: 28 March 2019  response. It is recommended that the EORTC QLQ -C30, EQ -5D-5L, BPI, PGIC , and MF 
Symptom Recall Form  are administered before any tests, procedures, or other consultations. After 
the PRO questionnaires have been administered, a symptom -directed physical exam ination  
including  spleen palpation will be conducted (see Section  9.2.1 ). Laboratory test results must be 
reviewed prior to administering study treatment. Adverse events and changes to concomitant 
medications will be recorded (see Section  17.5). Dose modifications will be made according to 
criteria described i n Section s 6.1, 6.2, and 6.3. The investigator will assess subject response to 
therapy using the efficacy measurements and disease response criteria according to the schedule 
described in Section 9.2.1 . 
Clinical evaluations and laboratory studies may be repeated more frequently, if clinically 
indicated. If a subject develops features of response ( eg, improvement in palpable or radiographic 
splenomegaly, improvement of symptoms, resolution of leukoerythroblastosis, decreased 
transfusion requirements, etc .) and CR or PR are clinically suspected at a time not specified on the 
Time and Events Schedule then all required disease assessment s should be performed. In order to 
confirm a CR or PR per modified IWG -MRT criteria, all disease assessments should be repeated 
12 weeks from time of CR or PR. If progressive disease is diagnosed, or the subject discontinues 
study treatment for other reasons, then the subject  will complete the End -of-Treatment Visit within 
30 days after the last dose of study treatment, and enter the Posttreatment Follow -up Phase.  
End-of-Treatment/Early Withdrawal  
An End -of-Treatm ent Visit will be scheduled within 30 days after the last dose of the last study 
treatment for all subjects, including those discontinuing treatment for any reason, except for lost 
to follow -up, death, or withdrawal of consent for study participation. Subj ects who discontinued 
from treatment due to disease progression, adverse event, or other reasons and enter the 
Posttreatment Foll ow-up Phase should have the End -of-Treatment Visit completed before starting 
any subsequent anti -MF treatment. If a subject is unable to  return to the site for the 
End-of-Treatment Visit, then the subject should be contacted to collect adverse events that occur 
within 30  days after the last dose of the last study treatment. Additional information on reporting 
adverse events may be  found in Section  12. The PGIC questionnaire and MF Symptom Recall 
Form shou ld also be completed at the End -of-Treatment Visit. If the PGIC assessme nt is conducted 
via a telephone call with the subject, then the subject’s questionnaire responses will be read over 
the telephone to the site staff who will record the data in the questionnaires. If the subject is unable 
to complete the assessment during t he Posttreatment Follow -up Phase, then the reason for not 
completing the questionnaire will be documented (ie, too ill, subject refused).  
9.1.4.  Posttreatment Phase (Follow -Up) 
The Posttreatment Follow -up Phase is the time between the End -of-Treatment Visit and the end of 
study participation or end of study. During this phase , contact will be made to determine survival 
status, and subsequent anti -MF treatment  every 16  weeks ± 7 days until study end. If the 
information on survival status and subsequent therapy is obtained via telephone contact, then 
written documentation of the communication must be available for review in the source 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
61 
Status: Approved , Date: 28 March 2019  documents. If the subject has died, then the date and cause of death will be collected and 
documented on the CRF. Where allowed by lo cal law, public records may be used to document 
death for the purpos e of obtaining survival status.  
During the Posttreatment Phase, sites should attempt to administer t he EORTC QLQ -C30, 
EQ-5D-5L and BPI assessments every 16 weeks  ± 7 days , unless death or study end occurs first. 
Subjects who visit the site for the follow -up assessments should complete the questionnaires at 
that time. If the assessments are conducted via a telephone call with the subject, then the subject’s 
questionnaire responses will be re ad over the telephone to the site staff who will record the data in 
the questionnaires. If the subject is unable to complete the assessments during the Posttreatment 
Follow -up Phase, then the reason for not completing the questionnaires will be documented (ie, 
too ill, subject refused).  
Note that a plasma sample for immunogenicity testing should be collected at the first follow -up 
visit, and a posttreatment MRI is required  3 months after the last dose  of study drug . Refer to the 
Time and Events Schedule for  the timing of all Post -treatment Follow -up Phase procedures.  
9.1.5.  Extension Phase  
Once the end of the main study has been reached, subjects in the Treatment Phase who are 
benefiting from  study  treatmen t may enter the Extension Phase and continue to receive  imetelstat . 
Treatment may continue  until there is loss of benefit or unacceptable toxicity, as determined by 
the investigator according to local standard of care . Subjects in the Posttreatment Follow -up Phase  
of the main study  will enter the Extension Pha se for continued follow -up of survival status .  
Subjects  enter ing the Extension Phase  must sign and date an updated ICF , at which time they will  
begin following the  Time and Events Schedule for the  Extension Phase . All requirements for 
administration of imetelstat, including guidelines for dose modification, will continue during the 
Extension Phase  (see Section 6). Treatment may continue until there is loss of benefit or 
unacceptable toxicity, as determined by the investigator  according to local standard of care . 
Subjects who discontinue imetelstat du ring the Extension Phase, or who have already discontinued 
imetelstat before entering the Extension Phase , will be contact ed to determine survival  status every 
16 weeks ±7 days until the Extension Phase ends . Procedures for documentation of survival 
follow -up are described in Section 9.1.4 . 
Data collection in the eCRF during the Extension Phase will be limited to imetelstat treatment 
information  and survival  status . Serious adverse event s will be collected using the Serious Adverse 
Event Form (see Section 12.3.2 ) from the time the subject signs and dates the  ICF for the Extension 
Phase until 30 days after the  subject ’s last dose of imetelstat . All serious adverse event information 
including i nformati on on concomitant medication, diagnostic procedures , and imetelstat 
administration associated with the serious adverse event  will be collected using the Serious 
Adverse Event Form and entered into the Global Safety database  for imetelstat  only, and not int o 
the clinical database . Pregnancy will be reported using the pregnancy notification form.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
62 
Status: Approved , Date: 28 March 2019  The Extension Phase will end approximately 2 years  after the clinical cutoff for the final analysis  
of the main study, or when the sponsor terminates the study, whichever occurs first . The full study 
will end at that time.  
9.2. Efficacy  
9.2.1.  Evaluations  
Imaging  
MRI of the abdomen will be performed to assess spleen volume. MRI will be performed at the 
time points specified in the Time and Events Schedule for disease evaluation.  The scans will be 
reviewed locally and also sent to and read by the Independent Review Committee (IRC) . Treatment 
decisions following any spleen volume assessments will be based  on the IRC assessment . 
Spleen Length  Measurement  
Spleen length measurement in centimeters will be assesed by manual palpation at every physical 
examination , disease evaluation study visit , end -of-treatment visit, and at the  3-month 
posttreatment follow -up (if feasible)  as noted in the Time and Events Schedule . Subjects who have 
their dose increased from 4.7 mg/kg to 9.4 mg/kg will have an additional spleen assessment before 
starting the higher dose. The edge of the  spleen sh ould be determined by palpation from the mid-
clavicular line at the costal margin on the left side of the abdomen  to the point of greatest splenic 
protrusion . 
Bone Marrow Assessment  
Bone marrow biopsy  and aspirate samples must be collected at the time points specified in the  
Time and Events Schedule for disease assessment and must be sent to the sponsor ’s approved 
central laboratory. Where clinically feasible, bone marrow aspirate  should also be collected at the 
time points specified and sent to the cen tral laboratory for cytogenetic assessment. In cases where 
it is not clinically feasible to collect an aspirate for cytogenetics, a peripheral blood sample will be 
collected for this testing. Central review of the bone marrow biopsy will be used to assess response 
to imetelstat for the efficacy analysis.  
Peripheral Blood Analysis  
Peripheral blood will be collected at the time points specified in the Time and Events Schedule for 
disease assessment and evaluated for hemoglobin, neutrophils and immature myeloi d cells. Central 
review of the peripheral smear will be us ed to assess response to imetel stat for the efficacy 
analysis . 
Screening Myelofibrosis (MF) Symptom Form  
The Screening MF Symptom Form (Attachment 10) should be completed during Screening so that 
eligibility (Inclusion Criteria #5) may be determined. The Screening MF Symptom Form is a 
single -use, paper version of the modified MFSAF v2.0 diary  that will be implemented in the study 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
63 
Status: Approved , Date: 28 March 2019  using a hand -held device, and is adapted from the published modified MFSAF v2 .0 questionnaire 
published by Mesa.25 
Modified Myelofibrosis Symptom Assessment Form  (MFSAF ) Diary 
Once eligibility has been confirmed via the Screening MF Symptom Form, s ubjects will be issued 
a hand -held electronic device to record answers to queries regarding MF symptoms. Questions on 
these symptoms are from the  modified MFSAF v2.0 questionnaire25 and will be completed by 
subjects each night beginning at Day -7, and continuing to  the Week 48 visit.  Symptoms will be 
assessed including night sweats, itchiness, abdominal discomfort,  pain under ribs on left side, early 
satiety, bone or muscle pain, and inactivity.  Scoring is from 0 (absent/as good as it can be) to 10 
(worst imaginable/as ba d as it can be) for each item. Detailed directions for the administration of 
the modified MFSAF v2.0 diary will be provided in a Reference Manual.  
Myelofibro sis (MF) Symptom Reca ll Form  
The MF Symptom Recall Form ( Attachment 11) should be completed, starting after Week 48, at 
the time  points specified in the Time and Events Schedule. The MF Symptom Recall Form is a 
paper questionn aire adapted from the modified MFSAF v2.0 diary , and includes a modified recall 
period of the average of the prior 7 days.  
Efficacy Response Assessment  
Respons e assessment for the response categories in Table 9 will be done per the modified 2013 
IWG -MRT criteria. Assessment of response should include radiogra phic imaging, evaluation of 
blood and bone marrow (if applicable), and modified MFSAF v2.0 diary . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
64 
Status: Approved , Date: 28 March 2019  Table 9: Response Categories  
Response Category  Required Criteria  
 For all response categories, benefit must last for >12 w eeksa to 
qualify as a response  
Clinical Improvement 
(CI) The achievement of anemia, spleen or symptoms response without 
progressive disease or increase in severity of anemia, 
thrombocytopenia, or neutropeniab 
Anemia Response  Subjects with baseline Hb <10 g/dL but not meeting strict criteria for 
transfusion dependen cy: a ≥ 2 g/dL increase in Hbc 
Transfusion dependent subjects  at baseline: becoming transfusion 
independent. Transfusion independence is defined as absence of any 
pRBC transf usions for at least  12 “rolling” weeksc 
Spleen Response  A baseline splenomegaly that is palpable at 5 -10 cm, below the 
LCM, becomes not palpable or  
A baseline splenomegaly that is palpable at >10 cm, below the 
LCM, decreases by ≥50% 
A spleen response requires confirmation by MRI showing >35% 
SVR  
Symptoms Response  A ≥50% reduction in the modified MFSAF v2.0 TSSd 
Progressive Disease  Splenomegaly requires MRI showing a ≥25% increase in spleen 
volume from baseline or  
Appearance of a new  splenomegaly that is palpable at least 5 cm 
below the LCM or  
A ≥100% increase in palpable distance, below LCM, for baseline 
splenomegaly of 5 -10 cm or  
A 50% increase in palpable distance, below LCM, for baseline 
splenomegaly of >10 cm or  
Leukemic transfor mation confirmed by a bone marrow blast count 
of >20% or  
A peripheral blood blast content of >20% associated with an 
absolute blast count of >1 X 109/L that lasts for at least 2 weeks  
Stable Disease  Belonging to none of the above listed response categorie s 
Relapse  No longer meeting criteria for at least CI after achieving CR, PR, or 
CI, or  
Loss of anemia response persisting for at least 1 month or  
Loss of spleen response persisting for at least 1 month  
a Benefit must last 12 weeks. This applies to clinical improvement, anemia response, spleen response, and symptoms respon se. 
b Increase in severity of anemia constitutes the occurrence of new transfusion dependency or a ≥2 .0 g/dL decrease in hemoglobin 
level from pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is  
defined as a 2 -grade decline, from pretreatment baseline, in platelet count or ANC , according to the Comm on Terminology 
Crite ria for Adverse Events (CTCAE) V ersion 4.03. In addition, assignment to CI requires a minimum platelet count of 
≥25,000 X 109/L and ANC  of ≥0.5 x 109/L. 
c Transfusion dependency before study enrollment is defined as transfusions of at l east 6 units of packed red blood cells (PRBC), 
in the 12 weeks prior to study  enrollment, for a hemoglobin level of <8.5 g/dL, in the absence of bleeding or treatment -induced 
anemia. In addition, the most recent transfusion episode must have occurred in th e 28 days prior to study enrollment. Response 
in transfusion -dependent patients requires absence of any PRBC transfusions during any consecutive “rolling” 12 -week 
interval during the treatment phase, capped by a hemoglobin level of ≥8 .5 g/dL. 
d Symptoms ar e evaluated by the modified MFSAF v2.0 TSS. The modified MFSAF v2.0 TSS is assessed by the patients 
themselves and this includes night sweats, itchiness, abdominal discomfort, pain under ribs on left side, early satiety, bone  or 
muscle pain, and inactivity . Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for 
each item. The modified MFSAF v2.0 TSS is the summation of all the individual scores, excluding inactivity (0 -60 scale). 
Symptoms response requires ≥50% redu ction in the modified MFSAF v2.0 TSS . After Week 48 symptom response will be 
assessed by the MF Symptom Recall Form.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
65 
Status: Approved , Date: 28 March 2019  For the response categories of CR and PR  the criteria in Table 10 will be used . 
Table 10: Remission Parameters  
Parameters  Complete Remission (CR)  Partial Remission (PR)  
(Scenario 1)  Partial Remission (PR)  
(Scenario 2)  
 For all response categories, benefit must last for >12 weeks to qualify as a response  
Bone marrow  Normocellular , <5% blasts , 
≤ Grade 1 fibrosis  Normocellular , <5% blasts , 
≤ Grade 1 fibrosis  Not meeting bone marrow 
remission criteria  
Immature myeloid 
cells in PB  <2%  <2%  <2%  
Hemoglobin  10 g/dL – ULN  8.5 – <10 g/dL  10 g/dL – ULN  
Neutrophils  1 x 109/L – ULN  1 x 109/L – ULN  1 x 109/L – ULN  
Platelets  100 x 109/L – ULN  50 - <100 x 109/L 100 x 109/L – ULN  
Spleen  Not palpable  and ≤350ml 
volume  ≥35% splenic  volumetric 
reduction by MRI or not 
palpable  ≥35% sple nic volumetric 
reduction by MRI  or not 
palpable  
EMH  No non -hepato -splenic 
EMH  No non -hepato -splenic 
EMH  No non -hepato -splenic EMH  
Symptoms  >70% improvement in 
symptom score per modified 
MFSAF v2.0 TSS >50% improvement in 
symptom score per modified 
MFSAF v2.0 TSS >50% improvement in 
symptom score per modified 
MFSAF v2.0 TSS 
CR=complete re mission ; EMH=extramedullary hematopo iesis; MFSAF TSS= Modified Myelo fibrosis  Symptom Assessment 
Form Total Symptom Score; MRI=magnetic resonance imaging; PR=partial re mission ; ULN=upper limit of normal  
 
Radiographic evaluations will be assessed by an independent radiologist , and bone marrow  fibrosis 
and peripheral blood smear assessments will be performed by an indepen dent pathologist . Detailed 
procedures will be described in a separate IRC charter.  
9.2.2.  Endpoints  
Primary Endpoint s 
The co-primary endpoints of this study are spleen response rate and symptom response rate. Spleen 
response rate is defined as the proportion of s ubjects who achieve ≥35% reduction in spleen 
volume at Week 24 from baseline as measured by imaging scans. Symptom response rate is defined 
as the proportion of subjects who have ≥50% reduction in TSS at Week 24 from baseline as 
measured by the modified MFSAF v2.0 diary .  
Secondary Endpoints  
• CR or PR  per modified 2013 IWG -MRT criteria  
• CI per  modified 2013 IWG -MRT criteria  
• Spleen response , symptoms response, and anemia response  per modified 2013 IWG -MRT 
criteria  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
66 
Status: Approved , Date: 28 March 2019  • Duration of spleen response , duration of symptoms response, duration of CR or PR, duration 
of CI, and duration of anemia response  
• OS 
• Patient reported outcomes including EORTC QLQ -C30, EQ -5D-5L, BPI, and PGIC   
• Safety profile of imetelstat  
• PK profile of imetelstat  
Explorato ry Endpoint s 
• TA, TL and hTERT at baseline and the change from baseline  
• Cytogenetic response and molecular response  
• Leukemia free survival  
9.3. Pharmacokinetic  and Immunogenicity Evaluation s 
9.3.1.  Sample Collection and Handling  
Plasma s amples will be collected from all subjects for measurement of plasma concentrations of 
imetelstat  and the generation of antibodies to imetelstat  the time  points specified in the Time and 
Events Schedule for PK Sampling . An optional bone marrow sample w ill be collected for 
measurement of concentration of imetelstat in the bone marrow.  
Samples will be used to evaluate the pharmacokinetics as well as the immunogenicity of  imetelstat  
(antibodies to imetelstat ). Plasma  sample s will be divided into 2 aliquots for pharmacokinetics 
analysis : 1 for testing and 1 for back -up. Plasma sample s will be tested for anti -drug antibodies.  
Samples collected for analyses of imetelstat  plasma concentration and antibody to imetelstat  may 
additionally be used to ev aluate safety or efficacy aspects that address concerns arising during or 
after the study period, for further characterization of immunogenicity or for the evaluation of 
relevant biomarkers or metabolites of imetelstat . Genetic analyses will not be perform ed on these 
samples. Subject confidentiality will be maintained. At visits where plasma concentration and 
antibodies to imetelstat  will be evaluated, 1 blood sample can be used.  
The exact dates and times of blood sampling  and bone marrow sampling  must  be recorded. Refer 
to the Laboratory Manual or equivalent document for sample collection requirements. Collected 
samples must be stored under the specified and controlled conditions for the temperatures indicated 
in the Laboratory Manual.  
Collection of plasm a and/or bone marrow samples may be deferred or suspended during the study 
if the objectives of PK/PD analysis are met.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
67 
Status: Approved , Date: 28 March 2019  9.3.2.  Analytical Procedures  
Pharmacokinetics  
Plasma samples will be analyzed to determine concentrations of imetelstat using a validated, 
specific, and sensitive hybridization ELISA method by or under the supervision of the sponsor . 
If required, some plasma samples may be analyzed to document the presence of circulating 
metabolites using a research characterization method. In addition, plasma PK  samples may be 
stored for future analysis.  
Bone marrow samples will be analyzed to determine concentrations of imetelstat using a qualified 
method.  
Immunogenicity  
The detection and characterization of antibodies to imetelstat  will be performed using a v alidated 
assay method by or under the supervision of the sponsor . All plasma samples collected for 
detection of antibodies to imetelstat  will also be evaluated for imetelstat  plasma  concentration to 
enable interpretation of the antibody data.  
9.3.3.  Pharmacok inetic Parameters  
Pharmacokinetic analysis will be the responsibility of the sponsor  in accordance with the sponsor ’s 
current Clinical Pharmacokinetics Guideline.  For all subjects who have serial pharmacokinetic 
blood samples collected, based on the indivi dual plasma concentration -time data, using actual 
sampling times, the following plasma pharmacokinetic parameters of imetelstat will be determined 
via non -compartmental analysis with validated Phoenix™ WinNonlin® software (Pharsight 
Corporation, Certara, L .P., St. Louis, MO):  
Cmax  maximum observed plasma concentration  
tmax   time to reach the maximum observed plasma concentration  
AUC 0-24h  area under the plasma concentration -time curve from time 0 to 24 hours postdose  
t1/2 elimination half -life associated with the terminal slope ( z) of the semi -logarithmic 
drug concentration -time curve, calculated as 0.693/ z 
Additional pharmacokinetic parameters may be determined as appropriate.  
Sparse Pharmacokinetic Blood Sample Collection  
Model -derived exposure paramet ers (eg, C max or AUC) may be selected to further explore 
pharmacokinetic/pharmacodynamic correlation between exposure with relevant clinical, 
pharmacodynamic, or biomarker information imetelstat.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
68 
Status: Approved , Date: 28 March 2019  9.3.4.  Immunogenicity Assessments  
Antibodies to imetelstat  (anti-drug antibodies  [ADA] ) will be evaluated in plasma samples 
collected from all subjects according to the Time and Events Schedule. Additionally, plasma 
samples should also be collected at the final visit from subjects who are discontinued from 
treatmen t or withdrawn from the study. These samples will be tested by the sponsor  or sponsor 's 
designee.  
Plasma samples will be screened for antibodies binding to  imetelstat  and the titer of confirmed 
positive samples will be reported. Other analyses may be perfo rmed to verify the stability of 
antibodies to  imetelstat  or to further characterize the immunogenicity of  imetelstat.  
9.4. Pharmacodynamic Evaluations  
Blood samples for PD analysis will be collected as outlined in the Time and Events Schedule to 
evaluate the ta rget engagement by examining the change in TA, TL and hTERT RNA expression 
levels . 
Additional blood samples will be collected per the Time and Events Schedule to assess target 
inhibition after dose escalation for subjects initially treated with 4.7  mg/kg who were  subsequently 
dose escalated to 9.4 mg/kg.   
9.5. Pharmacokinetic/Pharmacodynamic Evaluations  
A nonlinear mixed effects  PK model will be built to characterize and predict the overall exposure 
of imetelstat in MF subjects  and determine different PK parameters, such as, clearance (CL), 
volume of distribution (V), and metrics of systemic exposure AUC  and Cmax. PK/PD models will 
be constructed to describe and understand the relationship between imetelstat exposure and 
hematol ogical effects (hemoglobin concentrations in blood and platelets count) as well as efficacy 
(spleen volume and response). The immunogenicity effects on imetels tat pharmacokinetics and 
exposure –response relationships for efficacy and safety will be assessed . Model -based simulations 
will be conducted to optimize the dose and to help guide the design of future studies. If sufficient 
data are available, PK/PD modeling may be performed to explore the relationship between 
pharmacokinetic parameters (eg, C max or AUC) and pharmacodynamic biomarkers (eg, change of 
TA, TL or hTERT from baselines after treatment).  
9.6. Biomarkers  
Blood samples will be collected as outlined in the Time and Events Schedule for mutational 
analysis. Genomic DNA will be prepared from isolated gr anulocytes to characterize the mutation 
status on a panel of myeloid related genes by next -generation sequencing (NGS) or other 
methodology where necessary to evaluate the association with clinical response . 
Additional blood samples will be collected as ou tlined in the Time and Events Schedule and may 
be used to explore imetelstat effects on myeloid progenitor cells differentiated into terminal 
functional myeloid cells by immunophenotyping and functional profiling using flow cytometer, 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
69 
Status: Approved , Date: 28 March 2019  CyTOF or similar assa ys. A portion of the previously collected blood samples may be used to 
evaluate imetelstat effects on key cytokine and chemokines that are involved in inflammation, 
immune response, and repair by immuno -multiplexing analysis  or other methodology where 
necessary . 
Where clinically feasible, bone marrow aspirates will be collected as outlined in the Time and 
Events Schedule. Peripheral blood may be submitted in place of an aspirate only in cases where a 
bone marrow aspirate cannot be obtained . Every effort sho uld be made to continue collecting the 
same type of sample (bone marrow aspirate or peripheral blood) at screening and subsequent time 
points  when possible . Karyotype testing may be performed to characterize cytogenetic 
abnormalities at screening to correl ate to clinical response; and to evaluate eradication or reduction 
of a preexisting abnormality to assess the rate of cytogenetic response as defined by modified 2013 
IWG-MRT response criteria for MF .28 Sites will be notified if a subject’s baseline bone marrow 
aspirate does not show an abnormality and collection of samples for cytogenetics will cease for 
these subjects. Subjects who show a cytogeneti c abnormality at baseline will continue to have 
samples  collected . 
Stopping Analysis  
Biomarker analyses are dependent upon the availability of appropriate biomarker assays and 
clinical response rates. Biomarker analysis may be deferred or not performed, if  during or at the 
end of the study, it becomes clear that the analysis will not have sufficient scientific value for 
biomarker evaluation, or if there are not enough samples or responders to allow for adequate 
biomarker evaluation. In the event the study i s terminated early or shows poor clinical efficacy, 
completion of biomarker assessments is based on justification and intended utility of the data.  
Additional Collections  
If it is determined at any time before study completion that additional material is n eeded from a 
formalin -fixed , paraffin -embedded (FFPE) bone marrow sample for the successful completion of 
the protocol -specified analyses, then the sponsor  may request that additional material be retrieved 
from existing samples. Also, based on emerging sci entific evidence, the sponsor  may request 
additional material from previously collected bone marrow samples during or after study 
completion for a retrospective analysis. In this case, such analyses would be specific to research 
related to the study drug(s ) or diseases being investigated.  
9.7. Patient Reported Outcomes  
Additional PROs including health -related quality of life, pain, and overall change in patient’s 
health will be assessed using the EORTC QLQ -C30, EQ5D, the BPI and the PGIC at certain visits 
as indicated in the Time and Event Schedule. The EORTC QLQ -C30 and  instructions will be 
provided as separate documents. It is preferred that t he paper PRO assessment questionnaires are 
administered before any tests, procedures, or other consultations and they should be done in the 
same order at each visit for each subjec t to ensure that the subject is answering these as consistently 
as possible. These PRO data will be used to further validate the modified MFSAF v2.0. 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
70 
Status: Approved , Date: 28 March 2019  The EORTC QLQ -C30 includes 30 items resulting in 5 functional scales (physical functioning, 
role functioni ng, emotional functioning, cognitive functioning, and social functioning), 1 Global 
Health Status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items 
(dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The recall 
period is 1 week (the past week). The EORTC QLQ -C30 has been used widely among cancer 
patients. Scores are transformed to a 0 to 100 scale. Administration time is approximately 11 
minutes. Reliability, validity, and clinically mea ningful change have been demonstrated in patients 
with multiple myeloma .8,1 The focus of the PRO assessment will be the global health scale which 
is designat ed as a secondary endpoint. The remaining domains are included as exploratory 
endpoints.  
The EQ -5D-5L is a generic measure of health status. For purposes of this study, the EQ -5D-5L 
will be used to generate utility scores for use in cost effective analyses . The EQ -5D-5L is a 5 -item 
questionnaire that assesses 5 domains including mobility, self -care, usual activities, 
pain/discomfort and anxiety/depression plus a visual analog scale rating “health today” with 
anchors ranging from 0 (worst imaginable health s tate) to 100 (best imaginable health state) .11,24 
The scores for the 5 separate questions are categorical and are cannot be analyzed as cardinal 
numbers. However, the scores for the 5 dimensions are used to compute a single utility score 
ranging from zero (0.0) to 1 (1.0) representing the gener al health status of the individual.   
The BPI has become one of the most widely used measurement tools for assessing clinical pain. 
The BPI allows patients to rate the severity of their pain and the degree to which their pain 
interferes with common dimensio ns of feeling and function. Initially developed to assess pain 
related to cancer, the BPI has been shown to be an appropriate measure for pain caused by a wide 
range of clinical conditions.10 The BPI is a 9 -item measure that captures both pain intensity 
(severity) and the impact of pain on functioning (interference).  
The PGIC is used to capture the patient perspective of improvement or decline in MF symptoms 
over time. The PGIC has a 7 –point response scale ranging from 1 (very much improved) to 7 (very 
much worse), with 4 representing no change.  
9.8. Safety Evaluations  
All subjects who receive treatment will be considered evaluable for toxicity. Any clinic ally 
relevant changes occurring during the study must be recorded on the Adverse Event section of the 
CRF . Any clinically significant abnormalities persisting at the end of the study/early withdrawal 
will be followed by the investigator until resolution or  until a clinically stable endpoint is reached.  
The Sponsor ’s Committee will review all the safety data on a quarterly basis, or ad hoc, as needed. 
The study will include the following evaluations of safety and tolerability according to the time 
points pro vided in the Time and Events Schedule:  
Adverse Events  
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or 
the subject's legally acceptable representative) for the duration of the study . Adverse events will 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
71 
Status: Approved , Date: 28 March 2019  be followed by the investigator as specified in Section  12, Adverse Event Reporting. Adverse 
events will be reported and graded according to the Natio nal Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI -CTCAE), Version 4.03.  
Adverse Events of Interest  
Specific adverse events or groups of adverse events will be followed as part of standard safety 
monitoring activities by the sponsor . These events will be reported to the sponsor  within 24  hours 
of awareness irrespective of seriousness (ie, serious and nonserious adverse events) following the 
procedure described in the protocol for serious adverse events and will require enhanced data 
collection. For this study the adverse events  of special interest include:  
• ALT Grade ≥3 (>5.0 x ULN)  
• AST Grade ≥3 (>5.0 x ULN)  
• Bilirubin Grade ≥3 (>3.0 x ULN)  
• ALP Grade ≥ 3 (>5.0 x ULN)  
• All hepatic adverse events  
For these events laboratory assessments sho uld be repeated weekly until bilirubin with 
fractionation is <3x ULN, and ALT, AST and ALP is <5 x ULN.  Additionally, subjects with Grade 
1 and Grade 2 treatment emergent elevations in AST, ALT, ALP and bilirubin at the time of 
treatment discontinuation sh ould continue to have laboratory assessments monthly until resolution 
to at least baseline. All hepatic adverse events and LFT abnormalities will be reviewed by an 
Independent Hepatic Expert Committee , at least  quart erly, or as needed .  
Clinical Laboratory  Tests  
All laboratory tests should be performed at the laboratory facilities associated with the 
investigational site. Laboratory certificates or accreditation and normal ranges of the laboratory 
facility at the site must be submitted to the sponsor  before  the enrollment of any subject at the site. 
If the subject has the laboratory assessments conducted at a laboratory facility other than the one 
associated with the investigational site, then the investigator must submit to the sponsor  laboratory 
certificates or accreditation and normal ranges for that facility as well.  The laboratory reports must 
be filed with the source documents.  
Blood samples for serum chemistry and hematology to assess the safety of study treatment will be 
collecte d. Required laboratory tests must be performed within 48  hours prior to the scheduled visit. 
For Cycle 1, Day 1 only, clinical laboratory tests do not need to be repeated if the Screening tests 
were performed within 5 days of the first dose of study treatm ent. 
The investigator must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the adverse event section of the CRF. For example, 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
72 
Status: Approved , Date: 28 March 2019  laboratory abnormalities leading to an action regardi ng any study treatment (dose reduction, 
temporary stop, delay of the start of a cycle or permanent stop) or the start of concomitant therapy 
should be reported. For each laboratory abnormality reported as an adverse event, the following 
laboratory values s hould be reported in the  laboratory section of the CRF: the value indicative of 
the onset of each toxicity grade; the most abnormal value observed during the adverse event, and 
the value supporting recovery to Grade ≤ 1 or to baseline values.  
The following  tests will be performed by the local laboratory at the time points shown the Time 
and Events Schedule : 
• Hematology Panel  
-hemoglobin  -white blood cell (WBC) count  
-absolute neutrophil count  (ANC)  -platelet count  
-manual percent immature myeloid cells 
(blasts, promyelocytes, myelocytes , 
metamyelocytes and nucleated RBC)   
 
• Serum Chemistry Panel  
-sodium  -alkaline phosphatase  (ALP)  
-potassium  -lactic acid dehydrogenase (LDH)  
-blood urea nitrogen (BUN)  -albumin  
-creatinine  -serum ferritin  
-alanine aminotransferase (ALT)  -aspartate aminotransferase (AST)  
- total bilirubin  (with fractionation at 
screening ; with fractionation post-screening if 
total bilirubin is abnormal)  
  
• INR (or PT) and aPTT  
• Expanded LFT Panel  
- gamma -glutamyl transpeptidase (GGT)  - magnesium  
- chlori de - fractionated bilirubin  
- bicarbonate   
 
An expanded LFT panel is required for all subjects at screening and if an adverse event of 
interest is reported . For subjects with AST, ALT, ALP or bilirubin Grade ≥3, LFT  laboratory 
assessments need to be  repeated weekly until bilirubin with fractionation is <3x ULN, and 
AST, ALT and ALP are <5 x ULN. Additionally, subjects with Grade 1 and Grade 2 treatment 
emergent elevations in AST, ALT, ALP or bilirubin at the time of treatment discontinuation 
should continue to have laboratory assessments monthly until resolution to at least baseline . 
• Viral hepatitis: Screening for hepatitis should include hepatitis serology panel A through  E. 
Hepatitis D serology is only required if the subject tests positive for the hepatitis B surface 
antigen (HBsAg).  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
73 
Status: Approved , Date: 28 March 2019  • Peripheral Blood Smear: A peripheral blood smear should be performed at the time  points 
shown in the Time and Events Schedule . 
Electrocardiogra m (ECG)  
A 12-lead ECG will be performed at Screening . During the collection of ECGs, subjects should be 
in a quiet setting without distractions (eg, television, cell phones). Subjects should rest in a supine 
position for at least 5  minutes before ECG colle ction and should refrain from talking or moving 
arms or legs. If blood sampling or vital sign measurement is scheduled for the same time point as 
ECG recording, then the procedures should be performed in the following order: ECG(s), vital 
signs, blood draw . 
Vital Signs  
Temperature, pulse/heart rate, and blood pressure will be recorded , preferably while the subject is 
seated,  at the time  points specified in the Time and Events Schedule. Vital signs that are considered 
to be clinically relevant by the investi gator are to be documented as adverse events.   
Physical Examination  
Screening physical examination should include body weight, height, and the evaluation of head, 
eye, ear, nose, and throat (HEENT), cardiovascular, dermatological, musculoskeletal, respiratory, 
gastrointestinal, and neurological systems. Only a limited symptom -directed physical examination  
including spleen palpation  and weight assessment is required on Day 1 of all cycles after baseline. 
New or worsened abnormalities should be record ed as adverse events if appropriate.  
ECOG Performance Status  
The ECOG performance status scale will be used to grade changes in the subject’s activities of 
daily living.  
9.9. Sample Collection and Handling  
The actual dates and times of sample collection must be  recorded in the CRF or laboratory 
requisition form.  Refer to the Time and Events Schedule for the timing and frequency of all sample 
collections.  Instructions for the collection, handling, storage, and shipment of samples are found 
in the Laboratory Manua l that will be provided.  
10. SUBJECT COMPLETION/WITHDRAWA L 
10.1.  Completion  
A subject will be considered to have completed the study if he or she has finished all 
protocol -specified procedures before the end of the study, has not been lost to follow -up, or has 
not w ithdrawn consent for study participation before the end of the study.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
74 
Status: Approved , Date: 28 March 2019  10.2.  Discontinuation of Study Treatment  
Investigators are encouraged to keep a subject experiencing clinical benefit in the study unless 
significant toxicity puts the subject at risk or routi ne noncompliance puts the study outcomes at 
risk. If a subject's study treatment must be discontinued before the end of the treatment regimen, 
then this will not result in automatic withdrawal of the subject from the study.  
A subject's study treatment sho uld be discontinue d if: 
• The investigator believes that for safety reasons (eg,  adverse event) it is in the best interest of 
the subject to discontinue study  treatment  
• The subject becomes pregnant  
• The subject experiences overt disease progression or relapse  
• The subject experiences unacceptable toxicity  
• The subject refuses further treatment  
• A serious protocol violation has occurred, as determined by the principal investigator or the 
sponsor  
End-of-treatment and posttreatment follow -up assessments should be obtained . The reason(s) a 
subject discontinues treatment will be recorded on the CRF.  
10.3.  Withdrawal From the Study  
A subject will be withdrawn from the study for any of the following reasons:  
• Lost to follow -up  
• Withdrawal of consent  
• The sponsor  discontinues t he study  
If a subject is lost to follow -up, then every reasonable effort must be made by the study site 
personnel to contact the subject and determine the reason for discontinuation/withdrawa l. The 
measures taken to follow -up must be documented.  
When a subject withdraws before completing the study, the reason for withdrawal is to be 
documented in the CRF and in the source document. Study drug assigned to the withdrawn subject 
may not be assigned to another subject. Subjects who withdraw will not be replaced.  If a subject 
withdraws from the study before the end of the treatment phase, then end-of-treatment and 
posttreatment assessments should be obtained.  
Withdrawal From the Use of Sample s in Future  Research  
The subject may withdraw consent for use of sample s for research ( refer to  Section 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroyed after they are no longer needed for the clinical study. Details of the sample retention  for 
research are presented in the main ICF.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
75 
Status: Approved , Date: 28 March 2019  11. STATISTICAL METHODS  
Statistical analysis will be done by the sponsor  or under the authority of the sponsor . A general 
description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan.  
11.1.  Analysis Set  
The Treated Populat ion will consist of all subjects who receive at least 1 dose of study drug. 
Primary efficacy and safety analyses will be performed using the Treated Population.  The intent -
to-treat (ITT) population will consist of all subjects who are randomized.  
The PK/PD  Population will consist of all subjects who received at least 1 dose of study drug and 
had at least 1 sample collected during treatment to determine the drug concentration or 
pharmacodynamic  biomarker response.  
The treatment arms will be evaluated indepen dently. Continuous variables will be summarized 
using descriptive statistics such as mean, median, standard deviation  (SD) , 25th/75th percentiles,  
and range. Categorical variables will be summarized using frequency tables. For time -to-event 
variables, the Kaplan -Meier method will be used for descriptive summaries.  
11.2.  Sample Size Determination  
The study was originally designed to  enroll approximately 200 subjects ( approximately 100/arm). 
On the basis of historical data, the outcomes are poor for patients whose disease is  relapsed after 
or refractory to JAK inhibitor therapy. The expected spleen response rate (proportion of subjects 
who achieve ≥35% reduction in spleen volume at Week 24) and symptom response rate (proportion 
of subjects who have ≥ 50% reduction in  TSS at Week 24) in patients with salvage therapy or 
without treatment . 
For each treatment arm, the sample size is calculated based on the following assumptions:  
1. null hypothesis:  
2. alternative hypothesis:  
3. the null hypothesis is tested by the intersection -union test .6 Each of the co -primary endpoints 
is tested at one sided α=0.025, and the maximum Type I error rate for testing co -primary 
endpoints is the same as one sided α=0.025  
 
 
 
 
 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
76 
Status: Approved , Date: 28 March 2019   
 
The original study design allowed for enrollment of approximately 200 subjects ; however, 
following the first interim review of data, and in line  with Protocol Amendment 2 , enrollment of 
new subjects into Arm A was suspended and enrollment into Arm B was permanently closed . 
Therefore, total enrollment in the study may be approximately 1 60 subjects if enrollment in Arm 
A is resumed after the second interim review.   
11.3.  Subject Information  
The number of subjects enrolled, dosed, and discontinued will be summarized. Treatment 
discontinuation will be summarized according to the reasons for discontinuation.  
Demographic and baseline vital sign variables will include age, sex, race, ethnicity, height, weight, 
blood pressure, and weight. Baseline disease characteristics (documented in the source documents 
and CRF s) will be summarized.  
11.4.  Efficacy Analyses  
Planned efficacy analyses are as follows: (1) a first interi m review after approximately 20  subjects 
in each arm have been followed for at least 12 weeks; (2)  a second interim review with a clinical 
cutoff that is 6 months after the clinical cutoff used for the first interim review ; (3) the primary 
efficacy analysi s after all subjects have been followed for at least 24 weeks ; (4) the final analysis 
at the end of  the main  study, which is defined as 18 months after the last subject is enrolled or 
when  the sponsor  terminates the study ; and (5) OS -related analysis will be performed or updated 
when the Extension Phase has ended . 
Primary Endpoint  Analys es 
The analysis for the co -primary endpoints (spleen response rate and symptom response rate) will 
be based on the Treated Population. For each treatment arm, spleen response rate and symptom 
response rate will be presented along with their 95% 2 -sided exact confidence  interval . Sensitivity 
analysis may be performed on the intent -to-treat population and evaluable population in support 
of the primary analysis if deemed appropriate.  
Spleen response rate is defined as the proportion of subjects who achieve  ≥35% reduction in spleen 
volume at Week 24 from baseline as measured by imaging scans. The spleen response data 
reviewed by the IRC will be used for the interim data reviews, the primary analysis , and the final 
analysis. The response data assessed by the investigators will be used as a supportive analysis.  
Symptom response rate is defined as the proportion of subjects who have ≥50% reduction in TSS 
at Week 24 from baseline as measured by the modified MFSAF v2 .0 diary . The  TSS will be 
calculated as the 7 -day average of daily TSS, which is the summation of 6 individual symptom 
scores (night sweats, itchiness, abdominal discomfort, pain under ribs on left side, early satiety, 
bone or muscle pain).  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
77 
Status: Approved , Date: 28 March 2019  Secondary Endpoint  Analys es 
• Proportion of subjects with CR  or PR, and proportion of subjects with CI will be evaluated 
using the same statistical methods as for the primary endpoint s. 
• Proportion of subjects with spleen response, symptoms response, and a nemia response per 
modified 2013 IWG -MRT criteria will be reported along with a 95% confidence interval.   
• The distribution s of duration of spleen response and duration of symptom response  will be 
summarized  using Ka plan-Meier estimates  based on responding subjects . The estimated 
median will also be reported along with a 95% confidence interval. Duration of CR  or PR, CI, 
and anemia response will be provided descriptively using similar methods based on 
responding subje cts. 
• The d istribution of OS will be summarized  using similar Kaplan -Meier methods.  
• Change in spleen volume, change  in TSS, and change in PRO endpoints from baseline will be 
descriptively summarized over time.  
• Additional analyses to be performed for the su bjects who were initially treated with 4.7  mg/kg 
and subsequently dose escalated to 9.4 mg/kg per the guidance outlined in Section 6. 
11.5.  Pharmacokinetic Analyses  
Pharmacokinetic Blood Sample Collection  
Pharmacokinetic data collected from the sparse and intensive PK sampling will be pooled for the 
analysis. Nonlinear mixed eff ects modeling using NONMEM software will be used to develop the 
population PK model in MF subjects . Different structural and random effects models will be 
considered and compared. A stepwise covariate model building strategy will be adopted and 
covariate e ffects on PK parameters will be explored. Diagnostic plots, summary statistics, and a 
comparison of raw data to model predictions will be evaluated.  
Serial Pharmacokinetic Blood Sample Collection  
Data will be listed for all subjects with available plasma c oncentrations per treatment. Subjects 
will be excluded from the PK analysis in situations where extenuating factors preclude an accurate 
assessment of the PK parameters of interest (eg, incomplete administration of the study drug; 
concentration data not su fficient for PK parameter calculation due to missing PK draws at multiple 
visits; or early discontinuation from the study).  
All plasma concentrations below the lowest quantifiable concentration or missing data will be 
labeled as such in the concentration d ata presentations. Concentrations below the lowest 
quantifiable concentration will be treated as zero in the calculation of PK parameters and for the 
calculation of summary statistics of concentration -time data as per the PK analysis guideline. All 
subject s and samples excluded from the analysis will be clearly documented in the Clinical Study 
Report.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
78 
Status: Approved , Date: 28 March 2019  Mean and individual plasma concentrations of imetelstat  versus time profiles will be plotted. 
Descriptive statistics of imetelstat , including arithmetic m ean, SD, coefficient of variation, 
geometric mean ( PK parameters only), median, minimum, and maximum will be calculated for 
the imetelstat  plasma concentrations at each sampling time for imetelstat  and for all PK parameters 
of imetelstat.  
11.6.  Immunogenicity Analyses  
The incidence of antibodies to  imetelstat  will be summarized for all subjects who receive at least 
1 dose of  imetelstat  and have appropriate samples for detection of antibodies to  imetelstat  
(ie, subjects with at least 1 sampl e obtained after administration of at least one dose of imetelstat). 
The results will be summarized by treatment arm and subjects with appropriate samples for the 
detection of antibodies to imetelstat.  
11.7.  Pharmacokinetic/Pharmacodynamic Analyses  
Different PK/ PD models will be built to understand and characterize the exposure -response 
relationship for key efficacy and safety parameters, to detect the influence of covariates, and 
identify inter -individual variability in response. The exposure -response analysis f or efficacy 
parameters includes SVR from baseline at Week 12 and the proportion of subjects  with response 
(35% SVR from baseline at Week 12). The exposure -response analysis for safety parameters will 
characterize the time course of platelet counts and hem oglobin. If sufficient data are available, 
then the immunogenicity effect on imetels tat PK and exposure –response relationships for efficacy 
and safety will be assessed and the correlation between the exposure and the change of biomarkers 
will be explored. The details will be given in the modeling analysis plan.  If sufficient PD biomarker 
data are available, then the correlation between exposure and the change of PD will be explored.  
11.8.  Biomarker Analyses  
Biomarker measures and the change from baseline will be listed, tabulated, and plotted where 
appropriate. Subjects may be grouped by dose, or clinical response. Correlation of baseline or 
changes of biomarkers with clinical parameters will be analyzed by appropriate statistical methods 
(eg, parametric or non -parametric, univariate or multivariate).  
Results  of biomarker analyses may be presented in a separate report. Planned analyses are based 
on the availability of clinically valid assays and may be deferred if emerging study data show no 
likelihood of providing  useful scientific information.  
11.9.  Safety Analyses  
Safety analyses will be performed using the Treated Population. Safety will be evaluated using the 
NCI-CTCAE (Version 4.03). The safety parameters to be evaluated are the incidence, intensity, 
and type of adv erse events, clinically significant changes in the subject’s physical examination 
findings, vital signs measurements, clinical laboratory results (hematology and chemistry), and 
deaths. Exposure to study treatment and reasons for discontinuation will be ta bulated. Safety 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
79 
Status: Approved , Date: 28 March 2019  variables are to be tabulated by descriptive statistics (n, mean, median, SD, minimum, and 
maximum; or n and percent).  
Additional analyses will be performed for the subjects who were initially treated with imetelstat 
4.7 mg/kg and subsequently dose escalated to 9.4 mg/kg per the guidance outlined in Section 6. 
Adverse Events  
Treatment -emergent adverse events are adverse events that  occur after the first dose of study drug, 
through the Treatment Phase, and for 30 days following the last dose of study drug; any adverse 
event considered study drug -related regardless of the start date of the event; or any event that is 
present at baseli ne but worsens in severity or is subsequently considered drug -related by the 
investigator. The number and percent of subjects with treatment -emergent adverse events will be 
summarized according to intensity (NCI -CTCAE, Version 4.03) and drug relationship a s well as 
categorized by System Organ Class and preferred term by treatment arm.  
The verbatim terms used in the CRF by investigators to identify adverse events will be coded using 
the Medical Dictionary for Regulatory Activities (MedDRA). Treatment -emergen t adverse events 
are adverse events with onset during the treatment phase or that are a consequence of a pre -existing 
condition that has worsened since baseline. All reported adverse events will be included in the 
analysis. For each adverse event, the perc entage of subjects who experience at least 1  occurrence 
of the given event will be summarized by treatment arm.  
Clinical Laboratory Tests  
Laboratory data will be summarized by type of laboratory test. Reference ranges and markedly 
abnormal results (specified in the Statistical Analysis Plan) will be used in the summary of 
laboratory data. Descriptive statistics will be calculated for each laboratory analyte at baseline and 
for observed v alues and changes from baseline  at each scheduled time point . 
Parameters with predefined NCI -CTCAE toxicity grades will be summarized.  A summary of the 
shifts in selected laboratory hematology and serum chemistry parameters from baseline to the 
worst toxicity grade experienced by the subject during treatment  will be p rovided. The worst 
toxicity grade during the study will be tabulated.  
Electrocardiogram (ECG)  
Electrocardiogram data will be listed  by ECG parameter at Screening.  
Vital Signs  
Descriptive statistics of temperature, heart rate, respiratory rate, and blood pr essure (systolic and 
diastolic) values and changes from baseline will be summarized. The percentage of subjects with 
clinically important changes from baseline will be summarized.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
80 
Status: Approved , Date: 28 March 2019  11.10.  Interim Review  
The first interim data review was designed as follows: The fi rst interim review was performed  
after approximately 20 subjects were  randomized in each arm and followed for at least 12 weeks. 
The goal of the interim review was to assess safety and early efficacy and perform comprehensive 
exposure -response analyses. Ba sed on this analysis, if both doses were efficacious and had an 
acceptable safety profile, both arms will continue with enrollment until approximately 100 subjects 
per arm are enrolled. If only one dose was efficacious and had an acceptable safety profile, then 
that arm would continue enrollment , and enrollment would  be stopped in the other arm. In the case 
that both arms were  not efficacious and safe, an alternative dose may be selected based on the 
PK/PD exposure -response, effica cy, and safety analysis and a protocol amendment would  be 
implemented to reflect this. Study enrollment continue d at the time of interim review.   
Safety was evaluated using the following parameters (including but not limited to): adverse events, 
serious ad verse events, dose modifications and subject compliance.  PK/PD exposure -response 
analyses for efficacy parameters (e g, SVR  from baseline at Week 12), and for safety parameters 
(eg, platelets and hemoglobin) were be conducted.  Biomarkers such as change in T A, TL and 
hTERT from baseline was evaluated for subjects  with available data.  
Early efficacy was evaluated by SVR  by MRI and as assess ed by the investigator.  
 
 
 
 Other efficacy data including symptoms, peripheral 
blood counts and bone marrow data up to interim was reviewed as well. This guideline was 
intended to inform the decision, which was expected to be multifactorial taking into consideration 
safety, tolerability, and PK/PD modeling.  
At the time of Protocol Amendment 2, enrollment of new subjects in this study is suspended. A 
second interim review will be performed with a clinical cutoff that is 6 months after the clinical 
cutoff used for the first interim review . It is expected that approximately 35 subjects who were  
enrolled and treated in the 9.4 mg/kg arm will have been followed for at least 24 weeks. IRC 
assessment of SVR will be used for efficacy evaluation.  
 
 
 
 
 
 
11.11.  Data Analysis Committees  
A Sponsor  Committee including the  study physician, safety physician, study scientist and 
statistician will be established to monitor data on an ongoing basis to ensure the safety of the 
subjects enrolled in this study. The safety review wi ll focus on , but will not be limited to, deaths, 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
81 
Status: Approved , Date: 28 March 2019  treatment discontinuations, serious adverse events, Grade  ≥ 3 events, and events of special interest. 
The Sponsor  Committee responsibilities, authorities, and procedures will be documented in a 
charter.  
Addi tionally , an Independent Hepatic Expert Committee consisting of 3 hepatologists will be 
established to monitor liver data on an ongoing basis. The Hepatic Expert Committee will review 
all hepatic adverse events and LFT abnormalities on at least a quarterly  basis or as needed. The 
Hepatic Expert Committee responsibilities, authorities, and procedures will be documented in a 
charter.  
The Hepatic Expert Committee will meet to review all hepatic serious adverse events reported 
during the Extension Phase, and th e Sponsor Committee will continue to review study data . 
12. ADVERSE EVENT REPORT ING 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor , and are mandated by 
regulatory agencies worldwide. The sponsor  or its affiliates has established Standard Operating 
Procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting 
of safety information; all clinical studie s conducted by the sponsor  or its affiliates will be 
conducted in accordance with those procedures.  
12.1.  Definitions  
12.1.1.  Adverse Event Definitions and Classifications  
Adverse Event  
An adverse event is any untoward medical occurrence in a clinical study subject admi nistered a 
medicinal (investigational or non -investigational) product. An adverse event does not necessarily 
have a causal relationship with the treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal finding ), symptom, or disease temporally associated 
with the use of a medicinal (investigational or non -investigational) product, whether or not related 
to that medicinal (investigational or non -investigational) product. (Definition per International 
Conference o n Harmonisation [ICH]) . 
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.  
Note: The sponsor  collects adverse events starting with the signing of the ICF (refer to  
Section  12.3.1 , All Adverse Events, for time of last adverse event recording ). 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
82 
Status: Approved , Date: 28 March 2019  Serious Adverse Event  
A serious adverse event based on ICH and European Union ( EU) Guidelines on Pharmacovigilance 
for Medicinal Products for Human Use is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening   
(The subje ct was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or sig nificant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is a suspected transmission of any infectious agent via a medicinal product  
• Is Medically Important*  
*Medical and scientific judgment should be exercised in deciding whether expedited repor ting is 
also appropriate in other situations, such as important medical events that may not be immediately 
life threatening or result in death or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcome s listed in the definition above. These should 
usually be considered serious.  
Unlisted (Unexpected) Adverse Event/Reference Safety Information  
An adverse event is considered unlisted if the nature or severity is not consistent with the applicable 
product r eference safety information. For imetelstat , the expectedness of an adverse event will be 
determined by whether or not it is listed in the Investigator's Brochure.  
Adverse Event Associated With the Use of the Drug  
An adverse event is considered associate d with the use of the drug if the attribution is possible, 
probable, or very likely by the definitions listed in Section  12.1.2 . 
12.1.2.  Attribution Defini tions  
Not Related  
An adverse event that is not related to the use of the drug.  
Doubtful  
An adverse event for which an alternative explanation is more likely, eg,  concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causa l relationship is unlikely.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
83 
Status: Approved , Date: 28 March 2019  Possible  
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal rela tionship cannot be excluded.  
Probable  
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg,  concomitant drug(s), 
concomitant disease( s). 
Very Likely  
An adverse event that is listed as a possible adverse reaction and cannot be reasonably explained 
by an alternative explanation, eg,  concomitant drug(s), concomitant disease(s). The relationship in 
time is very suggestive (eg,  it is confirm ed by dechallenge and rechallenge).  
12.1.3.  Severity Criteria  
An assessment of severity grade will be made using the NCI -CTCAE (Version 4.03) as follows:  
Grade 1 (Mild) : Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with everyday activities.  
Grade 2 (Moderate) : Sufficient discomfort is present to cause interference with normal activity.  
Grade 3 (Severe) : Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal ever yday activities.  
Grade 4, Life -threatening : Urgent intervention indicated.  
Grade 5, Death : Death.  
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg,  laboratory abnormalities).  
12.2.  Spec ial Reporting Situations  
Safety events of interest on a sponsor  study drug  that may require expedited reporting and/or safety 
evaluation include, but are not limited to: 
• Overdose of a sponsor  study drug  
• Suspected abuse/misuse of a sponsor  study drug  
• Inadve rtent or accidental exposure to a sponsor  study drug  
• Medication error involving a sponsor  product (with or without subject/patient exposure to the 
sponsor  study drug , eg, name confusion)  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
84 
Status: Approved , Date: 28 March 2019  • Exposure to a sponsor study drug from breastfeeding  
Special reporting  situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the CRF.  
12.3.  Procedures  
12.3.1.  All Adverse Events  
All subjects who receive treatment will be considered evaluable for toxicity. All adverse events 
(with the exception of progression of MF) and special reporting situations, whether serious or 
nonserious, will be reported from the time a signed and dated ICF is obtained until completion of 
the subject's last study -related procedure (which may include contact for follow -up of safety). 
Serious adverse events, including those spontaneously reported to the investigator within 30  days 
after the last dose of study drug, must be reported using the S erious Adverse Event Form. The 
sponsor  will evaluate any safety information that is spontaneously reported by an investigator 
beyond the time frame specified in the protocol.  
As of Amendment 3, only serious adverse event s will be reported from the time the ICF for the 
Extension Phase is signed and dated until 30 days after the last dose of imetelstat .  
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a 
consequence of the underlying disease or condition under investigation (disease related) or 
background regimen. It is expected that subjects may experience p rogressive disease of MF  during 
the study ; however, disease progression  will be documented as a  study  endpoint  and NOT recorded 
and reported as an adverse event or anticipated event. I nstead , symptoms/clinical signs of disease 
progression may be reported.  Otherwise,  all events  that meet the definition of a serious adverse 
event will be reported as serious adverse events, regardless of whether they are protocol -specific 
assessments.  
All adverse events, regardless of seriousness, severity, or presumed relationship to study drug, 
must be recorded using medical terminology in the source document and the CRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory infection"). Investigators must record in the CRF their opinion concerning the 
relationship of the adverse event to study therapy. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.  
The sponsor  assumes responsibility for appropriate reporting of a dverse events to the regulatory 
authorities. The sponsor  will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs) . For 
anticipated events reported as individual serious adverse events, the sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessment. The 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
85 
Status: Approved , Date: 28 March 2019  sponsor will periodically evaluate the accumulating data and, wh en there is sufficient evidence 
and the sponsor has determined there is a reasonable possibility that the drug caused a serious 
anticipated event, they will submit a safety report in an expedited manner .  
The investigator (or sponsor  where required) must r eport SUSAR s to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless 
otherwise required and documented by the IEC/IRB . 
For all studies with an outpatient phase, including open -label studies, th e subject must be provided 
with a " wallet ( study ) card" and instructed to carry this card with them for the duration of the study 
indicating the following:   
• Study  number  
• Statement, in the local language(s), that the subject is participating in a clinical study  
• Investigator's name and 24 -hour contact telephone number  
• Local sponsor 's name and 24 -hour contact telephone number  (for medical staff only)  
• Site number  
• Subject number  
• Any other information that is required to do an emergency breaking of the blind  
12.3.2.  Serious Adverse Events  
All serious adverse events occurring during the study must be reported to the appropriate sponsor  
contact person by  study -site personnel  within 24  hours of their knowledge of the event.  
Information regarding serious adverse events wi ll be transmitted to the sponsor  using the Serious 
Adverse Event Form, which must be completed and signed by a physician from  the study site , and 
transmitted to the sponsor  within 24 hours. The initial and follow -up reports of a serious adverse 
event shoul d be made by facsimile (fax) . All serious adverse events that have not resolved by the 
end of the study, or that have not resolved upon discontinuation of the subject's participation in the 
study, must be followed until any of the following occurs:  
• The eve nt resolves  
• The event stabilizes  
• The event returns to baseline, if a baseline value/status is available  
• The event can be attributed to agents other than the study drug or to factors unrelated to study 
conduct  
• It becomes unlikely that any additional informa tion can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
86 
Status: Approved , Date: 28 March 2019  Suspected transmission of an infectious agent by a medicinal product will be  reported as a serious 
adverse event. Any event requiring hospitalization (or prolongation of hospitalization) that occurs 
during the course of a subject's participation in a study must be reported as a serious adverse event , 
except hospitalizations for th e following:  
• A standard procedure for protocol therapy administration will not be reported as a serious 
adverse event. Hospitalization or prolonged hospitalization for a complication of therapy 
administration will be reported as a serious adverse event.  
• The administration of blood or platelet transfusion. Hospitalization or prolonged 
hospitalization for a complication of such transfusion remains a reportable serious adverse 
event.  
• A procedure for protocol/disease -related investigations (eg, surgery, scans , sampling for 
laboratory tests, bone marrow sampling, pharmacokinetic or biomarker blood sampling). 
Hospitalization or prolonged hospitalization for a complication of such procedures remains a 
reportable serious adverse event.  
• Hospitalizations not intend ed to treat an acute illness or adverse event (eg, social reasons such 
as pending placement in long -term care facility) . 
• Surgery or procedure planned before entry into the study (must be documented in the CRF). 
Note: Hospitalizations that were planned befo re the signing of the ICF, and where the 
underlying condition for which the hospitalization was planned has not worsened, will not be 
considered serious adverse events. Any adverse event that results in a prolongation of the 
originally planned hospitalizat ion is to be reported as a new serious adverse event.  
Disease progression should not be recorded as an adverse event or serious adverse event term; 
instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of 
efficacy will be  reported if they fulfill the serious adverse event definition ( refer to  Section  12.1.1 , 
Adverse Event Definitions and Classifications) . 
Serious Ad verse Event Reporting Beginning With Amendment 3  
Beginning with Amendment 3, only serious adverse event information will be collected. The 
reporting period extends from the time the ICF for the Extension Phase is signed and dated until 
30 days after the  subject ’s last dose of imetelstat. Serious adverse  event information will be 
provided to the sponsor via the Serious Adverse Event Form. The following information is 
requested for all reports of serious hemorrhagic adverse events and serious hepatic adverse events:  
• Hemorrhagic serious adverse events: INR (or PT), aPTT, and platelet count should be assessed 
and reported in the serious adverse event report . 
• Hepatic serious adverse events: serum chemistry and an expanded liver panel will be assessed  
and reported ; if the event includes Grade 3 or 4 ALP elevation, ALP fractionation or 
5’neucleotidase  will also be assessed and reported.   
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
87 
Status: Approved , Date: 28 March 2019  12.3.3.  Adverse Events of Interest  
Specific adverse events or groups of adverse events will be followed as part of standard safety 
monitoring activities by the sponsor . These events will be reported to the sponsor  within 24  hours 
of awareness irrespective of seriousness (ie, serious and non serious adverse events) following the 
procedure described above for serious adverse events and will require enhanced data collection.  
12.3.3.1.  Elevated Liver Function Tests (LFTs ) 
Elevations in the following LFTs will be captured as adverse events of interest:  
• ALT Grade ≥3 (>5.0 x ULN)  
• AST Grade ≥3 (>5.0 x ULN)  
• Bilirubin Grade ≥3 (>3.0 x ULN)  
• ALP Grade ≥ 3 (>5.0 x ULN)  
12.3.3.2.  Hepatic Adverse Events  
All hepatic adverse events will be captured as adverse events of interest.  
12.3.4.  Pregnancy  
All initial reports of pregnancy in femal e subjects or partners of male subjects must be reported to 
the sponsor  by the study -site personnel  within  24 hours of their knowledge of the event using the 
appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study must discontinue further study treatment.  
The effect of the study drug on sperm is unknown . Therefore , pregnancies in partners of male 
subjects included in the study will be reported by the study -site personnel  within 24 hours of their 
knowledge of the event using the appropriate pregnancy notificat ion form.  
Follow -up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required . 
Pregnancy reporting, as described above, will continue during the Extension Phase.  
12.4.  Contacting Sponsor  Regarding Safety  
The nam es (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed on the Contact Information 
page(s), which will be provided as a separate  document.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
88 
Status: Approved , Date: 28 March 2019  13. PRODUCT QUALITY COMP LAINT HANDLING  
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by regulatory agencies worldwide. The sponsor  has established 
procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting 
of PQC information; all studies conducted by the sponsor  or its affiliat es will be conducted in 
accordance with those procedures.  
13.1.  Procedures  
All initial PQCs must be reported to the sponsor  by the study -site personnel within 24 hours after 
being made aware of the event . 
If the defect is combined with a serious adverse event, then the study -site personnel  must report 
the PQC to the sponsor  according to the serious adverse event reporting timelines (refer to 
Section  12.3.2 , Serious Adverse Events). A sample of the suspected product should be maintained 
for further investigation if requested by the sponsor . 
13.2.  Contacting Sponsor  Regarding Product Quality  
The names (and corresponding telephone numbers) of the individuals who sho uld be contacted 
regarding product quality issues are listed on the Contact Information page(s), which will be 
provided as a separate document.  
14. STUDY DRUG INFORMATI ON 
14.1.  Physical Description of Study Drug(s)  
The imetelstat  supplied for this study i s supplie d as a sterile lyophilized powder in a sealed, stoppered, 
clear glass vial . Each single -dose vial contains 210 mg of imetelstat sodium and is designed to 
deliver a minimum of 200 mg of reconstituted Imetelstat Sodium for Injection at a concentration 
of 33.33 mg/mL.  It will be manufactured and provided under the responsibility of the sponsor . 
Refer to the Investigator's Brochure (IB) for a list of excipients.  
14.2.  Packaging  
Imetelstat is supp lied in glass vials in a protective carton . It will be supplied to th e site/pharmacy 
as bulk supply . All packaging will meet applicable regulatory requirements.  
14.3.  Labeling  
Study drug labels will contain information to meet the applicable regulatory requirements.  Each 
vial will contain a study -specific label with a unique iden tification number.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
89 
Status: Approved , Date: 28 March 2019  14.4.  Preparation, Handling, and Storage  
All study drug must be stored in the original carton in a refrigerator ranging from 2°C to 8°C (36 F-
46 F, refrigerated) and must not be utilized after the expiry date printed on the label. The product 
must not be frozen. Imetelstat does not contain preservatives; therefore any unused portion 
remaining in the vial must be discarded.  
Imetelstat will be reconstituted with 0.9% Sodium Chloride. Refer to the Investigational Product 
Preparation Instructions ( IPPI) and SIPM for details  regarding dose preparation, storage, and 
handling of reconstituted and diluted solutions.  Once reconstituted, imetelstat must be used within 
the time frame specified in the IPPI . 
14.5.  Drug Accountability  
The investigator is responsibl e for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study. The study drug administered to the subject must be 
documented on the drug accountability form. All study drug will be stored and disposed of 
according to the sponsor 's instructions. S tudy-site personnel  must not combine contents of the 
study drug containers.  
Study drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions.  Unused study drug  must be available for verification by the sponsor 's 
study site monitor during on -site monitoring visits.  The return to the sponsor  of unused study drug 
will be documented on the drug return form. When the study site is an authorized destruction unit 
and study drug supplies are destroyed on -site, this must also be documented on the drug return 
form.  
Potentially hazardous materials such as used ampules, needles, sy ringes and vials containing 
hazardous liquids,  should be disposed of immediately in a safe manner and therefore will not be 
retained for drug accountability purposes.  
Study drug should be dispensed under the supervision of the investigator or a qualified member of 
the study -site personnel , or by a ho spital/clinic pharmacist. Study drug will be supplied only to 
subjects participating in the study. Returned study drug must not be dispensed again, even  to the 
same subject. Study drug may not be relabeled or reassigned for use by other subjects.  The 
investigator agrees neither to dispense the study drug from, nor store it at, any site other than the 
study sites agreed upon with the sponsor . 
15. STUDY -SPECIFIC MATER IALS  
The investigator will be provided with the fo llowing supplies:  
• Study Protocol  
• Subject study tools (appointment card, emergency ID card etc ., as applicable per country)  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
90 
Status: Approved , Date: 28 March 2019  • Investigator study tools and quick reference cards  
• Imetelstat IB 
• Trial Center File, and corresponding specific documentation  
• Investigational Product Preparation Instructions  
• Site Investigational Product Manual  
• Central laboratory and central imaging manual and supplies  
• NCI-CTCAE Version 4.03  
• PRO questionnaires and user manuals  
• Tablet devices for patient e -diary  
• IWRS Manual and su pplies  
• eDC Manual and eCRF Completion Guidelines  
• Sample ICF  
16. ETHICAL ASPECTS  
16.1.  Study -Specific Design Considerations  
This was originally designed as  a randomized, single -blind study to evaluate the efficacy and safety 
of 2 dose levels of imetelstat in subjects  with intermediate -2 or high risk MF who were previously 
treated with a JAK inhibitor. For these patients previously treated with a JAK inhibitor there is no 
effective or approved therapy and the prognosis is very poor. All subjects will receive treatment 
with imetelstat.  
Randomization was to  be used to minimize bias in the assignment of subjects to each dose level, 
and treatment will be blinded to the subject to reduce potential bias during data collection (ie, 
symptom assessment and PROs ). Beginning with Protocol Amendment 2  and suspension of new 
enrollment , neither subjects nor investigators will be blinded to subject treatment assignment.  
All participating subjects will receive full supportive care and will be followed closely for safety 
and efficacy thr oughout the study. Efficacy assessments will be performed according to modified 
2013 IWG -MRT response criteria for MF . Safety assessments will occur through regular clinic 
visits including laboratory analyses. The sponsor  will monitor data on an ongoing basis to ensure 
the safety of the subjects enrolled in this study.  
Potential subjects will be fully informed of the risks and requirements of the study and, during the 
study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may be 
withdrawn at any time with no reason given and without penalty or loss of benefits to which they 
would otherwise b e entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study, and provide their consent voluntarily will be enrolled.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
91 
Status: Approved , Date: 28 March 2019  The total blood volume to be collected from each subject will be approximatel y 604 mL. The total 
volume of blood includes laboratory assessments associated with screening and treatment 
including pharmacokinetic and biomarker samples. The volume of blood to be drawn is considered 
to be normal and acceptable for subjects participatin g in a cancer clinical study and is deemed 
reasonable over the time frame of the study.  
16.2.  Regulatory Ethics Compliance  
16.2.1.  Investigator Responsibilities  
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, cur rent ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country -specific requirements.  
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies  that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well -being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsink i, and that the study data are credible.  
16.2.2.  Independent Ethics Committee or Institutional Review Board  
Before the start of the study, the investigator (or sponsor  where required) will provide the IEC/IRB 
with current and complete copies of the following docum ents (as required by local regulations) : 
• Final protocol and, if applicable, amendments  
• Sponsor -approved ICF (and any other written materials to be provided to the subjects)  
• Investigator's Brochure (or equivalent information) and amendments/addenda  
• Sponsor -approved subject recruiting materials  
• Information on compensation for study -related injuries or payment to subjects for 
participation in the study, if applicable  
• Investigator's curriculum vitae or equivalent information (unless not required, as documented  
by the IEC/IRB)  
• Information regarding funding, name of the sponsor , institutional affiliations, other potential 
conflicts of interest, and incentives for subjects  
• Any other documents that the IEC/IRB requests to fulfill its obligation  
This study  will be u ndertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any , excluding the ones that are purely administrative, with no consequences for 
subjects, data or study conduct ), the ICF, applicable recruiting materials, and subject compensation 
programs, and the sponsor  has received a copy of this approval. This approval letter must be dated 
and must clearly identify the IEC/IRB and the documents being approved.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
92 
Status: Approved , Date: 28 March 2019  During the study the investigator (or sponsor  where required) wi ll send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:  
• Protocol amendments  (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)  
• Revision(s) to ICF and any other written materials to be provided to subjects  
• If applicable, new or revised subject recruiting materials approved by the sponsor  
• Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study, if  applicable  
• New edition(s) of the IB and amendments/addenda  
• Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB  (at 
least annually)  
• Reports of adverse events that are serious, unlisted/unexpected, and associated with t he study 
drug 
• New information that may adversely affect the safety of the subjects or the conduct of the 
study  
• Deviations from or changes to the protocol to eliminate immediate hazards to the subjects  
• Report of deaths of subjects under the investigator's c are 
• Notification if a new investigator is responsible for the study at the site  
• Development Safety Update Report and Line Listings, where applicable  
• Any other requirements of the IEC/IRB  
For all protocol amendments (excluding the ones that are purely admin istrative, with no 
consequences for subjects, data or study  conduct) , the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).   
At least once a year, the IEC/IRB wi ll be asked to review and reapprove this study , where required . 
The reapproval should be documented in writing (excluding the ones that are purely 
administrative, with no consequences for subjects, data, or study conduct) . 
At the end of the study, the inve stigator (or sponsor  where required) will notify the IEC/IRB about 
the study completion .  
16.2.3.  Informed Consent  
Each subject (or a legally acceptable representative) must give written consent according to local 
requirements after the nature of the study has bee n fully explained. The ICF(s) must be signed 
before performance of any study -related activity. The ICF(s)  that is /are used must be approved by 
both the sponsor  and by the reviewing IEC/IRB and be in a language that the subject can read and 
understand. The informed consent should be in accordance with principles that originated in the 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
93 
Status: Approved , Date: 28 March 2019  Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and 
sponsor  policy.  
Before enrollment in the study, the investigator or an authoriz ed member of the study -site 
personnel must explain to potential subjects or their legally acceptable representatives the aims, 
methods, reasonably anticipated benefits, and potential hazards of the study,  and any discomfort 
participation in the study may e ntail. Subjects will be informed that their participation is voluntary 
and that they may withdraw consent to participate at any time. They will be informed that choosing 
not to participate will not affect the care the subject will receive for the treatment  of his or her 
disease. Subjects will be told that alternative treatments are available if they refuse to take part and 
that such refusal will not prejudice future treatment. Finally, they will be told that the investigator 
will maintain a subject identifi cation register for the purposes of long -term follow up if needed 
and that their records may be accessed by health authorities and authorized sponsor  personnel  
without violating the confidentiality of the subject, to the extent permitted by the applicable law(s) 
or regulations. By signing the ICF the subject or legally acceptable representative is authorizing 
such access , including permission to obtain informati on about his or her survival status, and agrees 
to allow his or her study physician to recontact the subject for the purpose of obtaining consent for 
additional safety evaluations, if needed, and subsequent disease -related treatments, or to obtain 
informat ion about his or her survival status . 
The subject or legally acceptable representative will be given sufficient time to read the ICF and 
the opportunity to ask questions. After this explanation and before entry into the study, consent 
should be appropriately recorded by means of either the subject's or his or her legally acceptable 
representative's personally dated signature. After havi ng obtained the consent, a copy of the ICF 
must be given to the subject.  
If the subject or legally acceptable representative is unable to read or write, an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally date and sign the ICF after the oral consent of the 
subject or legally acceptable representative is obtained.  
16.2.4.  Privacy of Personal Data  
Personal data collected from subjects enrolled in this study will be limited to those data that are 
necessary to fulfill the objectives of the study  and processed in compliance with the Patient 
Information and Informed Consent Form (ICF) and agreement(s) with the sponsor governing the 
conduct of the study at the c linical sites . 
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the pers onal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be utilized . 
Sponsor  personnel whose responsibilities require access to personal data agree to keep the identity 
of subjects con fidential.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
94 
Status: Approved , Date: 28 March 2019  The informed consent obtained from the subject (or his or her legally acceptable representative) 
includes explicit consent for the processing of personal data and for the investigator /institution  to 
allow direct access to his or her original med ical records  for purposes such as study -related 
monitoring, audit, IEC/IRB review, and regulatory inspection. This consent also permits  the 
transfer of the data to other entities and to other countries  in compliance with applicable data 
privacy protection laws and regulations . 
The subject has the data privacy right s set out in the ICF and the applicable data privacy laws and 
regulations in the country in which the study is being conducted. The ICF directs subjects to submit 
data privacy requests to the stud y site. The site will report the request to the CRO and/or the 
sponsor . Reasonable steps will be taken to respond to such a request, taking into consideration the 
nature of the request, the conditions of the study , and the applicable data privacy laws and 
regulations.  
Exploratory pharmacodynamic  biomarker PK and immunogenicity research is not conducted 
under standards appropriate for the return of data to subjects. In addition, the sponsor  cannot make 
decisions as to the significance of any findings resulting from exploratory research. Therefore, 
exploratory research data will not be returned to subjects or investigators, unless required by law  
or local regulations . Privacy and confidential ity of data generated in the future on stored samples 
will be protected by the same standards applicable to all other clinical data.  
16.2.5.  Long -Term Retention  of Samples for Additional Future Research  
Samples collected in this study may be stored for up to 15 ye ars (or according to local regulations) 
for additional research. Samples will only be used to understand  imetelstat , to understand  MF, to 
understand differential drug responders, and to develop tests/assays related to  imetelstat  and MF. 
The research ma y begin at any time during the study or the post -study storage period.  
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples  to be 
stored for research ( refer to  Section 10.3, Withdrawal From the Study ( Withdrawal From the Use 
of Samples  in Future Research) . 
16.2.6.  Country Selec tion 
This study will only be conducted in those countries where the intent is to launch or otherwise help 
ensure access to the developed product, unless explicitly addressed as a specific ethical 
consideration in Section  16.1, Study -Specific Design Considerations.  
17. ADMINISTRATIVE REQUI REMENTS  
17.1.  Protocol Amendments  
Neither the investigator nor the sponsor  will modify this protocol without a formal amendm ent by 
the sponsor . All protocol amendments must be issued by the sponsor , and signed and dated by the 
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
95 
Status: Approved , Date: 28 March 2019  when the relevant competent authority has raised any grounds for non -acceptance, except when 
necessary to eliminate immediate hazards to the subjects, in which case the amendment must be 
promptly submitted to the IEC/IRB and relevant competent authority. D ocumentation of 
amendment approval by the investigator and IEC/IRB must be provided to the sponsor . When the 
change(s) involves only logistic or administrative aspects of the study , the IRB (and IEC where 
required) only needs to be notified.  
During the cou rse of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor  representative 
(see Contact Information page(s) provided separately). Except in emerg ency situations, this 
contact should be made before  implementing any departure from the protocol. In all cases, contact 
with the sponsor  must be made as soon as possible to discuss the situation and agree on an 
appropriate course of action. The data record ed in the CRF and source documents will reflect any 
departure from the protocol, and the source documents will describe this departure and the 
circumstances requiring it.  
17.2.  Regulatory Documentation  
17.2.1.  Regulatory Approval/Notification  
This protocol and any amend ment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.  
17.2.2.  Required Prestudy Documentation  
The following documents must be pro vided to the sponsor  before shipment of study drug to the 
study  site: 
• Protocol and amendment(s), if any, signed and dated by the principal investigator  
• A copy of the dated and signed  (or sealed, where appropriate per local regulations) , written 
IEC/IRB app roval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly identify the specific 
protocol by title and number and must be signed  (or sealed, where appropriate per local 
regulations)  by the chairman or authorized designee.  
• Name and address of the IEC/IRB, including a current list of the IEC/IRB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulatio ns. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a general statement may be substituted for this list.  If an investigator or a 
member of the study -site personnel  is a member of the IEC/IRB, documentation must be 
obtained to s tate that this person did not participate in the deliberations or in the vote/opinion 
of the study . 
• Regulatory authority approval or notification, if applicable  
• Signed and dated statement of investigator (eg,  Form FDA 1572), if applicable  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
96 
Status: Approved , Date: 28 March 2019  • Documentation of investigator qualifications (eg,  curriculum vitae)  
• Completed investigator financial disclosure form from the principal investigator, where 
required  
• Signed and dated Clinical Trial Agreement, which includes the financial agreement  
• Any other documentation re quired by local regulations  
 
The following documents must be provided to the sponsor  before enrollment of the first subject:  
• Completed investigator financial disclosure forms from all subinvestigators  
• Documentation of subinvestigator qualifications (eg,  curriculum vitae)  
• Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable  
• Local laboratory documentation demonstrating competence and test reliability 
(eg, accreditation/license), if applicable  
17.3.  Subject Identification, Enrollment, and Screening Logs  
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This docum ent will be reviewed by the 
sponsor  study -site contact for completeness.  
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study file. To ensure subject confidentiality, no copy will be made. All 
reports and communications relating to the study will identify subjects by subject identification  
and date of birth. In cases where the subject is not randomized into the study, the date seen and 
date of birth will be used.  
The investigator mu st also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study.  
17.4.  Source Documentation  
For the main study, a t a minimum, source documentation must be available for the following to 
confirm data collected in the CRF: subject identification, eligibility, and study identification; study 
discussion and date of signed informed consent; dates of visits; results of safety and efficacy 
parameters as required by the protocol; record of all adve rse events and follow -up of adverse 
events; concomitant medication; drug receipt/dispensing/return records; study drug  administration 
information ; and date of study completion and reason for early discontinuation of study drug or 
withdrawal from the study, if applicable.  
For the Extension  Phase , at a minimum, source documentation must be available for the following: 
subject identification and stud y identification;  discussion regarding closure of the main study and 
date of updated informed consent; dates of visits; drug dispensing records and study drug 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
97 
Status: Approved , Date: 28 March 2019  administration information; and record of all serious adverse events  and pregnancies and follow -
up of serious adverse event s and pregnancies . 
In addition, the author of an entry in the source documents should be identifiable.  
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly recor ded at the study site as a basis for standard medical care. 
Specific details required as source data for the study will be reviewed with the investigator before 
the study and will be described in the monitoring guidelines (or other equivalent document).  
Subject -completed scales and assessments designated by the sponsor  for the modified MFSAF 
v2.0 diary  will be recorded directly into an electronic device and will be considered source data.  
17.5.  Case Report Form Completion  
Case report forms are provided for each s ubject in electronic format.  
Electronic Data Capture (eDC) will be used for this study. The study data will be transcribed by 
study -site personnel from the source documents onto an electronic CRF, and transmitted in a 
secure manner to the sponsor  within t he timeframe agreed upon between the sponsor  and the study 
site. The electronic file will be considered to be the CRF.  
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subj ect's source documentation. All data relating to the 
study must be recorded in CRFs  prepared by the sponsor . Data must be entered into CRFs in 
English.  Study  site personnel must complete the CRF as soon as possible after a subject visit, and 
the forms should be available for review at the next scheduled monitoring visit.  
All subjective measurements (eg, pain scale information or other questionnaires) will be c ompleted 
by the same individual who made the initial baseline determinations whenever possible. The 
investigator must verify  that all data entries in the CRF s are accurate and correct.  
All CRF entries, corrections, and alterations must be made by the inves tigator or other authorized 
study -site personnel. If necessary, queries will be generated in the eDC tool.  The investigator or 
study -site personnel must adjust the CRF (if applicable) and complete the query.  
If corrections to a CRF  are needed after the initial entry into the CRF, this can be done in 3 different 
ways:  
• Study s ite personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated by the eDC tool) . 
• Study s ite manager can generate a query for resolution by the study -site personnel.  
• Clinical data manager can generate a query for resolution by the study -site personnel.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
98 
Status: Approved , Date: 28 March 2019  17.6.  Data Quality Assurance/Quality Control  
Steps to be taken to ensure the accuracy and reliability of data incl ude the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator and 
study -site personnel before the study, and periodic monitoring visits by the sponsor , and direct 
transmission of clinical labo ratory data from a central laboratory into the sponsor 's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.  
Guidelines for CRF completion will be provided and reviewed with study -site personnel bef ore 
the start of the study.   
The sponsor  will review CRFs for accuracy and completeness during on -site monitoring visits and 
after transmission to the sponsor ; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After uplo ad of the data into the study  database they will be verified for 
accuracy and consistency with the data sources.  
17.7.  Record Retention  
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that s upport the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section  8, Essential Documents for the Conduct of a Clinical 
Trial, and all study documents as specified by the applicable regulatory requirement(s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.  
Essential documents must be retained until at least 2  years after the last approval of a marketing 
application in an ICH region and until there are  no pending or contemplated marketing applications 
in an ICH region  or until at least 2  years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents will be retained for a longer period 
if requ ired by the applicable regulatory requirements or by an agreement with the sponsor . It is the 
responsibility of the sponsor  to inform the investigator/institution as to when these documents no 
longer need to be retained.  
If the responsible investigator ret ires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will accept 
the responsibility. The sponsor  must be notified in writing of the name and address of the new 
custodian.  Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor . 
If it becomes necessary for the sponsor  or the appropriate regulatory authority to review any 
document ation relating to this study, the investigator /institution  must permit access to such reports.  
17.8.  Monitoring  
The sponsor  will use a combination of monitoring techniques : On-Site Monitoring Visits, Remote 
Telephone Contacts and Central Data Surveillance to mon itor this study . 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
99 
Status: Approved , Date: 28 March 2019  The sponsor  will perform on -site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study site visit log that will be kept at the study site. The first post -
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the CRFs with the hospital or clinic records (source 
documents). The nature and location of all sou rce documents will be identified to ensure that all 
sources of original data required to complete the CRF are known to the sponsor  and study -site 
personnel  and are accessible for verification by the sponsor  study -site contact. If electronic records 
are mai ntained at the study  site, the method of verification must be discussed with the study -site 
personnel .  
Direct access to source documentation (medical records) must be allowed for the purpose of 
verifying that the data recorded in the CRF are consistent wi th the original source data. Findings 
from this review of CRFs and source documents will be discussed with the study -site personnel . 
The sponsor  expects that, during monitoring visits, the relevant study -site personnel  will be 
available, the source documen tation will be accessible, and a suitable environment will be provided 
for review of study -related documents. The monitor will meet with the investigator on a regular 
basis during the study  to provide feedback on the study  conduct.  
In addition to on -site m onitoring visits, remote contacts can occur. It is expected that during these 
remote contacts, study -site personnel will be available to provide an update on the progress of the 
study at the site.  
Central monitoring will take place for data identified by the sponsor  as requiring central review.  
17.9.  Study Completion/Termination  
17.9.1.  Study Completion  
The main study is considered completed 18 months after the last subject is enrolled or anytime the 
sponsor  terminates the study, whichever comes first. The full study, i ncluding the Extension Phase, 
will be completed  approximately  2 years  after the clinical cutoff for the final analysis of the main  
study, or when the sponsor terminates the study, whichever occurs first.  The sponsor  will ensure 
that subjects benefiting from treatment with imetelstat will be able to continue  their assigned 
treatment . The final data from the study  site will be sent to the sponsor  (or designee) after 
completion of the final subject assessment at that study site, in the time frame specified in the 
Clinical Trial Agreement.  
17.9.2.  Study Termination  
The sponsor  reserves the right to close the study  site or terminate the study at any time for any 
reason at the sole discretion of the sponsor . Study  sites will be clo sed upon study completion. A  
study  site is considered closed when all required documents and study supplies have been collected 
and a study -site closure visit has been performed.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
100 
Status: Approved , Date: 28 March 2019  The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early  closure of a  study  site by the sponsor  or investigator may include but are not 
limited to:  
• Failure of the investigator to comply with the proto col, the requirements of the IEC/IRB or 
local health authorities, the sponsor 's procedures, or GCP guidelines  
• Inadequate recruitment of subjects by the investigator  
• Discontinuation of further study drug development  
17.10.  On-Site Audits  
Representatives of the sponsor 's clinical quality assurance department may visit the study site at 
any time during or after completion of the study to conduct an audit of the study in compliance 
with regulatory guidelines and company policy. These  audits will require access to a ll study 
records, including source documents, for inspection and comparison with the CRFs. Subject 
privacy must, however, be respected. The investigator and study -site personnel  are responsible for 
being present and available for consultation during routin ely scheduled study -site audit visits 
conducted by the sponsor  or its designees.  
Similar auditing procedures may also be conducted by agents of any regulatory body, either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory submission. The investigator should immediately notify the sponsor  if he or she  has 
been contacted by a regulatory agency concerning an upcoming inspection.  
17.11.  Use of Information and Publication  
All information, including but not l imited to information regarding  imetelstat  or the sponsor 's 
operations (eg,  patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor  to the investigator and not 
previously published, and any data, including exploratory or biomarker  research data, generated 
as a result of this study, are considered confidential and remain the sole property of the sponsor . 
The investigator agrees to maintain this information in confiden ce and use this information only 
to accomplish this study, and will not use it for other purposes without the sponsor 's prior written 
consent.  
The investigator understands that the information developed in the study will be used by the 
sponsor  in connectio n with the continued development of  imetelstat , and thus may be disclosed as 
required to other clinical investigators or regulatory agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide t he sponsor  with all 
data obtained in the study.  
The results of the study will be reported in a Clinical Study Report generated by the sponsor  and 
will contain CRF data from all study sites that participated in the study,  direct transmission of 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
101 
Status: Approved , Date: 28 March 2019  clinical lab oratory data from a central laboratory and electronic diary data into the sponsor 's 
database. Recruitment performance or specific expertise related to the nature and the key 
assessment parameters of the study will be used to determine a coordinating invest igator. Results 
of exploratory or biomarker analyses performed after the Clinical Study Report has been issued 
will be reported in a separate report and will not require a revision of the Clinical Study Report. 
Study subject identifiers will not be used in  publication o f results. Any work created in connection 
with performance of the study and contained in the data that can benefit from copyright protection 
(except any publication by the investigator as provided for below) shall be the property of the 
spons or as author and owner of copyright in such work.  
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, t he sponsor  shall have the right to publish such primary (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary data are published. If an investigator wishes to publish 
information from the study,  a copy of the manuscript must be provided to the sponsor  for review 
at least 60  days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor  in 
writing, the investiga tor will withhold such publication for up to an additional 60  days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity or 
regulatory compliance, the sponsor  will review these issues with the investigat or. The sponsor  will 
not mandate modifications to scientific content and does not have the right to suppress information.  
For multicenter study designs and substudy approaches, secondary results generally should not be 
published before the primary endpoint s of a study have been published. Similarly, investigators 
will recognize the integrity of a multicenter study  by not submitting for publication data derived 
from the individual study site until the combined results from the completed study  have been 
submi tted for publication, within 12  months of the availability of the final data (tables, listings, 
graphs), or the sponsor  confirms there will be no multicenter study publication. Authorship of 
publications resulting from this study will be based on the guide lines on authorship, such as those 
described in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which 
state that the named authors must have made a significant contribution to the design of the study 
or analysis and interpretatio n of the data, provided critical review of the paper, and given final 
approval of the final version.  
Registration of Clinical Studies and Disclosure of Results  
The sponsor  will register and/or disclose the existence of and the results of clinical studies a s 
required by law.  
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
102 
Status: Approved , Date: 28 March 2019  REFERENCES  
1. Aaronson NK, Ahmedzai S, Bullinger M, et al. The EORTC core quality of life questionnaire: interim results 
of an international field study. In: Osoba, D, ed. Effect of Cancer on Quality of Life.  Boca Raton: CRC Press 
Inc; 19 91:185 -203. 
2. Abdelrahman RA, Begna KH, Al -Kali A, et al. Revised assessment of response and long -term discontinuation 
rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia . 
2014;doi:10.1038/leu.2014.286. Epub ahead of  print.  
3. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential 
anticancer agent. Cancer Res . 2003;63(14):3931 –3939.  
4. Baerlocher G, Leibundgut E, Spitzer G, et al. Imetelstat: a novel approach with robust hematolo gic and 
molecular responses in a phase 2 study in patients with essential thrombocythemia (ET) who are refractory or 
intolerant to prior therapy. [Abstract 4398]. EHA Annual Meeting, June 13 -16, 2013.  
5. Baerlocher GM, Leibundgut EO, Ayran C, et al. Imetelst at rapidly induces and maintains substantial 
hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or 
intolerant to prior therapy: preliminary  Phase II results. Blood . 2012;120:179.  
6. Berger, RL. Multiparameter hypothesis testing and acceptance sampling. Technometrics . 1982;24:295 -300. 
7. Bernard L, Belisle C , Mollica L, et al. Telomere length is severely and similarly reduced in JAK2V617F -
positive and –negative myeloproliferative neoplasm s. Leukemia.  2009;23:287 –291. 
8. Bjordal K, Kaasa S. Psychometric validation of the EORTC core quality of life questionnaire, 30 item version 
and a diagnosis specific module for head and neck cancer patients. Acta Oncol . 1992;31: 311 -321. 
9. Cervantes  F, Vannucc hi AM, Kiladjian  JJ, et al. Three -year efficacy,  safety,  and survival  findings  from  
COMFORT -II, a phase  3 study  comparing  ruxolitinib  with best available  therapy  for 
myelofibrosis.  Blood . 2013;122 (25):4047-4053. 
10. Cleeland  C, Turk  DC, Melzack  R. Brief  pain inventory.  In: Cleeland  C, Turk  DC, Melzack  R, eds. Handbook  
of Pain  Assessment.  New  York:  The Guilford  Press;  1991:378 –382. 
11. De Charro F, Rabin R. EQ -5D-5L from the EuroQol group: an update. QOL Newsletter.  2000.  
12. Ferraris AM , Mangerini R, Pujic N, et al. High telomerase activity in granulocytes from clonal polycythemia 
vera and essential thrombocythemia. Blood . 2005a;105(5):2138 –2140.  
13. Ferraris AM, Pujic N, Mongerini R, et al. Clonal granulocytes in polycythemia ver a and essential 
thrombocythaemia have shortened telomeres. Br J Haematology . 2005b;130:391 –393. 
14. Frink R, Peyton, M, Sullivan J, et al. Sensitivity and resistance of non -small cell lung cancer to the telomerase 
inhibitor imetelstat. Cancer Research.  2010;70 (8 Suppl):3577.  
15. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring 
System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and 
transfusion status. J Clin Oncol.  2011;29(4):392 –397. 
16. Harley CB. Telomerase and cancer therapeutics. Nat Rev . 2008;8:167 –179. 
17. Harrison C, Kiladjian JJ, Al -Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for 
myelofibrosis. N Engl J Med . 2012;366(9):787 –798. 
18. Harrison CN, Kiladjian J, Al -Ali, HK, et al. Results of a randomized study of the JAK inhibitor ruxolitinib 
(INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post -polycythemia vera -
myelofibrosis (PPV -MF) or post -essential thro mbocythemia -myelofibrosis (PET -MF). J Clin Oncol . 
2011;29(suppl):LBA6501.  
19. Herbert B -S, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3’ -P5’ thio -
phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene . 2005;24:5262 –
5268.  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
103 
Status: Approved , Date: 28 March 2019  20. Iancu -Rubin C, Mosoyan G, Parker CC, et al. Imetelstat (GRN163L), a telomerase inhibitor selectively affects 
malignant megakaryopoiesis in myeloproliferative neoplasms  (MPN). Blood . 2014;124(21):4582.  
21. Investigator Brochure: JNJ -63935937 (imetelstat) Edition 14. Janssen Research & Development ( 30 Oct 2018 ).  
22. Jabbour E, Hagop MK, Garcia -Manero G, et al. Outcome of patients (pts) with myelofibrosis (mf) after 
ruxolitinib (rux) therapy. Blood . 2013;122(21):1584 . 
23. Keohane C, Radia DH, Harrison CN. Treatment and management of myelofibrosis in the era of JAK inhibitors 
Biologics: Targets and Therapy . 2013;7:189 –198. 
24. Kind P , Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom 
national questionnaire survey. Brit Med J . 1998;316(7133):736 -741. 
25. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the myelofibrosis symptom assessment 
form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 
inhibitor (INCB018424) clinical trial. Cancer . 2011;117:4869 -4877.  
26. Mesa RA,  Niblack J,  Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative 
disorders (MPDs): an international internet -based survey of 1179 MP D patients.  Cancer . 2007;109:68 -76. 
27. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary 
myelofibrosis: a study by the IWG -MRT (international working group for myeloproliferative neoplasms 
research and t reatment). Blood . 2010;115(9):1703 –1708.  
28. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: international working group -
myeloproliferative neoplasms research and treatment (IWG -MRT) and European leukemia net (ELN) 
consensus  report. Blood . 2013;122(8):1395 –1398.  
29. Tefferi A, LaPlant B, Begna K, et al. Imetelstat, a telomerase inhibitor, therapy for myelofibrosis: a pilot study. 
Blood . 2014;124(21): 634.  
30. Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494 –3504.  
31. Terasa ki Y, Okumura H, Ohtake S, et al. Accelerated telomere length shortening in granulocytes: a diagnostic 
marker for myeloproliferative diseases. Exp Hematology.  2002;30:1399 –1404.  
32. Vannucchi AM, Verstovsek S, Jones MM, et al. Efficacy of ruxolitinib by baseli ne spleen volume in patients 
with polycythemia vera resistant to or intolerant of hydroxyurea . Blood . 2014;124(21):1840.  
33. Verstovsek S, Mesa RA, Gotlib J, et al. A double -blind, placebo -controlled trial of ruxolitinib for 
myelofibrosis. N Engl J Med . 2012;366(9):799 –807. 
34. Wang X, Hu CS, Li Y, et al. Effects of imetelstat on CD34+ cells of patients with myelofibrosis. Blood . 
2014;124(21):1879.  
 
 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
104 
Status: Approved , Date: 28 March 2019  Attachment 1: Modified Myelofibrosis Symptom Assessment Form v2.0  
(modified MFSAF  v2.0)  
 
 

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
105 
Status: Approved , Date: 28 March 2019  Attachment 2: European Organization for Research and Treatment of Cancer QLQ -C30  
(EORTC QLQ -C30)  
 
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
106 
Status: Approved , Date: 28 March 2019   
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
107 
Status: Approved , Date: 28 March 2019  Attachment 3: Brief Pain Inventory (Short Form ) (BPI) 
 
 
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
108 
Status: Approved , Date: 28 March 2019   
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
109 
Status: Approved , Date: 28 March 2019  Attachment 4: Patient’s Global Impression of Change ( PGIC ) 
 
Since the start of the treatment you’ve received in this study, your  
myelofibrosis symptoms are:  
 
 1. Very much improved  
 2. Somewhat improved  
 3. A little improved  
 4. No change  
 5. A little worse  
 6. Somewhat worse  
 7. Very much worse  
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
110 
Status: Approved , Date: 28 March 2019  Attachment 5: EuroQol -EQ-5D (EQ-5D-5L) 
 
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
111 
Status: Approved , Date: 28 March 2019   
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
112 
Status: Approved , Date: 28 March 2019     

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
113 
Status: Approved , Date: 28 March 2019  Attachment 6: World Health Organization (WHO) Diagnostic Criteria for Polycythemia Vera, 
Essential Thrombocythemia and Primary Myelofibrosis  
 
2008 WHO Diagnostic Criteria  
  Polycythemia Vera1)  Essential Thrombocythemia1  Primary Myelofibrosis1 
Major 
criteria  1 Hgb > 18.5 g/dL (men)  
> 16.5 g/dL (women)  
or 2) 1 Platelet count ≥ 450 x 109/L 1 Megakaryocyte proliferation 
and atypia3) accompanied by 
either  reticulin and/or 
collagen fibrosis, or4) 
2 Presence of JAK2V617F  
or JAK2 exon 12 
mutation  2 Megakaryocyte proliferation 
with large and mature 
morphology.  2 Not meeting WHO criteria 
for CML, PV, MDS, or other 
myeloid neoplasm  
3 Not meeting WHO criteria for 
CML, PV, PMF, MDS or 
other myeloid neoplasm  3 Demonstration of 
JAK2V617F or other clonal 
marker  
or  
no evidence of reactive 
marrow fibrosis  4 Demonstration of JAK2V617F 
or other clonal marker  
or  
no evidence of reactive 
thrombocytosis  
Minor 
criteria  1 BM trilineage 
myeloproliferation   1 Leukoerythroblastosis  
2 Subnormal serum Epo 
level  2 Increased serum LDH level  
3 EEC growth  3 Anemia  
4 Palpable splenomegaly  
Key:  BM, bone marrow; Hgb, hemoglobin; Hct, hematocrit; Epo, erythropoietin; EEC, endogenous erythroid 
colony; WHO, World Health Organization; CML, chronic myelogenous leukemia; PV, polycythemia vera; PMF, 
primary myelofibrosis; MDS, myelodysplastic syndromes;  LDH, lactate dehydrogenase  
1 PV diagnosis requires meeting either both major criteria and one minor criterion or the first major criterion and 2 
minor criteria. ET diagnosis requires meeting all 4 major criteria. PMF diagnosis requires meeting all 3 majo r 
criteria and 2 minor criteria.  
2 Or Hgb or Hct > 99th percentile of reference range for age, sex, or altitude of residence  or red cell mass > 25% 
above mean normal predicted or Hgb > 17 g/dL (men)/ > 15 g/dL (women) if associated with a sustained increase 
of  2 g/dL from baseline that cannot be attributed to correction of iron deficiency  
3 Small to large megakaryocytes with aberrant nuclear/cytoplasmic ratio and hyperchromatic and irregularly folded 
nuclei and dense clustering.  
4 In the absence of reticulin fibrosis, the megakaryocyte changes must be accompanied by increased marrow 
cellularity, granulocytic proliferation and often decreased erythropoiesis (i e, pre-fibrotic PMF) ) 
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
114 
Status: Approved , Date: 28 March 2019  Attachment 7: International Working Group for Myeloproliferative Neoplasms Research and 
Treatment (IWG -MRT) Recommended Criteria for Post -Polycythemia Vera and 
Post -essential Thrombocythemia Myelofibrosis  
 
Criteria for post -polycythemia vera -myelofibrosis   
 Required criteria:  
  1  Documentation of a previous diagnosis of polycythemia vera as defined by the WHO criteria  
  2  Bone marrow fibrosis Grade 2 –3 (on 0 –3 scale) or Grade 3 –4 (on 0 –4 scale) (see footnote for details)  
    
 Additional criteria ( 2 are required):  
  1  Anemia or sustained loss of requirement for phlebotomy in the absence of cytoreductive therapy  
  2  A leukoerythroblastic peripheral blood picture  
  3  Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥ 5  cm (distance of the 
tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly  
  4  Development of ≥ 1 of three constitutional symptoms: >10% weight loss in 6 months, night sw eats, 
unexplained fever (>37.5°C)  
    
Criteria for post -essential thrombocythemia myelofibrosis   
 Required criteria:  
  1  Documentation of a previous diagnosis of essential thrombocythemia as defined by the WHO  
  2  Bone marrow fibrosis Grade 2 –3 (on  0–3 scale) or Grade 3 –4 (on 0 –4 scale) (see footnote for details)  
    
 Additional criteria ( 2 are required):  
  1  Anemia and a ≥ 2  g/dL decrease from baseline hemoglobin level  
  2  A leukoerythroblastic peripheral blood picture  
  3  Increasing splenomegaly defined as either an increa se in palpable splenomegaly of ≥ 5 cm (distance of the 
tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly  
  4  Increased lactate dehydrogenase  
  5  Development of ≥ 1 of three constitutional symptoms: >10% weight loss in 6 months, night sweats, 
unexplained fever (>37.5°C)  
Note:  Grade 2 –3 according to the European classification: diffuse, often coarse fiber network with no evidence 
of collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of collagenization 
(positive trichrome stain).  Grade 3 –4 according to the standard classification: diffuse and dense increase in 
reticulin with extensive intersections, occasionally with only fo cal bundles of collagen and/or focal 
osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with coarse bundles of 
collagen, often associated with significant osteosclerosis.  
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
115 
Status: Approved , Date: 28 March 2019  Attachment 8: Dynamic International Prognostic Scoring System (DIPSS)  
 
 
  

GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
116 
Status: Approved , Date: 28 March 2019  Attachment 9: Eastern Cooperative Oncology Group ( ECOG ) Performance Status  
 
ECOG Grade   Scale  (with Karnofsky conversion)  
 
0 Fully active, able to carry on all predis ease performance without restriction. 
(Karnofsky 90 -100) 
 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work on a light or sedentary nature, eg, light housework, office work. (Karnofsky 
70-80) 
 
2 Ambulatory and capable of all self -care but unable to carry out any work activities. 
Up and about more than 50% of waking hours. (Karnofsky 50 -60) 
 
3 Capable of only limited self -care; confined to bed or chair more than 50% of 
waking hours. (Karnofsky 30 -40) 
 
4 Completely disabl ed. Cannot carry on any self -care. Totally confined to bed or 
chair. (Karnofsky 10 -20) 
 
5 Dead. (Karnofsky 0)  
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
117 
Status: Approved , Date: 28 March 2019  Attachment 10: Screening Myelofibrosis (MF) Symptom Form  
 
Instructions to Subjects: Please answer all questions to the best of your ability, based on your 
memory over the past 7 days (1 week). There is no right or wrong answer.  
 
1. During the past 7 days, how severe were your worst night sweats (or feeling hot or flushed) 
due to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
2. During the past 7 days, how severe was your worst itchiness due to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
3. During the past 7 days, how severe was your worst abdominal discomfort (f eel uncomfortable, 
pressure or bloating) due to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
4. During the past 7 days, how severe was your worst pain under the ribs on the left side due to 
MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9  10 (Worst Imaginable)  
 
5. During the past 7 days, at its worst, to what degree did you feel full quickly (early satiety) 
after beginning to eat due to MF?  
 
0 (Not at all) 1   2   3   4   5   6   7   8   9  10 (Worst  
Imaginable)  
 
6. During th e past 7 days, how severe was your worst bone or muscle pain due to MF (diffuse, 
not joint or arthritis pain)?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9  10 (Worst Imaginable)  
 
7. During the past 7 days, how severe was your worst inactivity (including work and social 
activities) due to MF?  
 
0 (Absent) 1   2    3   4   5   6   7   8   9  10 (Worst Imaginable)  
 
 
 
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
118 
Status: Approved , Date: 28 March 2019  Attachment 11: Myelofibrosis (MF) Symptom Recall Form  
 
Instructions: Please answer all questions to the best of your ability; circle the one number that 
describes the average of the worst level of each following symptoms on each day over the past 
week. There is no right or wrong answer.  
 
1. During the past week, how severe were your worst night sweats (or feeling ho t or flushed) due 
to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
2. During the past week, how severe was your worst itchiness due to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
3. During the past week, how severe was your worst abdominal discomfort (feel uncomfortable, 
pressure or bloating) due to MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
4. During the past week, how severe was your worst pain under the ribs on  the left side due to 
MF?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9 10 (Worst Imaginable)  
 
5. During the past week, at its worst, to what degree did you feel full quickly (early satiety) after 
beginning to eat due to MF?  
 
0 (Not at all) 1   2   3   4   5   6   7   8   9   10 (Worst  
Imaginable)  
 
6. During the past week, how severe was your worst bone or muscle pain due to MF (diffuse, not 
joint or arthritis pain)?  
 
0 (Absent) 1   2   3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
7. During the past w eek, how severe was your worst inactivity (including work and social 
activities) due to MF?  
 
0 (Absent) 1   2    3   4   5   6   7   8   9   10 (Worst Imaginable)  
 
 
  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
119 
Status: Approved , Date: 28 March 2019  INVESTIGATOR AGREEME NT 
PROTOCOL AMENDMENT ACCEPTANCE FORM  
TITLE:  A Randomized, Single -Blind, Multicenter Phase 2 Study to 
Evaluate the Activity of 2 Dose Levels of Imetelstat in 
Subjects with Intermediate -2 or High -Risk Myelofibrosis 
(MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor    
PROTOCOL:  63935937M YF2001, Amendment 5  
IND:  N/A 
EUDRACT NUMBER:  2015 -000946 -41 
STUDY DRUG:  Imetelstat Sodium for Injection (GRN163L for Injection)  
SPONSOR:  Geron Corporation  
149 Commonwealth Drive  
Menlo Park, CA 94025 USA  
 
 
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator’s Name (print)    
   
Principal Investigator’s Signature   Date  
 
 
Please return a copy to Geron at the address provided below.  Please retain the original for your study files.  
Geron Corporation , Clinical Operations  
149 Commonwealth Drive  
Menlo Park, CA 94025 USA  
GRN1 63L (imetelstat)   
  Clinical Protocol  63935937MYF2001 - Amendment 5  
120 
Status: Approved , Date: 28 March 2019   
